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Abstract 
Reports of inter-ethnic differences in metabolism for phenytoin and 
carbamazepine have raised questions concerning the importance of monitoring serum 
levels to the standardised population therapeutic concentrations. Although the 
pharmacokinetics of phenytoin, carbamazepine, valproic acid and phenobarbitone 
displayed both intra and inter-individual variations, the influence of ethnicity is still 
unclear. This thesis has thus set its objectives of investigating the impact of ethnicity 
on the efficacy of these therapeutic ranges and pharmacokinetics of these drugs. 
A total 1554 serum concentrations were randomly selected by a set of criteria 
from 470 Malays, 423 Chinese and 322 Indian of adult and paediatric patients. The 
Mantel-Haenzel method was used to estimate for inter-ethnic differences in response 
to the defined therapeutic ranges. The influence of ethnicity on pharmacokinetics was 
examined by the test of heterogeneity of the slopes estimates in the linear relationship 
of either serum concentration or clearance to dose. Coefficient of variation on the 
ratios of the above relationships was used to measure for inter-individual variation. 
The results showed a highly variable response to treatment within the defined 
therapeutic ranges. Therapeutic response is not dependent on ethnicity and age 
although the latter was determined on carbamazepine and valproic acid treated 
patients only. The pharmacokinetics of carbamazepine, valproic acid and 
phenobarbitone showed high inter-individual variations and were unaffected by 
weight, age or ethnicity. Similar high inter-individual variation for phenytoin 
pharmacokinetic parameters (Km and Vmax) were observed. However, Km and 
Vmax(mg/day) of adult Chinese patients were significantly lower than Malay or Indian 
patients. The relationship between Km and Vmax and age or weight were insignificant. 
These findings demonstrate that Malaysian patients only differed in handling 
phenytoin therapy and support the use of ethnic specific phenytoin pharmacokinetic 
parameters during therapy. 
V1 
Research summary 
The measurement of drug concentrations of established antiepileptic drugs 
such as phenytoin, carbamazepine, valproic acid and phenobarbitone in clinical 
practice is essentially to monitor patient response within a predetermined range or 
target range. Although these target ranges have been well documented, the influence 
of ethnic differences on the degree of effectiveness of these drugs have yet to be fully 
explored. Review of the literatures gave evidences that inter-ethnic differences in 
metabolism are confirmed for phenytoin, possible for carbamazepine and less likely in 
valproic acid and phenobarbitone. 
Pharmacokinetically, the relationship between dose and serum concentration of 
carbamazepine, valproic acid and phenobarbitone has still to be confirmed and high 
intra and inter-individual variation have being quoted as reasons for inconsistencies 
between studies. The relationship between inter-individual variation and inter-ethnic 
differences among ethnic groups is still uncertain. This thesis thus undertakes to 
examine these uncertainties by investigating the impact of inter-ethnic differences on 
the drugs present therapeutic concentrations and to determine whether factors such as 
ethnicity, age, weight, etc, can influence the steady-state pharmacokinetics of these 
drugs. 
Retrospective routine data of serum concentrations of patients taking either 
one or more of the studied drugs from the years of 1993 to 1996 were retrieved from 
five government run hospitals in Malaysia. Patients were selected based on a set of 
inclusion and exclusion criteria. A total of 1,215 from the 1,868 patients screened met 
the set criteria of which 874(71.93%) were adults and 341(28.07%) were children. 
Reasons for exclusion of about 34.96% of the shortlisted patients were inadequate 
patient data, non-compliance and lost files. The inter-ethnic composition comprises of 
470 Malays, 423 Chinese and 322 Indians. 
To evaluate the effectiveness of the documented target ranges of the four 
studied drugs on the control of seizures and to determine for inter-ethnic differences in 
response, the Mantel-Haenzel fixed effect model of odds ratios and for pooling across 
data was used. This method basically measures the odds-ratio of controlled to 
uncontrolled patients based on a random selection of a single dose and serum 
concentration pair and the subsequent seizure index of each drug. Seizure index is the 
rate of seizures per day at each hospital review. The estimated summary estimate of 
the pooled odds-ratio and the 95% confidence limits was used to test for heterogeneity 
across the three ethnic populations. 
The same data set was used to investigate the steady-state pharmacokinetics of 
carbamazepine, valproic acid and phenobarbitone. To examine inter-ethnic 
differences, the formula that determines the relationship of serum concentration and 
dose by Wagner (1965) was employed. Test of heterogeneity between ethnic groups 
was by examining the differences of the pooled estimates of the slope of the 
significant linear regression equation of either dose and serum concentration or 
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clearance was used. Phenytoin pharmacokinetics were determine by the Michaelis- 
Menten equation which uses two dose and serum concentration data sets. 
The differences in variables such as age, weight, sex, disease duration(length 
of disease) and epilepsy types was determined by one way analysis of variance. P 
value of 0.05 or less is set to test to significance. Coefficient of variation of mean 
values of serum/level ratio was used for interindividual variation. 
Results showed that routine monitoring of established antiepileptic drugs in 
relation to their target ranges is clinically ineffective and had little bearing to 
achieving good therapeutic response. Therapeutic response, which was measured by 
the degree of seizure control was not dependent on inter-ethnic differences. These 
results were confirmed as the differences observed between Malays, Chinese and 
Indians pooled odds ratio of controlled and uncontrolled patients in the defined 
therapeutic ranges were statistically insignificant. High inter-individual variation was 
clearly apparent in all ethnic groups showing that the use of these drugs should be 
individualised. Age was not an important factor for the association between 
therapeutic response and the target therapeutic range. This was confirmed by the 
pooled odds ratio of carbamazepine and valproic acid. Similar observation were not 
conclusive for phenytoin and phenobarbitone due to inadequacy of data. These 
observations are thus in-line with the recommendation outlined by the Commission on 
Antiepileptic drugs, International League Against Epilepsy 1993. 
The relationship between dose and serum level for carbamazepine is found to 
be curvilinear and thus verified its dose-dependent properties. Linear relationship 
between valproic acid dose and serum level is highly variable and found to be highly 
significant in patients on valproic acid monotherapy. Phenobarbitone dose and serum 
concentration relationship are highly correlated. This study also showed that neither 
valproic acid nor phenobarbitone displayed any dose-dependent kinetics. 
Factors such as weight, age or ethnicity have no influence on the relative 
relationship between dose and serum concentration for carbamazepine, valproic acid 
and phenobarbitone. The main factor that could have affected this relationship is the 
high interindividual variation between patients which clearly indicates that the use of 
these drugs must be individualised. 
Clearance is the pharmacokinetic parameter used in determining the trend and 
influence of ethnicity on the population pharmacokinetics of carbamazepine, valproic 
acid and phenobarbitone. Evidence of inter-ethnic differences among Malay, Chinese 
and Indian epileptic population in Malaysia was found to be statistically insignificant. 
High coefficient of variation of clearances displayed in all ethnic groups showed that 
interindividual variation is the important factor that could affect the relationship between clearance and dose. 
Evidence showed that there are inter-ethnic differences in phenytoin 
pharmacokinetic parameters (Km, mg/L and Vmax, mg/day) among Malay, Chinese 
and Indian adults patients of Malaysia but not for paediatric patients. Elimination rate 
constant with a value equal to the plasma concentration at which the rate is one-half 
the maximum (Km) was found to be lower for Chinese and differed significantly to 
viii 
that of Malay and Indian adult patients. Differences between Malay and Indian adult 
patients were insignificant. Metabolic rate capacity (Vmax, mg/kg. day) of all three 
ethnic groups were statistically similar. 
The relationship between Km with age and weight in both adult and paediatric 
patients were non-linear. Relationship between Vmax (mg/kg. day) with age or weight 
was weak although there is an inclination towards a linear relationship in paediatric 
patients. 
Finally, this study showed that Malay, Chinese and Indian patients did not 
differ significantly in handling carbamazepine, valproic acid and phenobarbitone. 
However, inter-ethnic differences between Chinese with both Malay and Indian 
patients signify that the therapeutic use of phenytoin on Malaysian patients must be 
adjusted to their racial background. 
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Part 1 
Background 
CHAPTER 1 
ANTIEPILEPTIC DRUGS : AN INTRODUCTION 
1.1 BRIEF HISTORY 
Epilepsy is a disease that has affected people for as long as history has been 
recorded. The term'epilepsy' is derived from a Greek word that means to take hold of, to 
possess or to seize. The ancient Greeks' belief was that an epileptic attack represented 
possession by the gods. By the year 400 BC, Hippocratic writers identified epilepsy as a 
physical disorder of the brain, and pointed out that damage of one side of the brain can 
lead to convulsions that affect mainly the opposite side of the body. It was later defined by 
a British neurologist Hughlings Jackson about a century ago as a recurrent, episodic, 
uncontrolled discharge of nerve tissue [Chadwick and Usiskin 1987]. 
Epidemiologically, about 0.5 to 1% of the population in the United Kingdom 
have recurrent seizures at some time of their lives. Chadwick and Usiskin (1987) further 
describe that incidence is highest at the first ten years of life while prevalence increases 
with age. 
In the United States of America, the prevalence of active epilepsy is 6.42 cases 
per 1000 population. In the 1980 census, at least 1.5 million people in America have 
active seizures [Scheuer and Pedley 1990]. Active seizures such as status epilepticus, 
which is characterised by a succession of fits without regaining consciousness between 
them, may cause brain damage. This is because the brain cells may become so overactive 
that the blood cannot transport enough oxygen to the brain and lead to these cells dying. 
The commonest reason as to why this happens is that patient stop taking the medication 
[Chadwick and Usiskin 1987]. Thus, the goal of drug therapy is to minimise the 
recurrence of seizures by ensuring compliance with no unwanted side-effects. 
1.2 WHAT IS EPILEPSY? 
Epilepsy is defined as a condition characterized by recurrent (two or more) 
epileptic seizures, unprovoked by any immediately known cause. It is usually a chronic 
disorder characterized not only by recurrent seizures but by a variety of medical and 
psychosocial implications. Manifestation usually consists of sudden and transitory 
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abnormal phenomena, which may include alterations of consciousness, motor, sensory, 
autonomic, or psychic events perceived by the patient or an observer. Its clinical 
manifestation is presumed to result from an abnormal and excessive discharge of a set of 
neurons in the brain. [Hopkins and Shorvon 1995] 
According to the International League Against Epilepsy, 1981, epilepsy can be 
broadly classified into four main groups. The first group of epilepsy are the localization- 
related (focal, local, partial) epilepsies and related syndromes. The other three groups are 
the generalized epilepsies and syndromes, epilepsies and syndromes undetermined 
whether focal or generalized and finally epilepsies due to special syndromes. Special 
syndromes are epilepsies that are usually situation-related. Examples are febrile 
convulsions, isolated seizures and those that occur only when there is an acute metabolic 
or toxic event. Table 1.1 summarised the modified classification by the Commission in 
1989. 
Table 1-1: International classification of epilepsies and epileptic syndroms 
Localization-related (focal, local, partial) epilepsies and epileptic syndroms 
a. Idiopathic with age-related onset 
1. Benign childhood epilepsy with centrotemporal spikes 
2. Childhood epilepsy with occipital paroxyms 
b. Symptomatic 
II. Generalized epilepsies and epileptic syndroms 
a. Idiopathic with age-related onset 
1. Benign neonatal epilepsy 
2. Childhood absence epilepsy (Pyknolepsy) 
3. Juvenile myoclonic epilepsy (impulsive petit mal) 
4. Juvenile absence epilepsy with generalized tonic-clonic seizures on 
awakening. 
b. Secondary (idiopathic or symptomatic) 
I. West syndrome (infantile spasms) 
2. Lennox-Gastaut syndrome 
c. Symptomatic 
I. Nonspecific etiology (early myoclonic encephalopathy) 
2. Specific syndromes (epileptic seizures that may complicate many 
diseases, e. g Ramsay Hunt syndrome, Unverricht's disease) 
Modified and abbrevaited from Commission(1989) -(Mattson RH 1995) 
As for seizure types, there are categorically classified into three main groups 
[International League Against Epilepsy, 1989]. These are partial seizures beginning 
locally, generalized seizures (convulsive or nonconvulsive) and lastly seizures that are 
unclassified. (Table 1-2) The unclassified epileptic seizures include some neonatal seizures 
which can feature as rhythmic eye movements, chewing and swimming movements. 
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Table 1-2: International classification of epileptic seizures 
Partial (focal, local) seizures 
a. Simple partial seizures 
b. Complex partial seizures 
1. with impairment of consciousness at onset 
2. simple partial onset followed by impairment of consciousness 
c. Partial seizures evolving to generalized tonic-clonic seizures (GTCS) 
1. Simple partial seizures evolving to GTCS 
2. Complex partial seizures evolving to GTCS, including those with 
simple partial onset 
II. Generalized seizures (convulsive or nonconvulsive) 
a. Absence seizures 
b. Atypical absence seizures 
c. Myoclonic seizures 
d. Clonic-tonic seizures 
C. Tonic clonic seizures 
f. Atonic seizures 
III. Unclassified epileptic seizures, including some neonatal seizures 
Modified and adapted from commission (1981) - (Mattson RH 1995) 
1.3 ANTIEPILEPTIC DRUGS 
Antiepileptic drugs are drugs that are used in the treatment of epilepsy. They are 
usually administered over a long period, and will decrease the incidence or severity of 
spontaneously seizures occurring in patients with epilepsy. Among the commonly used or 
established antiepileptic drugs are phenobarbitone, phenytoin, carbamazepine and sodium 
valproate [Gardner-Thorpe et at 1977]. Phenobarbitone was the earliest drug to be used in 
the treatment of epilepsy in 1912 while sodium valproate was licensed for clinical use in 
the United Kingdom in 1973. The four drugs are structurally different and their 
mechanisms of actions are still not clearly defined. 
The use of newer generation AED such as vigabatrin, gabapentin, lamotrigine 
topiramate, felbamate etc are however dependent on availability and on the licensing 
conditions in each country. Vigabatrin, gabapentin, lamotrigine and topiramate have been 
used in the United Kingdom since 1996 for partial and secondarily generalized seizures. 
All four drugs are currently used in adults while vigabatrin and topiramate are also 
recommended for use in children [BNF 1996]. As for the United States, these four drugs 
and felbamate have being approved for use since 1996 [Dichter and Brodie 1996]. Others 
that include clobazam, oxacarbazepine, tiagabine and zonisamide are currently being 
approved for use in certain countries in Europe, Canada and Japan. The use of these drugs 
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in epilepsy are standardised worldwide and table 1-3 and 1-4 summarizes the selection of 
standard antiepileptic drugs and the dosage guidelines in adults and children. 
1.4 MECHANISM OF ACTIONS OF ANTIEPILEPTIC DRUGS 
1.4.1 The Established Few. 
Carbamazepine is a iminodibenzyl derivative and chemically related to the 
tricyclic antidepressants. It is a neutral compound and poorly soluble in water. Phenytoin 
is an hydantoin derivative, poorly soluble and a weak acid. As for their mechanisms of 
action, both have been shown to interact with voltage-dependent sodium channels at 
concentrations found free in plasma [MacDonald RL 1989]. These drugs were 
demonstrated to reduce the frequency of sustained repetitive firing of action potential in 
neurons in cell culture [McLean and McDonald 1983]. Antiepileptic drug action appeared 
to be caused by a shift of sodium channels to an inactive state that was similar to the 
normally occurring inactive state but from which recovery was delayed. 
Phenobarbitone is found to enhance GABA receptor (GABAR) activity by 
binding to an allosteric regulatory site on the receptor site on the receptor. Results from 
fluctuation analysis suggest that phenobarbitone increase the mean channel-open duration 
of GABAR currents without altering channel conductance [Olsen RW 1987, MacDonald 
et al 1989b, Twyman et al 1989]. Sodium valproate is a short chain fatty acid and is only 
slightly soluble in water. Its effect on sodium channels has been less studied but is found 
to block sustained high-frequency firing of neurons in culture [McLean et al 1986a]. 
Both phenytoin and carbamazepine have a wide spectrum of activity covering 
partial, generalized and unilateral seizures. Sodium vaiproate, although having some 
activity against all three types of seizures, is more well known for its efficacy against 
primary generalized seizures with particular value in idiopathic generalised seizures. 
Phenobarbitone activity is more restricted to partial seizures and tonic, clonic or tonic- 
clonic seizures [Shorvon S 1995]. 
1.4.2 The Newer Generation Antiepileptic Drugs 
The newer AED such as gabapentin, lamotrigine and felbamate are used as an 
add-on drugs in adults with partial or secondarily generalized seizures. All the three drugs 
have no published target range for serum concentrations but, a minimum of 2 ug/ml and a 
4 
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maximum of 20ug/ml is observed to be effective for gabapentin. As for lamotrigine, 
serum concentrations higher than 10 ug/ml are tolerated by most patients [Dichter et al 
1995]. 
The mechanism of action of gabapentin is still unknown, but it is observed to bind 
to a specific receptor in the brain, [Hill et al 1993]. This inhibits the voltage-independent 
sodium currents [Wamil et al 1994] and may enhance the release or actions of alpha- 
aminobutyric acid [Kocsis et al 1994]. Lamotrigine however has similar antiseizure and 
mechanism of action to that of phenytoin and carbamazepine [Cheung et al 1992]. As for 
felbamate, which is also prescribed in children with partial or generalized seizures 
associated with the Lennox-Gastaut syndrome, is thought to enhance the inhibitory 
actions of alpha-aminobutyric acid, and blocks N-methyl-D-aspartate receptors [Rho et al 
1994]. Table 1-5 lists the mechanism of action of the antiepileptic drugs described above. 
1.5 Pharmacokinetic model 
By the word 'pharmacokinetic' is meant the application of kinetics to pharmacon 
which is a Greek word for drugs and poisons. World Health Organisation however 
defined pharmacokinetics as'the study of the absorption, distribution, metabolism, and the 
excretion of drugs'. Objectively, the purpose of pharmacokinetics studies are to reduce 
data to meaningful figures or parameters, to use the reduced data to make predictors of 
results of future experiments or predictors of results of a host of studies. 
By modelling in pharmacokinetics analysis is meant displaying results in different 
representations. Shahin et al 1984 defined the essence of model building as; 
"Model building is as much an art as it is a science. It involves intuition, 
imagination, and skill. It is impossible to state a set of rules to build a 
mathematical model as much as it is not possible to draw a picture or 
paint a landscape following a list of regulations. It depends upon the 
viewpoint and judgement of the modeler to decide what information 
should be included or emphasized and to what extend in the model. 
However, it is possible to offer a set of guidelines or a framework around 
which the modeler can develop and improve his skill and imagination to 
build a model" 
Basically, there are three important reasons for modelling; descriptive, predictive 
and explanatory. Descriptive modelling approach is when the data is described in a 
simple, efficient and easily communicated means. This is usually in the form of graphs 
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such the scatter plot or line graph where certain specific measurements such as clearance 
can be calculated using the area under the curve (AUC) methodology. Descriptive models 
are thus attempting to relate the interaction of a drug to a biological environment by 
choosing a mathematical model and using the data to define values of unknown model 
parameters. The model parameters, determined from the fit of the model to the observed 
data, also function as measures for comparisons of results both within and between 
experiments. 
The second reason for modelling is its predictive capabilities. Studies on time 
course after multiple dosing based on a single data or determination of absorption profile 
of a certain drug would certainly benefited by pharmacokinetics modelling. Modelling in 
this case offers an easy and flexible method of predicting certain unknown relationship 
between two determinants. 
Pharmacokinetic modelling is useful in explaining unclear or unusual observation. 
A clear example is the model to elucidate the outcome of complex mechanism such as the 
glucose-insulin model [Ackerman et al 1964 & 1965]. Other good examples are 
phenytoin capacity-limited metabolism [Arnold & Gerber 1969, Lund et al 1974, Chang 
& Glazko 1982] and carbamazepine autoinduction properties [Rapeport et al 1983, 
Bertilsson & Tomson 1986]. 
In most pharmacokinetics studies, the estimation of parameters from condensed 
data is critical. The quantification of parameters from the system kinetics is best assumed 
by some form of pharmacokinetics modelling. This is an important aspect since the 
parameters are actually numbers that quantitate the pharmacokinetics of the system 
studied. 
1.5.1 Constants, parameters and variables 
These expressions are commonly stated in pharmacokinetics modelling. The 
meaning of each can be easily explain by the following simple model; 
Cr = 0. e "k' (egn. 1.0) 
V 
where D(dose) is a time constant of known value and stays constant. Volume of 
distribution(P) and the elimination rate constant(k) are parameters to be estimated by 
fitting the model to the data. Time(t) and model predicted concentration(C: ) are variables. 
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The relationship between observed and predicted variables and the measurement error(s) 
is given by ; 
C= Cd +E (egn. 1.1) 
where Cd can be a time value or a mean value. 
Since pharmacokinetics modelling involves some form of regression, the main 
goal is to understand how a response variable example concentration or effect, depends on 
one or more predictors such as dose, clearance, time, age, weight and even concentration. 
The response variable is called dependent variable, and the predictor variable may be 
called independent explanatory variable or covariate. 
1.5.2 Parameter estimates 
i. Linear and non-linear models 
Assuming a series of concentration(Yth) and N as the number of observation being 
denoted by the following model; 
Yrrh =f (Xd. ßd) +e (eqn. 1.3) 
Xd = (x1, X2,....... ) (egn. 1.4) 
ßd = (ß1, f32 ........ ) (egn. 
1.5) 
where Xd is the vector of independent variables corresponding to the observation and ßd 
signifies the vector of model parameters which must be estimated. The function f (Xd. ßd ) 
represents the true deterministic concentration corresponding to Xd and ßa, and e denotes a 
random unobservable error. The distribution of error( c) is assumed as normal, and has a 
mean of zero and a variance of a2. 
C= N(0, off) (eqn. 1.6) 
Except for the magnitude of the random error e, given the values of X and A, the 
exact value of Y can be determined. This model is then said to be deterministic and termed 
as linear if, 
f( d9 ßd) = Xd " 
ßd (egn. 1.7) 
i. e, f is the product ofXd and ßd. Examples of linear models are; 
Y=0+ ßI . Xd (eqn. 1.8) 
Y=dP+p. Xd + P2. Xd 
The first model is a simple linear model and would appear as a straight line with 
intercept ßo and slope ßl. Equation 1.8 is a quadratic regression model and may not 
10 
appear as a straight line. However, this model is still considered linear because it is a 
linear function of the parameters of (3j and (32. 
It is possible to determine if a model is linear by looking at the associated partial 
derivatives. As an example, in equation 1.8 the partial derivative of ßo is 1, ßl is Xd and 02 
is d 2. Since none of these derivatives involved ß, ß, , and P2, the model 
is said to be 
linear. 
A non-linear model is the opposite of a linear model where the partial derivatives 
are inter-dependent, i. e 
'ß2 Xd 
Y= (3o + (3i. e (egn. 1.10) 
For the above equation, the partial derivative of 01 clearly depends on ß2. Another 
characteristic of a non-linear model is Ycannot be expressed as a product ofXd and ßj 
Finally, linear pharmacokinetics models such as the first order kinetic models are 
generally non-linear regression models; 
C(t) = D. e 'IV (eqn. 1.11) 
in which case, k and V vis-a vis are the dependent variable of C(t), while C(t) and k is not 
directly proportional to each other. However, the non-linearity can be linearized by taking 
the logarithm of both sides of the equation. 
1.5.3 Criteria for best fit - Minimisation methods 
The three most used criteria for best fit are the ordinary least square(OLS), 
weighted least squares(WLS), and the extended least squares(ELS). These criteria are 
achieved by minimizing the following quantities which are often called objective 
function(O) ; 
n 
flocs =I (Ci - Cdi)2 (eqnl. 12) 
i=1 
n 
- Cdi)2 owls = EWi. P (eqn. 1.13) 
i=1 
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n 
OELs = E( (Ci - Cdi)2 + lnVar(Cdi)J (egn. 1.14) 
i= 1 
where Cdi denotes the predicted value of Ci based on the model. 
The correct criteria for best fit depends upon the assumption underlying the 
functional form of the variances of the dependent variable C. The most commonly 
employed variance model is ; 
Var(C) = 02. f(Xd, )6d)'l (eqn. 1.15) 
Draper and Smith (1981) defined the theoretically correct weight based on the 
maximum likelihood consideration as the reciprocal of the variance of the observation. 
This gives large variances less weight as compared to small variances. 
The value and accuracy of the three equations depend on the X. If X=0, variances 
of C; are identical and constant, OLS, WLS and ELS are equivalent. However, if the 
weights are constant ( which means it does not involve any parameters which must be 
estimated), then estimation of parameters using WLS and ELS is equivalent. 
The suitability for any type of least square methodology in modelling also depends 
on the function of Xd and Pd. WLS is appropriate when the variance is some function of 
the Xd only. If it also depends on ßd, then the modified version of the WLS least square 
namely called the iterative reweighted least square(IRLS) is more appropriate 
[Gabrielsson and Weiner 1997]. 
ELS, which employs a maximum likelihood procedure [Sheiner and Beal 1985], 
estimated the value of %. Gabrielsson and Weiner (1997) commented that this method 
offers no practical advantage over IRLS and can produce parameters more biased or have 
greater variability than those produced by IRLS [Metzler 1987, van Houweligen 1988]. 
1.5.4 Pharmacokinetics compartmentalisation 
The metabolism of drugs occurs mainly through the liver and is dependent on the 
capacity of the drug metabolism system. Drug metabolism in the liver enzymes is capacity 
limited and hence the kinetics are non-linear when the entire concentration range of 
substrate(drug) is considered. The limitation may arise because of the limited amount of 
12 
enzymes, limited amount of co-factors involved in biotransformation, and a limited 
amount of reactant as in the availability of sulphate in sulphate conjugation. 
Two pharmacokinetics models that best describe this behavior are the linear 
compartmental and non-linear compartmental model. Linearity is a term defined by the 
indicator that for a given drug and individual all concentration-time profiles that are 
normalized for time and size should be superimposible. Non-linearity thus implies that 
such profiles are not superimposible due to one or more time and dose-related 
dependencies [Rowland and Tozer 1989, Tozer et al 1981]. Basically, linearity is a direct 
proportion of transfer rates to concentration or concentration differences. An important 
consequence of a linear system on pharmacokinetics is that the total area blood(plasma or 
serum) concentration, and time curve following intravenous administration is a linear 
function of the dose administered. 
The compartmentalized system in pharmacokinetic modelling is referred to as an 
approximation of the biological system. For example, a one compartment model for a 
single intravenous dose has five main assumptions. The first is the `body', in this case the 
human body, is represented by a single compartment with volume V. Secondly, there is no 
distribution phase. Thirdly, the single dose is put instantaneously into a single 
compartment at time zero. Fourthly, unchanged drug is measured in plasma and the 
plasma concentration is assumed to be C at time t. Finally, loss from the `body' is 
assumed to be first order(linear relationship between concentration against time) and the 
elimination rate constant is represented by k. 
Pharmacokinetics models are equations or sets of equations which describe the 
proposed system. The schematic diagram that is sometimes employed is not a 'model' but 
rather a pictorial representation from which the appropriate mathematical equation can be 
derived. Further explanation is given in section 1.5.5 
1.5.5 Blood levels of drug at the equilibrium state after multiple dosing 
There is ample evidence [Steward et al 1938, De Jongh et al 1948, Van Gemert 
and Duyff 1950, Burns et al 1953, Wigand et al 1963] that when a fixed dose of drug is 
administered in fixed multiple-dose regimen, the blood levels of drug will eventually 
reach a steady state. In this event, the blood level time curve during any dosage interval is 
the same as it is in the preceding and in the following dosage interval. This equilibrium 
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state is defined as the condition in which input of drug to the body' is equal to output of 
drug from the body in a given dosage interval. 
Wagner et al (1965) derived an equation which can be used to predict the average 
blood levels during multiple-dose regimen from basic parameters estimated from single 
dose studies. The equation is; 
C=F. D (Eq. 1.16) 
Vd. Ke. z 
where C is the average blood concentration, F is the fraction of each dose which is 
absorbed (bioavailability factor), D is the dose(weight) given at the beginning of each 
dose interval, Ke is the first order rate constant for overall loss of drug from the blood, and 
Vd is the apparent volume of distribution of the drug. Equation 1.16 will hold under the 
following conditions, (a) transfer from the blood is first order, (b) F, D, Vd, Ke, and 'c are 
constant for each dose of a multiple-dose regimen in a given patient, and (c) input to the 
blood and transfer from the blood to any number of possible compartments and back to 
the blood may be described by a system of simultaneous linear differential equations. 
However, this equation will be invalidated by several known phenomena ( Table 1-6 ) 
i. Carbamazepine, sodium valproate and phenobarbitone 
The pharmacokinetic model for the three antiepileptic drugs at steady-state is 
often depicted basically as one compartmental [Rawlins et al 1975, Kudriakova et al 
1992, Yukawa et al 1992, Botha et al 1995a, Bruni et al 1978, Botha et al 1995b] and thus 
fulfils the above conditions. Based on this, the proposed schematic model is as follows, 
Ka Ke 
FDFC, > 
Figure 1-1: The proposed model for carbamazepine, sodium valproate and 
phenobarbitone at steady-state. 
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where F is the bioavailability, D is dose, Ka, is the absorption rate constant, C is serum 
concentration, Vd is the volume of distribution, and Ke is the elimination rate constant. In 
chronic therapy (steady-state), rate of absorption is assumed to equal to rate of 
elimination. The formula to estimate the relationship of variables such as volume 
distribution(Vd), apparent elimination rate constant(Ke), and clearance(Cl) from the 
corresponding serum concentration(Css) and dose was determined by Wagner et al 
(1971); 
C. = Dose. F 
Vd. Ke. T 
(eq. 1.17) 
where F is the bioavailability factor and T is the dosage intervals in hours. 
However, the relationship between dose and clearance can be estimated as 
follows; 
since Cl = Ke . Vd (eq. 1.18) 
then Cl = Dose. F (eq. 1.19) 
Css. T 
ii. Phenytoin 
Chemically named as 5-5-diphenyl-2,4-imidazolidinedione is a drug 
unquestionably difficult to interpret. Three dosage forms are currently available for oral 
administration. Both phenytoin acid and phenytoin sodium are in tablet or capsule form 
but, the suspension form is currently available. The important difference between 
phenytoin acid and phenytoin sodium is the salt form factor(S) of 0.92 and 1 [Winter and 
Tozer 1991] respectively. This factor is important since their bioavailability(F) had been 
shown to be substantially different. However, Jusko et al (1976) demonstrated that 
bioavailibility can be almost unity for high quality products. 
Phenytoin exhibits a so-called capacity-limited or saturable metabolism [Winter 
and Tozer 1995] where at near optimum therapeutic concentration there is a 
disproportionate increase in the plasma concentration as the rate of administration is 
increased. Figure 1-2 highlights a model for the kinetic behaviour of phenytoin. 
Phenytoin elimination appears to be rate-limited by a single metabolic step, 
presumably to an epoxide intermediate. It is characterized by the Michaelis-Menten 
enzyme kinetic parameters Km and Vmax. This phenomenon is assumed to follow 
16 
Michaelis-Menten kinetics in which the rate of the metabolism( v) is dependent upon the 
substrate concentration in plasma Cp. 
Figure 1-2: Pharmacokinetics model associated with phenytoin administration. 
Absorption Phenytoin Vmax, Km 
in body 
phenytion 
in urine(1-5%) 
.i 
Phenytoin "epoxide" ""º 
where Vmax is the maximum rate of metabolism (metabolic capacity) in milligram per 
day, while Km is a constant with a value equal to the plasma concentration at which the 
rate of metabolism is one-half of the maximum. Some elimination occurs by renal 
excretion but its contribution is negligible. 
v= Vmax . Cp (Eq. 1.20) 
Km + Cp 
Consequently, capacity-limited metabolism is most readily observed at steady- 
state. This is usually in chronic therapy where the drug is administered at a fixed rate(R) 
until the rate of elimination and the dosing rate(S. F. R) are equal. 
S. F. R = Vmax . Css (eq. 1.21) 
Km . Css 
where S is the salt factor, F the bioavailability ,R 
is the dose, and Css is the serum 
concentration at steady-state. Equation 1.21 can be rearranged or linearized to; 
S. F. R 
S. F. R= Vmax - Km. (eq. 1.22) 
Css 
where [S. F. R / Css] is conventionally called clearance, i. e, it is the parameter that relates 
the rate of elimination to the plasma concentration. A plot of clearance versus dose would 
give a straight line with the y-intercept as the Vmax and the slope as the Km. 
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1.5.6 What is the "Therapeutic Window" concept? 
Most antiepileptic drugs have attributed to them a so-called "therapeutic range" or 
"therapeutic window". By definition "therapeutic range" is a range of concentrations 
within which the drug is effective and the probability of unacceptable toxicity is low. 
Below this range the probability of a positive response is considerably less and above the 
range there is a considerably increase in the probability of toxicity without any appreciable 
increase in response [Evans 1991]. Hypothetically, the potential benefits of achieving a 
drug concentration in the therapeutic range would ensure that the optimum clinical 
efficacy of the drug can be achieved. 
Figure 1-3 : Relation between drug concentration and drug 
effects fora hypothetical drug 
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This concept can be depicted graphically in Figure 1-3 for a hypothetical drug. As 
can be seen, the probability of the desired therapeutic effect is very low (i. e, <5%) when 
drug concentrations are low ( i. e, <5ug/I ), as is the probability of toxicity. These 
reasonable conclusions cannot deny the fact that some small possibility of either the 
desired response or toxicity even in the absence of a measurable drug concentration. Such 
incidence would be expected in a large study, assuming that some patients will recover 
spontaneously without any drug therapy, and that some will develop an adverse effect 
which is unrelated but coincidental with drug administration. More importantly, as drug 
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concentration increases between 5 and 1 Oug/l, the probability of response increases from 
less than 20% to 75%, then plateaus. Over the same concentration range, the probability 
of toxicity increases more slowly, from less than 5% to only about 10%, then begins to 
increase more rapidly as concentrations exceed 7ug/l. 
Table 1-7: Clinical situations and times in which antiepileptic drug blood 
level determinations can be valuable 
After starting therapy 
Phenytoin (after 2-3 weeks) 
Carbamazepine (at 3,6,9 weeks) 
Valproate (after 3-4 days) 
After adding or discontinuing other drugs 
Possible toxicity ( measure peak level) 
Breakthrough seizures ( measure trough level) 
Suspected compliance 
Adapted from Mattson RH 1995 
Despite the value of therapeutic drug monitoring in epilepsy, several factors 
complicate its individual use. They are individual seizure frequency patterns, spectrum of 
activity of AED, therapeutic range of AED and significant differences in patients' ability 
to absorb and metabolize these drugs [Welty et al 1983]. However, there are certain 
clinical situations and times when serum determinations are valuable. Among them is 
during initiation of therapy and when toxicity is suspected (Table 1-7). 
Table 1-8 Therapeutic range and pharmacokinetics data's important during 
interpreting blood levels ofAED 
Steady-state 
Drugs Time to staedy Target serum Half-life Absorption (F)- Vd (LIkg) Protein 
state(days) levels(mg/Ly (hour) % bindin 
Phenobarbitone 14-21 15-40 100 slow(90-100) 0.6-1.0 48-54 Phenytoin 7-28 10-20 24b slow(85-95) 0.5-0.7 90-93 
Carbamazepine 3-4 4-12 24-35c slow(75-85) 0.8-1.6 70-80 
10-15° 
Valproate 2-3 50-120 10 rapid(100) 0.1-0.2 88-92 
'; Lower or higher concentrations may be optimal for some patients, ; Concentration-dependent '; At initiation, °; Chronic administration 
Adapted from : Mattson RH 1995 
Individual seizure patterns vary from patient to patient. Those with frequent 
seizures tend to respond to therapy quicker while patients with seizures at long intervals 
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may require consistent treatment for a considerable period before the success or failure of 
a drug regimen is known. 
Spectrum of activity for AED is fairly well defined but until now there is no in 
vitro test for sensitivity of the seizure to a particular drug. Drug therapy is entirely 
dependent on accurate diagnosis of a seizure disorder by means of the clinical 
presentation and encephalographic studies [Scheuer and Pedley 1990]. 
Measurements of total serum levels are however questionable since these drugs 
are known to be heavily protein bound and the unbound or free drug fraction is the active 
component. The metabolites of these antiepileptic drugs are also not inert. Some 
antiepileptic drugs (AED) have metabolites that appear to contribute to therapeutic effect 
but not routinely monitored. These include the 10,11-epoxide of carbamazepine [Faigle et 
al 1977] and phenylethylamonamide derived from primidone [Schottelius 1982]. Again, 
measurement of total, the free form and metabolites are not usually available and are 
costly to undertake. 
The current therapeutic ranges that are widely used for phenytoin, phenobarbitone, 
carbamazepine and sodium valproate are summarized in table 1-8.. These values are still 
not absolute and other ranges are also recommended [Welty et al 1983, Shorvon 1995]. 
Routine serum measurement is controversial because a single serum measurement yields a 
good approximation of a steady state only for antiepileptic drugs with long half-lives. 
These include phenytoin and phenobarbitone but those with short half-lives, such as 
sodium valproate, where random measurement are virtually unpredictable [Loiseau et al 
1982] due to the wide fluctuation in concentration over a 24 hour period [ Rowan et al 
1979]. 
There are further reasons for doubting the value of AED blood monitoring. The 
upper limit that is defined as the concentration at which toxic effects are likely to appear 
but this is most consistent only for phenytoin. But even then some patients can tolerate of 
serum levels greater than 20ug/ml [Gannaway et al 1981]. The lower limit is difficult to 
define and many epileptic patients are controlled by serum concentrations well below the 
optimal range [Turnbull et al 1985]. A study by Dooley et al (1993) further showed 
discrepancies among paediatric neurologist regarding the upper and lower limits of the 
therapeutic ranges and the clinical application of levels. They also suggest that both the 
value and use of antiepileptic drug level need further study. 
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1.6 Controversial issues about antiepileptic drugs 
Although the theories of therapeutic window and therapeutic ranges have been 
well accepted, complications occur when these concept are implemented across 
population. As yet, no review has ever been undertaken to confirm the existing findings. 
Reviews of the therapeutic range for these antiepileptic drugs(AED) are hindered by 
insufficient clinical trials or limitations of AED studies itself. This has resulted in 
inconsistent and contradictory conclusion. Thus, Delgado Escueta et al (1983), outlined 
specific principles in designing clinical trials for AED. Mattson et al (1983) subsequently 
proposed both selection or inclusion and exclusion criteria in designing prospective 
evaluation of AED for adults. Looking further, a method of quantification for the 
evaluation of AED drug therapy was recommended by Cramer et al (1983). 
Currently, the uses of these drugs in treatment are highly individualized. However 
several studies have reported population-based and individual-based pharmacokinetic data 
for specific patient groups aiming primarily to simplify and improve drug treatments. 
These pharmacokinetic data were derived using mathematical and statistical computer 
software. However, population-based and individual-based pharmacokinetics data from a 
specific group cannot necessarily be used on another group of patients and such 
application can lead to treatment failure. Although the drugs have long been recognized to 
display large inter-individual variations, the value of inter-ethnic differences are however 
rarely studied [Edeki and Brase 1995]. This raised the issue concerning its unknown 
relationship to ethnicity and possibly the need to have ethnic-based population 
pharmacokinetics. 
Studies on ethnic differences are few and often contradictory. Although most 
results showed that it is not an important contributory factor, conclusions about the dose 
and the efficacy of AED are made solely from results obtained from the western 
population and those of the Japanese community. Dam et al (1977) have indicated that 
ethnic differences may have significant influence on the plasma clearance of antiepileptic 
drugs. Peiris et al (1988), found otherwise in that there is no systematic significant 
difference in pharmacokinetics between Sri Lankan and European population. 
Unfortunately, they further commented that the Sri Lankan population used were not a 
representative sample of the epileptic patients population and care should be exercised in 
generalizing the results. 
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Studies and reviews on the interethnic variation of metabolism and disposition of 
phenytoin among different ethnic groups have yet to be quantified. The theory of 
polymorphism has been attributed to phenytoin and is linked to certain specific genes 
[Wilkinson et al, 1980]. Essentially phenytoin is metabolized to the glucuronic acid 
conjugate of the (S)-enantiomer of 5-(4-hydroxyphenyl)-5-phenylhydantoin by the P450 
hepatic enzymes, specifically by cytochrome P4502C9 [Veronese et al, 1991, Veronese et 
al, 1993]. Individuals who have a deficiency of these enzymes are termed as poor 
metabolizers in contrast to extensive metabolizers who have no enzyme's deficiency. Poor 
metabolizers are homozygous for an autosomal recessive trait affecting the P4502C9 
gene. Studies on familial [Kutt et al 1964, Vasko et al 1980, Vermeij et al 1988] and 
interethnic differences [Arnold and Gerber 1970, Andoh et al 1980, Kromann et al 1981] 
distinguished its importance especially in decisions regarding dosing. 
Carbamazepine has been known to have autoinduction properties but recent 
reports showed it too have inter-ethnic differences. These reports were from three Asian 
countries namely Japan [Yukawa et al 1996], South Korea [Yoon et at 1996] and Taiwan 
[Lin et at 1991]. However, no similar studies on sodium valproate and phenobarbitone 
have been reported although these drugs also showed large interindividual dose and blood 
concentration variation. 
The above variations in therapeutic response are linked with the current 
information above the relevance of heredity to person-to-person differences in response to 
drugs and environmental substances [Weber WW 1997]. These variations or currently 
known as pharmacogenetics variations have led to investigators examining the 
relationship between the metabolic fate of a foreign chemical(drug) in humans and the 
genetic control of human drug response. 
1.7 What is pharmacogenetics ? 
"Pharmacogenetics" studies were started about 40 years ago when early 
investigators realized the genetics approach to human response to foreign chemicals. With 
the availibality of modem technology, they managed to separate similar proteins and 
distinctive patterns of drug metabolites to be identified in different individuals. 
Pharmacogenetic is then defined by Freidrich Vogel as a study of the effect of heredity on 
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drug response. It is an experimental science concerned with person-to-person differences 
in drug response that arise because of the unique genetic constitution of individuals. 
1.7.1 Human variation in drug response. 
The principles of pharmacokinetics are extensively used in the investigation of the 
pharmacology and interindividual variability in human drug response. These studies 
elucidate quantitative relationships between the response of individuals to a given drug 
and the levels of the drug and its metabolites in fluids and tissues. By doing this, the 
pharmacological mechanism for the person-to-person variability can be unravelled and 
can be characterized to a particular pharmacogenetic trait. Mathematical expressions that 
relate drug concentrations to other standard pharmacokinetic parameters such as dose, 
dosing interval, bioavailability, rate of elimination, apparent volume of distribution, half- 
life, and clearance are often adopted to define the relative importance of absorption, 
distribution, and elimination in the response or collectively known the pharmacokinetics 
of the drug.. 
Figure 1-4: Profile of human drug response [adapted from Weber WW 1997] 
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The pharmacological profile of human drug response can be briefly presented in 
figure 1-4. Drug response begins the moment the drug is administered and enters the 
blood stream and ceases when the drug and its metabolites are completely eliminated. As 
elimination proceeds, three mechanisms that can affect the disposition of the drug to the 
recipient will occur. First, the drug will move forth and back between the blood stream 
and fluids and tissues, or it may be transformed if it comes into contact with the enzymes 
of the liver and other tissues, or a portion of the drug might bind to receptors within or on 
the cells that result in the characteristic response. 
These responses are reversible and short-lived since elimination is essentially 
complete within a few hours or a few days after exposure to the last dose. Responses may 
be prolonged if the amount of drug metabolised is small and the drug tends to accumulate 
in certain tissues such as fat, kidney, lung or bone. In this case, the drug may persist at 
very low concentration at receptor sites for long periods thereby extending the duration of 
response. 
Table 1-9: Person-to-person variation in plasma elimination half-life 
values for several agents widely used in medical theranv 
Drug Variation 
Half-life 
Fold variation 
Antipyrine 5-15 hours 3 
Carbamazepine 18-55 hours 3 
Dicumarol 7-74 hours 10 
Indomethacin 9-53 hours 6 
Isoniazid 0.5-7.5 hours >10 
Rapid acetylators 0.5-1.8 hours >3 
Slow acetylators 1.8-7.5 hours >4 
6-Mercaptopurine <0.5->1.6 hours >3 
Nortriptyline 15-90 hours 6 
Phenylbutazone 12-73 days 6 
Phenytoin 10-42 hours 4 
Primidone 33-12.5 hours 4 
Tolbutamode 410 hours 2.5 
Warfarin 15-70 hours >4 
1.7.2 Studies on pharmacogenetic- pharmacokinetics diferences. 
The extent of intersubject variability in the pharmacokinetics of a given drug is 
demonstrated in table 1-9. The table shows that three established antiepileptic drugs, 
namely carbamazepine, phenytoin and primidone(phenobarbitone) have half-lives varying 
between three and four fold. Pharmacolcinetic variability(half-lives) of this magnitude is 
significantly important since drugs for example phenytoin, which exhibit the so-called 
saturation kinetics ( Michaelis-Menten kinetics ), is link to its two common 
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pharmacokinetics constant ( Vmax and Km ). It has been shown that Km and Vmax can 
vary to at least 16 fold( 4- 60umol/L) and 10 fold(100 - 1000mg/day) [Garrettson & 
Jusko 1975, Eadie et al 1976, Mawer et al 1974, Gerber and Wagner 1972, Allen et al 
1979]. Similarly, the extent of interindividual variability in carbamazepine and primidone 
have made establishing the pharmacokinetics of these drugs difficult. Thus, studies on 
variation of person-to-person (inter-individual) in the pharmacokinetics of antiepileptic 
drugs are critical in ensuring the desired therapeutic response. 
1.7.3 Drug dose-response relationships in pharmacogentics 
Drug dose-response relationships depend on the the drug pharmacological 
mechanisms of response. Currently there are three main mechanisms that are asssociated 
to interindividual variation. These mechanisms are grouped as pharmacokinetic, 
pharmacodynamic and those which are classified as unknown and examples are presented 
in table 1-10. 
Table 1-10: Altered pharmacologic mechanism that contribute to individual 
variation in human drug response 
Pharmacologic mechanism Drug Specific pharmacogenetic trait and 
effect on individual response 
1. Pharmacokinetic mechanism 
-Altered rate of systematic, 
decreased metabolism 
-Altered drug interactions, 
Enzyme inhibation 
Enzyme subrate competition 
2. Pharmacodynamic mechanism 
-Altered abundance or function of target receptor 
Decreased abundance 
-Altered affinity of receptor 
Decreased affinity 
3. Phannacologic mechanism unknown 
-Altered immune response 
Mechanism unknown 
Isoniazid Rapid acetylation predisposes to 
therapeutic ineffectiveness 
Phenytoinrisoniazid Interaction predisposes slowest of the slow 
R&S isomers of acetylator phenotypes to phenytoin 
mephenytoin toxocity 
Insulin Insulin-resistant diabetes mellitus 
Warfarin, dicumarol Altered clotting factor receptor 
predisposes to antocoagulant resistance 
Hepatitis B Vaccine Resistance to hepatitis B vaccine 
The relationship between the dose of a drug administered and its response is 
another important tool to analyze interindividual variability in human drug response. 
There are two ways to apply this concept in the quantitative analysis of drug effects on 
biological systems. The first involves the measurement of the intensity of a specified 
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response relative to the concentration or dose of the drug to produce a graded dose- 
response relationship. Secondly, the measurement of the frequency of the response 
relative to the drug concentrations or doses to produce a quantal dose-response 
relationship. Ideally, the concentration used should be those present at receptor sites, but 
since these are difficult to measure, the concentration of the drug in blood or plasma or the 
dosage, is usually substituted. Both these methods can be employed in pharmacogenetic 
analysis in search of pharmacologic differences between ethnic groups. 
1.8 Conclusions 
Epilepsy is a disease that has yet to be fully understood. Drug therapy has long 
been used in treatment and newer antiepileptic drugs are still ineffective for complete 
seizure control [Pellock 1995]. The complications and difficulty of drug therapy have 
made almost 33% of epileptic patients suffer unnecessary side-effects and poor 
therapeutic response either to a single drug or a combination of drugs [Mattson et al 
1995, Mattson et al 1990]. Although treatment is complemented by the use of the 
therapeutic window concept, population-based and individual-based pharmacokinetics 
and individualized therapy, the search to simplify their use is badly needed. Reports of 
inter-ethnicity differences have paved the way on research towards the concept of ethnic- 
specific therapy. The concept of ethnic-specific population-based pharmacokinetics could 
improve treatment considerably since it can be modelled towards a specific group of 
people. However, the influence of ethnicity on the efficacy of these therapeutic ranges and 
pharmacokinetics of established AED's have yet to be confirmed and this thesis will try to 
assess its importance. 
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Chapter 2 
Objectives 
The objectives of this thesis are based on the use of four established 
antiepileptic drugs, namely phenytoin, carbamazepine, sodium valproate and 
phenobarbitone in five major government-run hospitals in Malaysia. Studies on these 
drugs are important due to the relative lack of pharmacokinetic information on Malaysian 
patients. These drugs are being studied because of three main reasons. The first is their 
characteristics of having a target concentration range or therapeutic window in 
optimizing therapy. Secondly, these drugs tend to exhibit high inter and intraindividual 
variation and finally the concern about reports of inter-ethnic differences in these drugs 
metabolism and pharmacokinetics. These problems are of clinical importance since the 
multi-ethnic Malaysian society of Malays, Chinese and Indian, might display differences 
in handling these drugs and therapeutic responses. 
Information regarding the use of these target range and inter-ethnic differences 
in response is important since the overall treatment outcome may depend on how these 
factors play its part in the final management of disease. Since Malaysian epileptic 
patients are predominantly of Malay, Chinese and Indian origin, this study hope to 
establish the link of the two important characteristics towards drug therapy. 
Determination on the possible differences would benefit the medical care as a whole 
and provide invaluable data in countries such as Malaysia where the stress on research 
and development is currently the main priority. Thus, the main objectives of this 
study are; 
1. to investigate the degree of effectiveness of the present therapeutic range 
among different ethnic groups. 
2. to determine the relationship of dose and serum concentration relationship of 
carbamazepine, valproic acid and phenobarbitone. 
3. to establish the factors( such as age, weight, and ethnicity) which might 
influence the relationship between dose and serum concentration. 
4. to compare the influence of ethnicity on the population pharmacokinetic 
relationship of these drugs. 
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Chapter 3 
Theories and statistical methods used in studies on 
population pharmacokinetics of antiepileptic drugs 
3.1 Introduction 
Pharmacokinetic studies can be categorised into two main types; population-based 
investigation and individual-based (compartmental or non-compartmental) research 
studies [Powers 1993]. Population-based studies investigate pooled drug concentrations 
across more than 1 individual subject. These data are estimated by specially designed 
computer programmes. Although several computer programs have been tried into practice 
[OPT by Kelman et al 1982, MULTI-ELS by Yamaoka et al 1987], NONMEM [Sheiner 
et al 1980] seems to be the most popular to evaluate this information. 
Individual-based pharmacokinetic studies require fewer assumptions and involve 
estimates being calculated for each individual in the study. This requires multiple samples 
from each patient and is best carried out in the laboratory setting. 
Antiepileptic drug population pharmacokinetic values are determined in studies 
either utilizing the traditional (prospective study design) or routine patient data approaches 
[Sheiner et al 1977]. These approaches however, can give different and sometimes 
contradicting findings. Although qualitative reviews have been useful for confirmation, 
the emergence of systematic reviews which verified findings through quantitative 
statistical analysis have meant that uncertainties between different findings can be 
summarised and appraised. 
Comparatively, traditional methods such as prospective studies [Henriksen and 
Johannessen 1982, Mihaly et al 1979] are more controlled and less biased than those from 
routine patient data. Traditional methods are however restricted by problems of cost, 
choice of patients and the lack of serendipity. These problems are not encountered in the 
routine patient data approach and made it more appealing although it has its drawbacks. 
The disadvantages of the routine data approach [Botha et al 1995a] include the 
possibility of bias from concomitant variables that are correlated with included variables, 
reliability and statistical inefficiency. Several statistical methodologies and computer 
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software such as NONMEM and MULTI-ELS has shown reasonable accuracy and the 
problems of data reliability, statistical inefficiency, and methodology can be controlled. 
Although reports of pharmacokinetic studies on these drugs are quite common, 
antiepileptic drug population-based or individual-based studies on specific racial or ethnic 
groups are however rather limited. Reports and reviews on drug metabolism and 
disposition [Hvidberg 19861 had shown that antiepileptic drugs such as phenytoin, do 
exhibit interethnic differences. Statistical methodologies employed in systematic reviews 
can provide the degree of significance and provide power in outcome estimation and 
strengthen the use of population-base studies in pharmacotherapy. Thus, this chapter has 
two main objectives. First, it is aimed to discuss the various methods of estimating 
individual and population-based studies of antiepileptic drugs. Secondly, to highlight the 
importance of employing statistical methods commonly used in systematic review to 
population based studies in order to solve unanswered questions especially in the field of 
medicine. 
3.2 Population-based studies 
The current interest in determining the population characteristics of 
pharmacokinetic parameters describing drug metabolism and disposition have led to the 
great deal of experimental work directed towards it. Population based studies 
characteristically include three main objectives. The first is to estimate the mean values of 
parameters, their quantitative relationship to individual physiology and fmally their 
variability across population [Sheiner et al 1977]. These are particularly important for 
optimal design of dosage regimens for individual patients and to provide information into 
the mechanism by which drugs are absorbed and eliminated. 
The clinical use of pharmacokinetic methods for individualizing drug therapy is 
initiated with the aid of population pharmacokinetic data. A knowledge of population 
pharmacokinetics provides the basis for the initial drug regimen. Usually, one or just a 
few drug concentrations taken from the patient and interpreted in the context of the 
population data enable one to estimate individualized pharmacokinetics which may lead to 
further refinement of the dosage regimen. 
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There are two requirements for applying population data to the individual: 
i. a relevant population pharmacokinetic data base 
ii. a framework for linking patient to the population. 
Population pharmacokinetics thus entails the summarization of pharmacokinetic studies in 
groups of patients and the establishment of relationships between individual patient 
characteristics and pharmacokinetic parameters. 
3.2.1 Statistical methods employed in population-based studies 
Pharmacokinetic parameters such as bioavailability, volume of distribution and 
clearance, have traditionally been estimated by studies of drug disposition in a group of 
homogenous patients. This value is typically termed as population-typical value. This is 
usually in the form of mean or average values. The extent to which these values differ 
from the population is estimated by measuring the interindividual deviation and is term as 
population-variability value. The mean and standard deviation thus summarize the 
population distribution of pharmacokinetic parameters. The mean and standard deviation 
for a "normal" distribution may be interpreted parametrically, i. e, the mean is located in 
the center of the normal distribution and the ± one standard deviation accounts for 68% 
of population values [Hannagan 1986]. For a skewed distribution, the log of the parameter 
often transforms the distribution to a normal curve [Gabrielsson and Weiner 1997]. 
Findings from population based studies described above suffer from inadequacy 
due to restriction in study design. These results are not estimates of `real' population. 
Thus, the Sheiner & Grasela (1991) mixed effect model technique of using information 
generated during routine patient care to estimate population pharmacokinetics should 
provide an alternative in generating results from wide group of individuals. The 
individuals should exhibit a range of patients' characteristics that are thought to influence 
drug disposition. These characteristics should include a group of patients with varying 
disease states, weight, ages, and certain important laboratory tests. This is done 
deliberately so as to establish relationships between individual patient characteristics and 
population pharmacokinetic parameter distributions. The uncovered relationships may be 
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categorically quantitative as in the observation that smokers tend to have 50% to 60% 
higher theophylline clearance values than non-smokers[Matsunga et at 1989]. 
Hashimoto and Sheiner (1991) have compared the population approach with the 
individual-based approach, along with the advantages of having population 
pharmacokinetic data available to estimate pharmacodynamic parameters. Their 
conclusions were; 
i. Even small amounts of pharmacokinetic data, (even if) suboptimally sampled, 
can markedly improve population pharmacodynamic parameter estimates when the 
analysis model is correctly specified. 
The conclusion was however unclear since there was no mention of reasons as to 
why a small amount of sample is adequate to specified pharmacokinetic data study 
designs. 
ii. In general, for both pharmacokinetic and pharmacodynamic data, designs 
involving more individuals, even if many are sparsely sampled, dominate designs calling 
for a more complete study of fewer persons. 
iii. A full population analysis which combines pharmacokinetic and 
pharmacodynamic investigation, generally deals with sparse data more flexibly than 
individual-based analysis. When the model is mis-specified, then a population analysis 
emerges as more powerful than an individual based one. 
iv. Randomising times of sampling for sparse pharmacokinetic data designs in 
general does no harm, and , when the model is misspecified, provides considerable 
protection. Randomising dosages adds useful information and also protects against model 
misspecification. 
Other benefits of the population based approach also require fewer design criteria 
and are adaptable to the clinical setting, i. e subjects can be patients currently being treated 
with the drug under consideration. Another distinct advantage is the flexibility of 
sampling times and the capability of the clinician to use information from the critically ill, 
the geriatric patient or even from the very young. These patients would not be available 
for an individual-based type of study because of the relatively large number of patients 
needed [Powers JD 1993]. 
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3.2.2 Data analysis methods 
Jelliffe et al 1998 summarises population pharmacokinetic models into three main 
categories. These are parametric population pharmacokinetic models[Rowland et al 
1985], semi-nonparametric and hierarchical Bayesian population models [Wakefield et al 
1994 and Davidian and Gallant 1993] and the nonparametric population models [Mallet 
1986 and Schumitzky 1991]. Parametric population modelling methods involved 
estimating means and SD's of the pharmacokinetic parameters, and correlation (or 
covariances) between them. Semi-nonparametric and hierarchical Bayesian population 
models follow the Bayesian strategy of sampling and Bayesian inference about a 
population. Non-parametric population methodology is actually a discrete(not 
continuous), spiky (not smooth) probability distribution in which no preconceived 
parametric assumptions (such as lognormal) have to be made about its shape (Mallet 
1986). 
Basically, the three common methods of population-based pharmacokinetic 
studies of antiepileptic drugs employ the parametric population pharmacokinetic models. 
The first is called the naive pooled data approach, second, the standard two-stage 
approach, and finally the NONMEM approach. NONMEM is an acronym for analysis of 
a non-linear mixed effect model [Sheiner and Beal 1980]. The first method was proposed 
to be abandoned due to inaccuracy and the availability of more precise and robust 
methodology. Two-stage and NONMEM approaches applies parametric strategies in 
pharmacokinetic modelling and NONMEM have since been the most widely used 
population pharmacokinetic computer software in antiepileptic drug studies. 
The limited use of the naive pooled data approach is mainly because of the need 
of an accurate and consistent estimation of both population-based and individualised- 
based pharmacokinetic parameters. The naive pooled data approach lacks this ability since 
the method analyzes all data as though it all come from one individual. If, taking as an 
example, of the famous Michealis-Menten equation as the pharmacokinetic model, 
Rij = Vmj . Cpss, ý (egn. 3.0) 
(Kmj + Cpssü 
Ay = Ry + Ey (eqn. 3.1) 
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where Ru is the weight adjusted dosage rate(mg/kg/day) for the ith pair in the jth patient; 
Vmj is the maximum elimination rate for the jth patient, Cpssy is the steady-state plasma 
concentration(ugiml) measured in the jth patient, and Kmj is the Michealis-Menten 
constant for metabolism in the jth patient. 
Since the naive approach analyses all patients as one single individual, the j 
disappear from the equation 3.0 and 3.1 and the subscript i indexes all R-Cpss pairs. 
Although this method can estimate for population parameters such as Vm and Km and the 
corresponding confidence interval, no estimation of the standard errors(c) for Vm and 
Km are obtained. This method thus measures variability from all sources with no effort to 
determine either intraindividual and interindividual variation. The NONLIN computer 
software for nonlinear least square approach [Metzler et al 1974] provide actual data 
fitting for this method. 
The naive pooled data approach employs regression technique in population- 
based studies. Regression objectively attempts to show the relationship between two 
variables by providing a mean line that best indicates the trend of the points or coordinates 
on a graph. The slope indicates the rate of change in one variable against the other and 
regression shows this slope. Correlation coefficients do not provide any information on 
the slope of the line between two variables. 
The equation that describes a linear regression line is usually in the form of y=a 
+ fix, where a is the intercept and is the ß regression coefficient. Botha and, 8 are used 
as population parameters. The regression equation is an example of what is termed a 
model with which one attempts to model or describe the relationship between y and x. On 
a graph, a is the value of the equation when x=0 and ßl3 is the slope of the line. The 
method of calculating of this relationship is called the method of least squares. 
Since a and /3 are characteristics of a population obtained from estimates from a 
sample of a population, the estimates are labelled as a and b. The estimates of a and b for 
any subject i, xi and y; can be predicted from the estimated regression equation of Yf =a+ 
b x, , where Y is called the residual sum of squares. The regression line is thus drawn 
through the n points on the scatter diagram so as to minimise the sum of squares of the 
distances, y; - Y,,, of the points from the line, these distances being measured parallel to the 
y-axis. This then leads to the value of a and b being called the least square estimates of the 
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population parameters of a and ß. The model is now y, = a+ ßx; + c; = Y; + ei, where E 
are the amount the observed value differs from the predicted from the model and is 
assumed to be normal with the average being equal to zero. 
A linear regression line fitted by least squares can be typically demonstrated by 
the following presentation. The straight line equations ;y=a+ bx, where y and x are two 
variables, a represents the intercept, and b represents the slope or gradient of the line. The 
equations for finding the slope and the intercept are: 
(-) 
b=n (eqn 3.2) 
Its- (TX)2 
n 
or b= (nZvy - FxEy) (eqn 3.3) 
nTic2 - (F. ß)2 
and a=y-bx, where y and x are the mean of the two 
variables. This can be presented by the following simple example ; 
Example 1. The Least square method 
No. Dose(x) Level(y) x2 y2 xy 
11 2 1 4 2 
22 4 4 16 8 
33 9 9 81 27 
44 12 16 144 48 
55 17 25 289 85 
66 10 36 100 60 
sum(E)21 54 91 634 230 
x=21/6=3.5 y=54/6=9, 
b= 230 - (21 x 54)/6 = 2.34 
91 - (21 x 21)/6 
since a=y+b. x, then, a=9-2.34(3.5) = 0.81 
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The equation of the regression line is y=0.81 + 2.34 (x), and graphically shown as 
below. 
Regression equation of dose and level 
18 
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2 
0 
0 
It should be noted that the least square regression technique is limited to linear 
relationship between the variables y and x. As stated earlier(chapter 1), most first order 
models are non-linear, thus transformation by logarithm of data which is crucial for 
linearization(normal distribution) of the model. 
The two stage approach uses each individual patient dose and serum level pairs to 
calculate the parameter estimate. This method does account for intraindividual and 
interindividual variation where the statistical errors(c) of parameters are obtained from 
the residuals of regression. The use of lognormal treatments are not only to transform the 
exponential equation into linearized equations but also to account for any intraindividual 
and interindividual errors in the real world. 
Intraindividual error is meant to represent all uncertainty caused by intraindividual 
time variation in Kmm and Vmj, pharmacokinetic model misspecification, analytical error 
in Cpssy and reporting error in R°y. Interindividual error encompassess all differences 
between individuals such as genetic and ethnic background. Both intraindividual and 
interindividual errors are independent and identically distributed with mean zero and 
variance equal to &. 
Estimation of parameters are obtained from two or more sets of data from each 
individual and the arithmetic average is chosen as the estimated population parameters. 
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The estimate of variance( aE ) for the population is taken to be the square root of the sum 
of the individual residual sums of squares over all individuals, divided by the total residual 
degrees of freedom. The estimate of variance for Vm (a,, ) and Km (ßw) is then estimated 
by the sample standard deviation of each individual. This method is however has its 
limitation in that no confidence intervals or standard errors for estimates(6v. and ßw ) 
can be calculated. 
The NONMEM approach describes by Sheiner and Beal (1980) is currently the 
only method that takes into account the weaknesses of the above methods. The method 
employed the extended least squares approach which is actually the maximum likelihood 
approach and being used widely for all four drugs. Its objective function assumes 
uncorrelated statistical errors having constant variance, where the standard errors and their 
95% confidence levels are easily computed. 
ii. Curvilinear relationship. 
The straight line equation relationship mentioned above is a good empirical 
statement of the relationship between two variables even when the true relationship 
between two variables is more complex than the straight line portrayed. It may be just as 
important to know the exact or approximate "form" of the relationship as it is to have an 
empirical statement of it. For this reason, it is necessary to consider other ways of 
expressing a relationship than a straight line. 
Other ways to represent relationships are by curves. The equations of a number of 
curves which can be useful in statistical analysis of the relationship between variables are; 
Y= a+bX+cX2 (egn3.4) 
LogY = a+bX (egn3.5) 
LogY= a+blogX (egn3.6) 
Y= a+b log X (eqn 3.7) 
Y= 1/(a + bX) (egn3.8) ' 
Y= a+bX+cX2+dX3 (egn3.9) 
Y= a+bX+c(1/X) (egn3.10) 
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Figure 3-1: Curves illustrating a number of different types of mathematical 
functions[ adapted from Ezekiel & Fox (1965) ] 
Y=a+bX+ct 
Y=a+bX+cX2 +dX: 1 
log Y=a+bX+cX2+dX3 
-n4-hIti Y 
I Y=a+bX+C 2 
:a+b (Iog X) +c (Iog X)1 +d (log X)3 
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logY=a+bX+cX2 
In. Y--1 1A Ind Y 
log Y= a+b (log X)+ c (log X) 2 
Figure 3-1 illustrates the different of type of curve for each of the above equations. 
The diversity in the shape of the different curves is striking and the differences in the 
shapes depend solely on the particular form of equation used to compute them. There are 
certain types of relationship that can be accurately represented by each of these equations. 
When it is "fitted" to data where that type of relation is really present, it can give a curve 
that accurately represents the central tendency of the data. However, if the same equation 
is fitted to data for which the underlying relationship follows a different function, the 
resulting curve gives a distorted representation of the true relation. Thus, the 
representation of each equation only shows the relation in so far as it is possible to do so 
within a particular limit. 
3.2.3 Limitation in estimating one variable from one known values of another 
The limitations in estimating one known variable from known values of another 
can be verified by examining the "closeness" with which the line or curve fits the original 
data. This then led to the importance of measuring accuracy of estimate and the degree of 
correlation. 
i. Correlation 
When both x and y are random variables, an index called product-moment correlation or 
simply correlation coefficient may be useful to measure the extent the relationship 
between them. Correlation coefficient (r) can be defined by 
r= LI(x - x)(y - j)I (egn3.11) 
1'II(x - 
z)2L'(. v - y)ZI 
For any set of data, r falls within the range of -1 to +1. r will equal to one if both variables 
increases together, while r will be -1 if one variable decreases as the other increases. 
The squared correlation coefficient (r-squared) is the fraction by which the sum 
of squares ofy is reduced to give the sum of squares of deviations from the regression on 
x. Similarly r-squares values will range from 0 <_ r2 <_ 1. 
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i. Sampling errors in regression and correlation 
The above calculations take into consideration that in the whole population the mean 
value of y does not change with x, i. e the null hypothesis should be ß=0. To test the 
hypothesis, the t distribution test on n-2DF, is employed. 
t=b (eqn 3.12) 
SE (b) 
where b= %3, SE(b) is the square root of the variance of b or alternatively 
t=r f (n-2)/(1-? )J (egn3.13) 
Confidence limits for, 6 or b at 95% level can be obtained as 
bf to . 2,0.05 
SE(b) (eqn 3.14) 
The 95% confidence limits for the predicted value of y at a any value of x, eg. xo is given 
by 
Y±tn 
-2,0.05 So Y 
u1/n+(x0- 
x)2/£(x- x)2] (egn3.15) 
where S. is the residual mean. The width of the confidence interval increases with (xo -x 
2, and therefore a minimum when xo = x. Reason for the increase in width of the 
interval is any slight sampling errors of b will have a greater effect for values of xo distant 
from x than for those near x. 
3.2.4 Multiple regression 
In multiple regression, each individual provides observations simultaneously on 
several variables which then means that the data are multivariate. Thus, in order to explore 
the relationship of one variable to more than one other variable, the method of multiple 
regression is employed. This approach expresses the mean value of the dependent variable 
in terms of a set of other variables, usually termed as independent variables, predictors, 
explanatory variables or covariates. Example of these independent variables could be 
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age, height or arm length. The regression equation can be satisfied if all the variables are 
given in their mean values. Thus, 
y=a+b, x, +bsx2+........ + bpx, (egn3.18) 
where bi, b1, and bp are called partial regression coef cients, a is the intercept. x j, x2, and 
xp are the predictor variables. The number of predictor variables, p, should be less than the 
number of observations, n, and the same p predictor variables must be available for each 
individual in any one analysis. 
By utilizing multivariate regression equations, the final result serves to sum up all 
the evidence of a large number of observations in a single statement. This equation 
expresses in a condensed form the extent to which differences in the dependent variable 
tend to be associated with differences in each of the other variables. 
3.3 Methods for estimating measurement 
Population outcome measurement can be analysed by the use of methods 
employed in meta-analysis. The common analytic theme expressed in techniques for 
combining results across studies is the weighted average of study-specific results. Among 
the statistical methods that are commonly used are those by Mantel and Haenszel (1959) 
and Yusuf et al (1985) (Peto Method), which use the odd-ratios to deal with variability 
among study results. Characteristically, both these methods are very similar and are based 
on a fixed effect model and an explanation for the Mantel-Haenzel method is presented in 
the following example. 
Arrangement of data and table notation for application of Mantel-Haenzel and Petos 
methods 
Treated Not treated Total 
Diseased ai bi gi 
Not diseased ci di hi 
Total ei fi ni 
where ai, bi, ci, di are the number of patients treated and not treated in either disease or 
non-disease group. gi is the total of ai + bi, hi = ci + di, ei = ai + ci and finally fi = bi + 
di. 
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The summary odds ratio of Mantel Haenzel(ORmh) can be calculated by the 
formula 
ORmh _ 
where OR; _ 
while weight; (w; ) _ 
and variance; _ 
95% confidence interval(C. I) 
swn(weiglht; X OR; ) 
sum weight; 
ai x di 
bixci 
1/ (variance; ) 
ni / (bi x ci ) 
95% C'. 1 = e1nORmh 
± 1.96 4 (variance ORmh) 
where variance ORmh is calculated by the method of Robins, Greenland and Breslow 
1986. 
VarianceORmh 
where F 
G 
H 
R 
S 
+ 03 + 31 , ZP 
2D2 2xERx0 22Y 
ai x di x [(ai + di)/ n12 ] 
[aixdi x(bi+ci)+(bixcix(ai+di)] 
nil 
[bixcix(bi+ci)J/nip 
[aixdi]/ ni 
[ bi x ci ]/ ni 
Regression methods have also been used by Steinberg et at (1991) but 
Longnecker et al 1988 used this technique to estimate the slope of the dose-response 
relationship between alcohol and breast cancer adjusting for study quality. The 
combination of means or mean difference across studies is also possible and sometimes 
appropriate [Fleiss 1986 ]. 
The methods described above employed the so-called "fixed effects" models, 
which assume the existence of a single effect of exposure common to all studies. The 
among-study variability in summarizing relative risks and ratios is thus ignored. 
DerSimonian and Laird (1986) proposed the "random effect" model. In this case, the 
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existing studies are viewed as a random sample of a population of studies and treat 
among-study variability as an integral part of the data. 
Population outcome measurement can be from primary or secondary data. Primary 
data are data from true experiments either prospective or retrospective. However, 
prospective data used in meta-analysis are usually gathered from published or unpublished 
literature. This involves an intensive search of all literatures through the electronic 
databases such as the Medline or BIDS, and using specific key words and the percentage 
of recovery is between 80 - 90% [Dickersin et at 1994]. Currently, evidence based 
pharmacotherapy had been using this method extensively for verification of many drug- 
disease problems [Mumford and Dam 1989, Piccinelli et at 1995, Marson et at 1996, 
Marson et at 1997]. 
Primary data from routinely monitored patient's drug serum concentration have 
been used in estimating population pharmacokinetics in phenytoin [Skieiner and Beal 
1980], carbamazepine [Delgado Iribarnegaray et al 1997 ], sodium valproate [Botha et at 
1995b] and phenobarbitone [Yukawa 1991]. The main component of the analysis is to 
obtain a summary estimate of outcome measures and to test for homogeneity across both 
variables and covariables. 
Heterogeneity is a statistical phenomena when a sampling variation is unlikely to 
explain two groups of incidences. This can be due to the trials characteristic are different 
and analysis on the confounding variables needs to be explored. Thus, the following 
methods are recommended. 
3.3.1 Stratified analysis 
This method employed the fixed effect model and is effective either to include and 
exclude any confounding factors involved in the analysis. Fixed effect model is validated 
by the following assumption: a) summary effect estimates(0S) which is calculated from 
each of the individual estimate(0; ), satisfies the distributional relationship OS - N(0;, w; t) 
where 0, is the individual estimate in the ith study. w; is the asymptotic variance 
(reciprocal of weight) of O. b) the weighted summary estimates(w, %) satisfies the 
distributional relationship of w,, O, N(w, O1, w, ") with the null hypothesis of H; : 0; = 0, 
w, 8; - N; (0, w; ). 
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The procedures include grouping each study into different groups according to the 
possible confounders (variables) such as sex, age, race etc and analyzing each group 
separately. The method although simple is restricted as only one or two confounders can 
be investigated [Kleinbaum 1982]. 
3.3.2 Mixed effect regression analysis 
Both of the above methods deal on a fixed effects model. However, when 
heterogeneity across the study still remains unexplained, the mixed effect regression 
analysis should be considered. This method is based on turning the results from a fixed 
effect model into the random effect model where the variations among studies are 
accounted for and a weighted average effect is estimated. It is in fact incorporating the 
meta-regression analysis into the random effects model [Huque 1994] by decreasing 
between study variance. 
This difference between fixed and random effects can be distinguished by the 
following analogy. Let supposed the effect estimate 0 of the fixed effect model that 
satisfies the distributional relationship 8s - N( O j, wi l) , 
is now 6; - N( 0, i 2), where the 
observational effect from each study is independent from N( 0, )[ DerSimonian & 
Laird 1986 ] and tie is the asymptotic variance for each study. This assumption 
theoretically allows heterogeneity across studies by following the marginal distribution of 
6s, that is, 93 -N (0, wi +i 2) =O-N (8, (wj* )"1). The formula to estimate (wj* 
and the steps to undertake the random effect model is as follows; 
1. Step 1 
The effect estimate of 0, can be calculated from the equation given by Whitehead (1991), 
Os = Ewi"81/IwI* (egn3.19) 
Step 2. 
Calculate the statistic(I9 
U= (E'wj*©i)2/Ewi" (eqn 3.20) 
where it follows a chi-square distribution with 1 degree of freedom under the null 
hypothesis, Ho: 0=0. 
Step. 3 
The corresponding approximate 95% confidence interval is 
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O± 1.96 
\(1/ 
w, *) (eqn 3.21) 
where W1* =( wj I +, r 2 )'I, ,r2 is estimated by DerSimonian & Laird (1986), while ti 2 is 
calculated by; 
r2= maz(O, Q- (k- 1) 1 (egn322) 
mow, -(Zw, 
2)/E 
w; 
if r2 = 0, wj+ = wj , the random effects model will produces a result similar to the 
fixed 
effects model. This will then indicate homogeneity across studies. 
Homogeneity test is similar to fixed effect model, using the Q statistic, i. e 
Q=Ew; (0; -05)1 (eqn 3.23) 
which is a weighted sum of squares of deviation. If the treatment effects are homogenous, 
Q follows a chi-square distribution with (k - 1) degrees of freedom. [Cochran 1954]. 
To demonstrate the random effect model, the following example is illustrated. 
Study el WI Wl 
1 0.5 30 7.5 
2 1.0 40 8 
3 1.5 10 5 
For the fixed effect model, the calculation yield 
Zwj =80, Zwi2=2600, Ew}. 01=70,. Ewi. 01 Z=70, 
and the summary effect estimate ( Bs ), 
9S = 70/80 = 
Confidence interval(C. I), 95% _ 
U statistic = 4900/80 = 
Test of homogeneity(Q) _ 
0.9 
0.7,1.1 
61.5 
70-(0.9)2.80 
5.2 (p>0.05) 
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The fixed effect test statistic U showed a highly significant relationship. The test for 
homogeneity also show there is homogeneity across studies. 
If the above data are to follow the random effect model, then the calculation is as 
follows, 
2 = (5.2-2) 
(80 - 2600/80) 
= 0.1 
E w, * = 20.5 
E OJ. w, " = 19.3 
6S = 20.5/19.3 
= 1.1 
U* statistic = 134.7/20.5 
= 6.6(p < 0.05) 
95%, Confidence interval = -0.1,2.3 
The results not only showed a wider confidence interval than that of the fixed effect 
model but also showed that the summary effect is heterogenous. The result higlighted that 
the summary effect is affected by variability between studies. 
3.3.3 Statistical issues in meta-analysis 
Studies that measure effects on a continuous scale are often subjected to meta- 
analysis. Meta-analysis is important since it is able to estimate an overall measure of effect 
and the relationship between disease and some measure of intensity of exposure. The use 
of statistical models in meta-analysis is however useful in examining the reasons for 
heterogeneity or to explore the relationship between various study description and effect 
size. There are methods that are not recommended and these issues will be addressed and 
discussed. 
a. Effect size 
i. Outcome measure of same scale 
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Cochran 1954 described the methods to combine results from different experiment using 
the analysis of variance analogy. Both the fixed and random effect models were described 
extensively and it was its application towards of mixed effect models was also possible. 
Yudkin et at 1991 duly used this method in describing the change in Kutzke disability 
status scale at two years in four randomized trials of the effect of azathioprine treatment in 
multiple sclerosis. 
ii. Effect size of different scales 
This is a method where summary estimate of studies with different scales to measure 
effect can be calculated. This method requires that an estimate of effect size for each study 
must be made into a common metric. Hedges (1982) provided the formula to estimate a 
summary effect size for studies that compare two groups taking into account the size of 
the two groups; 
d3 =2' wi . d, ) (eqn 3.24) 
1 wi 
where ds is the summary estimate of the difference in the effect size measured in a 
common metric, w; is the weight assigned to each study, and d; is the effect size. 
wi =1 
variance; 
where 
(eqn 3.25) 
d; _ (meane - mean, ) (eqn 3.26) 
Sdp; 
where d; is the common metric that measures effect size in the ith study, meane is the 
mean in the experimental ( or exposed group ), mean, is the mean in the control (or 
unexposed) group, and SDp; is the pooled estimate of the standard deviation of the effect 
measure for each study. When the study involves a before-after comparison, meane and 
mean, are the mean differences. 
iii. Test of homogeneity 
Both the above methods can be tested for homogeneity using the Q statistic [Cochran 
1954]. Q referred to the chi-square distribution is calculated and used to test the 
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hypothesis of homogeneity. If there is no statistical evidence of lack of homogeneity, a 
95% confidence limit for the summary estimate of effect is calculated. The formula to test 
homogeneity is describe as follows; 
Q= E(weight(w) .( means - mean; )l) (eqn 3.26) 
where means is the summary mean obtained by the formula; 
means = 4(w, . mean, )/E(w1) (eqn 3.27) 
95% confidence interval( C. I ), 
95% = means ± (1.96. ivariances) (eqn 3.28) 
variances -- 1/1(w1) (eqn 3.29) 
iv. Strength and limitations 
The methods employed above use standard deviation as a measure of outcome but 
are not accepted by all statisticians. Greenland, Schlesselman, and Criqui (1987) gave 
examples where studies with identical results can spuriously appear to yield different 
results when the effect measures are converted to units of standard deviation. The 
argument here is that when instruments and scales are different and unless the effect can 
be converted to a common metric, meta-analysis is impossible. Accordingly, when there is 
no reason to convert the measures of effect to unit of standard deviations, natural units 
should be used. 
b. Estimating trends 
Estimating trends between the risk of expose and unexpose groups towards 
certain condition is critical in the assessment of the causality of the association. Greenland 
(1987) describes a method to estimate the summary measure of risk or trend using the 
slope from regression equation. The method used ordinary weighted least square 
regression to estimate b(beta), the slope of the trend of disease. The formulas to estimate 
the summary measure of slope, a statistic to test homogeneity, and 95% confidence 
interval are as follows; 
Step. 1 Summary measure of slope 
Slopes W. slope; )/E(w, ) (eqn 3.30) 
Weight(w; ) = 1/variance; (eqn 3.31) 
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where slope; and variance; is the slope and variance of the ith study [Greenland and 
Longnecker 1992 or Greenland 1992]. 
Step. 2 Test of homogeneity 
Q= Z( wi . (slopes - slope02) (eqn 
3.32) 
where Q is referred to the chi-square distribution with degrees of freedom equal to the 
number of studies minus 1. 
Step. 3 95% confidence interval 
95% CI = slopes ± (1.96. Vvariances) (eqn 3.33) 
variances = 1/E(w; ) (eqn 3.34) 
where the weight( w; ) are estimated as above. 
3.4 Conclusions 
This chapter presents the rationale and some common pharmacokinetic model and 
statistical methods that can/are employed on population based studies. Approaches on 
how population-based study data and outcome measurements should be summarized were 
defined. The significance of employing these statistical methods on population based 
studies and how the fmal outcome can affect in optimising therapy was highlighted. 
The statistical methods proposed can be beneficial especially in the field of 
evidence based medicine where the medicine assessment of pharmacoepidemiology and 
pharmacotherapy can improve treatment strategies. It can be concluded that these 
statistical methodologies can act as a scientific tool to summarize, appraise and 
communicate the results and implications of various unanswered questions. 
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Chapter 4 
Ethnicity in established antiepileptic drugs: A review of its 
importance in optimizing antiepileptic drug dosing 
4.1 Introduction 
The population pharmacokinetics of established antiepileptic drugs(AED) such 
as phenytoin, carbamazepine, sodium valproate and phenobarbitone in man had been 
previously reviewed [Bertilsson and Tomson 1986, Gram and Bentsen 1985, Lester ] 
and validated [Evans et al 1991, Thomson & Broody 1992, Davis et al 1994]. The use 
of population pharmacokinetics in optimizing drug dosing is specially important 
during initiation of therapy since these drugs have different pharmacological and 
pharmacokinetic properties. These drugs are also known to be most effective and safe 
at certain therapeutic concentrations [Brody and Dichter 1997]. 
Dose and serum concentration relationship of phenytoin is well-known to 
behave nonlinearly due to the saturation of hepatic metabolism or is commonly 
referred as saturable kinetics. The relationship between dose and serum concentration 
of carbamazepine, valproic acid and phenobarbitone has been studied but has yet to 
be established. Reports on carbamazepine [Eadie and Tyrer 1980, Dodson 1987], 
sodium valproate [Schapel et at 1980, Henriksen and Johannessen 1982, Turnbull et at 
1983, Schobben et at 1975] and phenobarbitone [Eadie et at 1977, Painter and 
Pippenger 1978] are still inconclusive and these drugs are currently thought to behave 
non-linearly. The reasons behind the non-linear behaviour of these drugs is the many 
reports of the existence of high intraindividual and interindividual variation on the 
way patients respond to these antiepileptics [Welty et al 1983]. 
Pharmacologically, all four antiepileptic drugs are metabolised in the liver, 
moderate(phenobarbitone) to highly protein bound(phenytoin, carbamazepine, 
valproic acid) and only the free-drug fraction is in equilibrium with the brain 
[Chadwick 1994] and is therefore pharmacologically active. Valproic acid 
demonstrate inhibitory behaviour towards liver P450 microsomal enzyme while the 
rest are inducers [Patsalos and Duncan 1993]. Autoinduction is unique to 
carbamazepine [McNamara et al 1978] and the saturable kinetics of phenytoin 
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[Bochner et al 1972, Borofsky et al 1972, Mawer et al 1974, Richens and Dunlop 
1975] in high dosage can both make therapy complicated. 
In theory, pharmacokinetic-ethnic differences are associated with the liver 
cytochrome P-450's activity across species. These are the liver enzymes involved in 
the metabolic clearance of many drugs. Pharmacokinetic parameters such as 
clearance(CL) can be considered to be the product of organ blood flow and organ 
intrinsic clearance. For a drug cleared by the liver, the systemic clearance is; 
QCLI 
CLs 
CL1 +Q 
Where Q is the organ blood flow and CL1 the intrinsic clearance of the organ. For 
metabolically cleared drugs such as phenytoin, CLI relates to the parameters Vmax or 
Km of the enzymes involved [Smith 1991]. 
The level at which the liver is involved clearly shows that factors such as age, 
weight, height, sex, and certain disease conditions can play a vital part when using 
population pharmacokinetic parameters during therapy. Weight has been found to be 
an important criterion in estimating the population pharmacokinetics of phenytoin 
[Houghton and Richens 1975], carbamazepine [Summers and Summers 1989], sodium 
valproate [Chiba et al 1985] and phenobarbitone [Yukawa et al 1992]. Wilmore 1995 
reviewed and reported that phenytoin, carbamazepine and sodium valproate are 
affected by age. Several authors have reported that age is linearly related to 
dose/serum level ratio in carbamazepine [Yukawa et al 1992], phenobarbitone [Rossi 
et al 1979] and sodium valproate [Cloyd et al 1993]. Certain diseases of the liver and 
kidney have been found to affect the protein binding capacity and pharmacokinetics of 
all four antiepileptic drugs [Thomson and Brody 1992]. Changes in protein binding in 
pregnancy is however more pronounced with phenytoin than the other antiepileptic 
drugs[Brody 1990b]. 
Studies on estimating population pharmacokinetic variables of antiepileptic 
drugs used different methodologies and treatment patient groups. The traditional and 
well-known method used is the individualized approach but the population approach 
is becoming more prominent [Jelliffe et al 1998]. The most commonly employed 
treatment methods used either healthy or diseased patients and then categorised them 
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into patient groups of children, adult or both. However studies on patients with 
different racial or ethnic background are less common and the few that were published 
dealt mainly with phenytoin. 
Studies on phenytoin among different ethnic groups had been reviewed by 
Edeki and Brase (1995). Although, the influence of ethnicity on the population 
pharmacokinetic of carbamazepine has been reported by Yoon et al 1996, the few 
studies on phenobarbitone [Botha et at 1995] or sodium valproate [Botha et al 1995] 
showed its effects are insignificant. To date, the observations on carbamazepine, 
phenobarbitone and sodium valproate are yet to be substantiated. 
Ethnicity and genetic differences has been quoted in several phenytoin studies 
[Houghton and Richens 1975, Kromann et al 1981] as being one of possible 
contributing factors. These differences are referred to as polymorphism and their 
occurences among different ethnic groups can lead to interindividual variation in the 
drug pharmacokinetic and pharmacodynamic characteristics. The explanation given 
for genetically controlled ethnic differences can be described by the concept of 
acetylation polymorphism [Clark 1985] and is meant by the distribution of acetylation 
phenotypes in different population. 
Pharmacogenetic and phenotype differences and polymorphism in metabolism 
and their relation to ethnicity have been reviewed or reported in phenytoin [Grasela et 
al 1983, Edeki and Brase 1995, Odani et al 1997]. Pharmacogenetic aspects of 
phenobarbitone and carbamazepine in humans were investigated by Vessel and Page 
(1969) and Eichelbaum et al (1985). Evidence towards these relationships was 
reported for phenytoin and phenobarbitone and not for carbamazepine. 
Reports on these relationships were however confined to certain population 
groups( American, European and Japanese) and their results are currently being 
generalised almost world-wide. A direct implementation of these published 
pharmacokinetic profiles onto the local population may be inappropriate and can lead 
to treatment failure. These values should be best used as a guideline only until a 
proper quantitative analysis of the local population pharmacokinetics are available. 
Thus, this review was designed to highlight the extent at which these relationship 
were studied and the impact of ethnicity on phenytoin, carbamazepine, sodium 
valproate and phenobarbitone pharmacokinetics. 
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4.2 Phenytoin 
Phenytoin or 5,5-diphenyl-2,4-imidazolidinedione has been used as an 
antiepileptic drug to control generalized and partial epilepsy for more than fifty years. 
It is inexpensive and used worldwide. The pharmacokinetic properties of phenytoin 
are characterised by the saturable metabolic pathway, dose dependent kinetics and the 
therapeutic range of serum concentrations [Arnold and Gerber, 1969; Lund et at 1974; 
Chang and Glazko, 1982]. 
The problems of phenytoin therapeutic as currently used therapeutically are 
associated with that of drug metabolism, nonlinear pharmacokinetics, intraindividual, 
interindividual and interetlinic differences [Evans et al 1992]. The nonlinear dose and 
serum concentration relationship in phenytoin is explained by the saturation of hepatic 
metabolism where the maximum rate of metabolism occurs at concentrations within 
the therapeutic range(10 to 20ug/ml), where small incremental increases can lead to 
large increases to plasma concentration. The lower end of the therapeutic range is still 
not well defined [Hayes 1993] and many patients with generalised epilepsies can be 
controlled at lower concentration. The upper end is often associated with adverse drug 
reactions such as lethargy, ataxia and nystagmus although there are patients observing 
excellent therapeutic responses at concentrations above 20ug/ml. 
Population and individual based studies are currently investigating methods to 
reduce variations among individuals and across population. Studies on specific ethnic 
groups are still few in numbers but their potential importance may be crucial in the 
determination of phenytoin pharmacokinetics across population. 
4.2.1 Variations in metabolism and pharmacokinetics 
Glazko (1973) proposed the following pathways for phenytoin 
metabolism(figure 4-1). The main urinary metabolite is the glucuronic acid conjugate 
of the (S)-enantiomer of 5-(4-hydoxyphenyl)-5-phenylhydantoin(para-HPPH) [Fritz et 
al 1987]. The para hydroxylation is carried primarily by the family of cytochromes 
P450 called P4502C9 [Veronese et al 1991, Veronese et al 1993]. This enzyme also 
hydroxylates tolbutamjde [Chen et al 1993] and warfarin [Rettie et al 1992, Kaminsky 
et al 1993]. Familial differences of reduce ability to hydroxylate phenytoin indicate a 
genetically link hypometabolism of phenytoin [Kult et al 1964, Vasko et al 1980]. 
Individuals with this problem are observed to be having an apparent deficiency of 
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cytochrome P4502C9 and appears to be inherited as an autosomal recessive trait 
[Vermeij et al 1988]. These individuals are referred to as poor metabolisers and Inaba 
(1990) estimated the recessive trait to occur with a frequency of 1 in 500 in the 
Caucasian general population. 
Figure 4.1: Proposed phenytoin metabolism and final metabolites 
>Diphenylhydantoin acid(minor component) 
DPH >meta or para-HPPH >glucuronic acid 
conjugates 
>Epoxide-- >3,4-dihydrodiol > Catechol 
1 
(conjugates) 3-0-Methyl- 
catechol 
Studies on the relationship between ethnic groups and phenytoin 
pharmacokinetics are limited and difficult to compare. This is because these studies 
were distinctly different in both research methodology and outcomes measurement. 
These studies can however be broadly categorised into three main type; comparative, 
individualised and population studies. 
4.2.2 Comparative studies 
Table 4-1 highlighted some of the studies which reported observed differences 
between groups. The pharmacokinetic parameters reported were the rate of 
metabolism and disposition of phenytoin metabolite namely para-hydroxyphenytoin 
(p-HPPH), half-lives, clearance, Michaelis-Menten rate constant (Km), serum 
level/dose ratio and its steady-state concentration. 
The relationship between ethnicity and p-HPPH is clearly demonstrated by 
Andoh et al (1980) where their results showed Black Ghanaians excreted the 
metabolite at a rate 3 to 4 times lower than Caucasians after a single 200mg dose. 
Although this suggests that Blacks would have a longer half-lives than Caucasians, 
results of Black population from Ghana and the United States showed otherwise. 
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Table 4-1: Comparative studies on pbenytoin pharmacokinetics. 
Reference Population Sample 
size 
Dose / Route Pharmaco- 
kinetic 
parameters 
Conclusion 
Dam et al 1974 Eskimos versus 45: 45 not stated oral Total clearance Eskimos > 
Caucasians Caucasians 
Dam et al 1977 Eskimos versus 45: 45 not stated Steady-state Eskimos > 
Caucasians oral concentration Caucasians 
Kromann et at 1981 Eskimos versus 33: 21 1.4-1.5mg/kg Total clearance Eskimos > 
Caucasian oral Caucasians 
Arnold & Gerber 1969 Blacks versus 17: 28 100mg tds X3 half-lives(t, rz) Blacks > 
Caucasians days Caucasians 
oral 
Buchanan et al 1977 Blacks 12 18mg/kg oral half-lives(tin) Blacks < 
Caucasians 
Andoh et al 1980 Blacks 8 single dose-200mg Rate of excretion Blacks < 
oral of p-HPPH Caucasians 
Grasela et al 1983** Japanese versus 104: 218 Multi-dose Km, Vmax VmaY: is 
Caucasian retrospective dependent on 
weight 
Km: Japanese < 
European 
Peiris et at 1988 Caucasian versus Sri 47: 47 na serum level, Caucasian=Sri 
Lankans(Asians) prospective relative serum Lankan 
concentration 
Watanabe Met al 1997 Japanese: 13: 5 Multi-dose Km, Vmax Vmax : 
Normal vs slow prospective Slow metabolisers 
metabolisers > normal 
metabolisers by 
70% 
Km : 
No significant 
difference 
The first published study on interethnic differences between Blacks and 
Caucasian was published about 29 years ago by Arnold and Gerber (1969). Their 
study reported the mean half-life of 26.5 hours of American Black volunteers was 
significantly higher than the mean of 18.5 hours in Caucasian. Buchanan 1977 later 
found that the half-life of adult Black paraplegic volunteers in South Africa(15.9 
hours) to be similar to American Caucasian but gave no explanation was given for the 
observed difference. Edeki and Brase (1995) reported of an ongoing trial of Black 
American volunteers having a mean half-life( 25.6 hours) similar to that reported by 
Arnold and Gerber (1969). The variation of results between American Blacks and 
African Blacks could be accredited to the probable presence of interethnic differences 
among the assumably homogenous Black population. 
Dam et al (1974) and Kromann (1981) examined the difference in phenytoin 
clearance of the Eskimos and Caucasians population of Danish nationality. Both 
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studies showed that Eskimos total phenytoin and p-HPPH clearance were higher than 
Caucasian by fifty percent. The claim of interethnic differences were further 
strengthened by observations made by Dam et al (1977) which showed Eskimos 
steady-state serum concentration of phenytoin at a mean dose of 5.6mg/kg is 
significantly lower than Caucasian. 
Sheiner et al (1982) and Grasela et al (1983) quantitatively compared 
phenytoin rate of metabolism(Km, mg/L) and the maximum elimination 
rate(Vmax, mg/day) between Japanese and Caucasian populations. Their 
results(mean, se) statistically showed that Km values of Japanese(3.8mg/L, 0.65mg/L) 
are fifty-seven percent lower than Caucasian(5.7mg/L, 0.61mg/L) patients(aged more 
than 15 years ). For patients aged less than 15 years, their results showed that Km of 
the Japanese(2.2mg/L, 0.18mg/L) population is about 67% of 
Caucasians(3.2mg/L, 0.37mg/L). These indicate that the rate of metabolism in 
Japanese patients is almost half than that of Caucasians. Their results nevertheless 
showed that Vmax for the smaller body weight size Japanese population were 
statistically no different to that of Caucasian. These results again demonstrated the 
existence of interethnic differences between Japanese and Caucasian population 
Other than interethnic differences, phenotype differences among population 
can lead to significant pharmacokinetic variation. Contradictory results among the 
black population from the continent of Africa and United States could be explained by 
their phenotype composition. Watanabe et al (1995) presented the importance of 
phenotype composition in estimating phenytoin population pharmacokinetic in a 
largely homogenous society of Japan. Their results showed that slow metabolisers had 
a significantly lower Vmax to that of normal volunteers. Similarly, Odani et al 1997 
later found that slow metabolisers of genetic polymorphism of the CYP2C subfamily 
in the Japanese population had up to 14 percent lower Vmax that that of normal 
metabolisers. The rate of metabolism(Km) were however not affected by phenotype 
differences in Japanese population. This thus showed that other than ethnicity, 
phenotype differences can be the contributing factors for observed high intraindividual 
and interindividual variation on phenytoin pharmacokinetics. 
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4.3.3 Individual based studies 
I. Studies on healthy volunteers 
Hvidberg (1986) reviewed the pharmacokinetics of phenytoin on healthy 
Caucasian subjects. The trials consisted of reports from the United States, England, 
Denmark, and spanned the years of 1974 to 1981. To date, two studies of Black 
volunteers of Zimbabwean and American nationalities had been reported. A summary 
of these studies is presented in table 4.2. 
Table 4.2: Phenytoin pharmacokinetics in healthy Caucasian and Black volunteers 
Reference Country Sample size Age(years) Dose/ Route of Pharmacokinetic 
range or administration parameters 
mean, sd 
Arnold & Gerber Denmark 28: 17 21-54 100 mg X 3days Half-lives 
1969 -Caucasian and oral 
Blacks 
Buch Andreassen 100 mg(single), Clearance 
et al 1974 -Caucasian intravenous 
Perruca et at United States 3 26-38 92 mg(single) Elimination 
1978 -Caucasian intravenous constant(Ke), Half-live(tin), 
Volume of 
distribution(Vd), 
Clearance(CL) 
Bach et al 1981 Denmark 28 young 100 mg(single) Clearance 
-Caucasian 28.8 , 8.3 
intravenous 
elderly 
83.5.7.1 
Kromann et at Denmark 21 23-62 100 mg(single) Clearance 
1981 -Caucasian intravenous 
Hayes et al 1975 United Kingdom 41 20-86 oral/intravenous Clearance 
-Caucasian 60mg X3 days 
Gugler et al 1976 United States 6 not stated single 300mg oral Half-lives(tv2), 
-Caucasian single 300 intravenous clearance 
14 day X 300mg /day oral 
Nhachi et at 1992 Zimbabwean 15 >22 years 200 single dose/oral/ Half-lives(t, n) 
-Blacks prospective 
Edeki & Brase United States 58 adult 100 mg single oral dose Half-lives(gR) 
1995 -Blacks 
As indicated in- table 4-2, studies were generally on adult volunteers given 
phenytoin either by the oral or intravenous route. These trials objectively investigated 
the half-life and clearance for both intravenous and oral preparation of phenytoin. 
Individuals selected consisted mostly of adults although those in the elderly age( more 
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than 65 years old ) were included. Nevertheless, one trial did examine the influence of 
individuals in the elderly age group on phenytoin pharmacokinetics [Bach et al 1981]. 
This study compared the difference in clearance in young and elderly adults with the 
mean(SD) age of 28.8years(8.3years) and 83.5years(7. I years). Studies on the mixed 
age group patients by Dam et al (1977) consisted of patients in the range of 4 to 60 
years. Summary of the final results reported by each study is in Table 4-3. 
Table 4-3: Results ofphenytoin pharmacokinetics in healthy Caucasian and Black volunteers 
Reference Country Half-lives Elimination rate Volume of distribution Clearance 
(hours) constant(hour ') (Liters/kilogram) range 
-mean, se -mean, se -mean, se (ml/min) 
-mean, se 
Arnold & Gerber United States 7-42 - - - 
1969 -Caucasian -18.5,1.15 
Arnold & Gerber United States 11.5-38.5 - - - 
1969 -Blacks -26.5,1.94 
Buch Andreassen Denmark -- - 6.5-43.2 
et al 1974 -Caucasian 
Perruca et al United States 8.3-38.1 0.04 t 0.04 41.53 ± 9.08 37.06 t 
1978 -Caucasian -24.10 8.65 26.45 
Bach et at 1981 Denmark adults - adult(Liters) adults 
-Caucasian 26.5 , 2.36 40.9 ± 8.5 48.1± 
4.44 
elderly elderly(Liters) elderly 
29.5 , 2.42 44.4 ±18.1 50.5 ± 9.86 
Kromann et al Denmark - 18.3-81.7 
1981 -Caucasian 
Hayes et al 1975 United Kingdom -- - adult: - 
-Caucasian 30.5 ± 4.5 
Elderly:. 
49.3 ± 6.5 
Gugker et al 1976 United States -- - 25 ± 2.5 
-Caucasian 
Nhachi et al 1992 Zimbabwean 36.7-40.5 - - - 
-Blacks -40.2.7.36 
Edeki & Brase United States 11.5 - 54 - - 1995 -Blacks -25.6,2.39 
Studies reporting on the half-lives of phenytoin after single oral doses showed 
a clear distinction between adult Caucasian and Black population. Generally the half- 
lives(95% confidence interval) in the black population ranged between 22.70-33.30 
hours [Arnold & Gerber 1969], 20.92-30.28 hours [Edeki & Brase 1995] and 25.85- 
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54.62 hours [Nhachi et al 1992] were significantly higher than that of Caucasians 
[Arnold & Gerber 1969: 16.25-20.75 hours]. However, the mean half-lives obtained 
from single dose intravenous studies by Perruca et al (1981) (7.15-41.05) and Bach et 
al (1981) (21.87-31.13) showed no such difference. This observation can possibly be 
explain by the different mode of administration and the existence of genetic 
polymorphism among the Caucasian volunteers [Horsmans et al 1997]. 
ii. Studies on epileptic volunteers 
Table 4-4 highlighted eleven individual-based trials in Caucasian, Japanese, 
Chinese, Blacks, Arabs, Danish Greenland Eskimos and Malaysian epileptic patients. 
The pharmacokinetic parameters investigated were the Michealis-Menten 
constant(Vmax, Km), estimated by employing the modified linearised Michealis- 
Menten equation, half-life(tl12) and dose/serum level ratios. 
Studies on the metabolic rate constant(Km) on paediatric and adult Caucasians 
showed that there are no significant differences between the population of Germany, 
England and United States. The reported Km values(95% confidence interval, mg/L) 
for the adult population of 5.48-6.54mg/L, 4.89-13.91mg/L and 5.4-5.8mgIL were 
homogenous although the values from England showed a wider coefficient of 
variation. Km values of 5.06-9.93mg/L and 6.08-6.92mg/L for the paediatric 
population nevertheless showed that inter-individual differences was more 
pronounced in the English Caucasian population. 
Results from the Asian community also showed similarities between Japanese, 
Saudis and Malaysian population. Studies between Saudi(4.45-9.03mg/L) and 
Japanese(2.88-4.52mg/L) paediatric population showed that the Km values of the 
former were higher than that of Japanese but the difference was not statistically 
significant. 
Comparing mixed population Km values for Malaysian(4.03-9.40mg/L), 
Saudis(5.18-8.32mg/L) and Caucasians of German origin(5.48-6.54mg/L) again 
showed the absent of interethnic differences between them. Significant difference was 
however present between Japanese [Chiba et al 1980] and Caucasian paediatric 
populations. Km values for the Caucasian range between 5-9mg/L was lower than that 
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observed in the Japanese population(2.88-4.52mg/L). This thus showed that evidence 
of interethnic differences is apparent and needs investigation. 
Table 4.4: Phenytoin individualised-based pharmacokinetics in epileptics of various ethnic zroups 
Reference Population Sample Age Dose / route / Pharmaco- Overall results 
(country) size range study type kinetic (mean, se) 
-mean, parameters 
sd(yrs) 
Rambek et al Caucasian 178 6-72 Multi-dose / Kam, V. 
1979 (Germany) years oral/prospective 
Cranford et al Caucasian 139 17-94 continuos infusion clearance, 
1977 (Unites States) mean-52 (mean dose-18 volume of 
mg/kg)/prospective distribution 
Dam et at 1977 Caucasian 45 4-60 not stated/ Clearance 
(Denmark) mean: oral/prospective 
21.3 
years 
Dam et al 1977 Eskimos 45 5-59 not stated/oral! Clearance 
(Denmark) mean: prospective 
20.7 
years 
Chiba et al 1980 Japanese 104 <16 Multi-dose/oral/ K,,, V- 
(Japan) years prospective 
Blain et al 1981 Caucasian 40 children: Multi-dose/oral/ K,,, V. 
(England) <8 years prospective 
>18 
years 
Baur et al 1983 Caucasian 92 >20 Multi-dose/oral / K,,,, V- 
(United years prospective States) 
Baur et al 1983 Caucasian 155 <16 multi-dose A.,, V- (United years /oral/prospective 
States) 
EI-Sayed et al Saudis 17 mixed Multi-dose/oral K,,, V,,,,, 
1989 (S. Arabia) age /prospective 
children 
<18 
years 
-5 
adult 
-12 
K,,: 
6.01 , 0.27mg/L) V-: 
355 , 7.94(mg/day) 
CL: 0.0157,0.0011 
Iiters/hr. kg 
Va: 0.78 , 0.0.01Ukg 
CL-17,7.90 ml/min 
CL: 66.54 
, 
25.03 
ml/min 
K.: 
3.7,0.42(mg(L) 
V_: not shown but 
stated to decrease with 
age 
Children: 
K. -7.5 , 1.24 (mg/L) V,.. 20.4,2.07 
mg/kg. day or 238,125.5 
mg/day 
Adult- 
K. -9.4.2.3 (mg/L) 
V-e 8.7,0.71 
mg/kg. day or 542.2,37 
mg/day 
V.: 
--2 -11(mg/lcg/day) 
K,,: 
5.4 - 5.8 (mg(L) 
K,,: not increase with 
age 
-6.26,0.09(mg/L) 
V-: increase with age 
-10.22,2.27 
(mg/kg. day) 
Children: 
K,, - 6.74,1.17 (mg/L) 
V,, ý-10.20 10.20 (mg/kg. day) or 234, 
54.85mg/day 
Adult: 
K. -6.75,1.08 (mgfL) 
V, o. -6.87,1.55 (mg/kg. day) or 
59 
433.75,19.72mg/day 
V. is dependent to age 
and weight 
Lai 1985 Chinese 70 mixed Multi-dose/oral/ Steady-state Dose and not age nor 
(Taiwan) age prospective serum sex affected dose/serum 
concentration level relationship 
Lee et al 1989 Chinese/ 330 >15 multi-dose steady- Indian > Chinese and 
Malay/ Indian years (oral/prospective state/dose ratio Malay 
(Singapore) 
Ismail & Fatah Malay/ 15 mixed Multi-dose/oral/ K,,, V,,,,,, K,,: 
1990 Chinese age prospective 6.72,1.37(mg/L) 
(Malaysia) Vý: 
8.45 , 0.36 (mg/kg. 
day) 
or 406 39,31.66mg/day 
Vmax among mixed populations of Caucasian origin by Rambek et al 
1979(339.43-370.56mg/day), Saudis(317.08-432.92mg/day) and Malaysian(344.34- 
468.44mg/day) patients showed no significant difference. However, the results from 
the Malaysian population might not portrayed the true picture since the values were 
from a mix of Malay and Chinese patients. This fact was clearly showed by Lee et al 
1989 where the serum concentration/dose ratio of Chinese was higher than that of 
Malay patients and could probably affect the overall mean(Vmax) of the Malaysian 
population. 
Reported Vmax values for Caucasian paediatric population by Blain et at 
(1981) (16.34-24.46mg/kg. day) and Baur et at (1983) (5.77-14.66mg/kg. day) were 
found to differ significantly. However, the possibility that inter-ethnic differences 
existed between American and English population cannot be confirmed due to 
different patient study age groups. Studies on similar age group paediatric patients by 
El-Sayed et al (1989) and Baur et al (1983) showed no significant difference was 
observed between Saudis(8.22-12.18mg/kg. day) and Caucasians(5.77- 
14.66mgkg. day). 
4.3.4 Population-based studies 
Altogether, ten trials published phenytoin pharmacokinetic trials on specific 
ethnic populations. The trials covered eleven different nationalities from four different 
continents namely North America, Europe, Africa and Asia. Their diverse ethnic 
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background can be classified into Caucasian, Japanese, Chinese, Blacks, Arabs, and a 
mix of Malay, Chinese and Indian from the multi-racial country of Malaysia. 
Table 4.5 summarises ten population-based studies of phenytoin which 
mentioned the ethnicity of the studied epileptic groups. These studies employed the 
non-linear mixed effect model by using specialised computer software( OPT and 
NONMEM ) in estimating the population pharmacokinetics of each population 
groups. 
Table 4.5: Population-based studies of epileptics of various ethnic groups using computer software 
of non-linear mixed effects models(OPT** and NONMEM*) 
Reference Population 
(country)/ 
Sample 
size 
Age 
(yrs) 
Dose / route 
/study type 
Pharmaco- 
kinetic 
parameters 
Overall results 
(mean, se) 
Voseh et al Caucasian 32 >22 Multi-dose, K. V. K,,,: 7.22,0.25 mg/L 
1981* (Switzerland) years retrospective V. : 
-epileptics 4.44 , 0.40 
mg/kg. day 
Grasela et al Caucasian 178 mixed Multi-dose K,,, V. K,: 5.7,0.21 
1983* (Germany) age retrospective V.: 355,5.32 
-epileptics mg/day 
Grasela et al Japanese 104 <16 Multi-dose K,., V. K,,,: 2.2 , 0.12mgfL 1983* (Japan) retrospective V,,,,: 208 2.45 
-epileptics mg/day 
Grasela et al Caucasian 40 <8 Multi-dose K., V,,,. K,.: 3.2 , 0.25mglL 1983* (England) retrospective V. -138,436 
-epileptics mg/day 
Miller et al Blacks 37 mixed Multi-dose K. V_ K,,: 3.43 , 0.27mg/L 1987* (S. Africa) - age retrospective Vm.: 6.5 , 0.28 
-epileptics mg/kg. day 
Chan et al Chinese 121 mixed Multi-dose K_ K.: 2.31 . 0.04mg/L 1990** (Singapore) age retrospective no difference 
-epileptics between children and 
adult 
Yukawa et at Japanese 220 mixed Multi-dose, K,,, V. K. (60kg individual): 
1990* (Japan) age retrospective 3.67,0.28mg/L 
-epileptics V. (60kg 
individual): 
369,9.82mg/day or 
6.15 , 0.16mg/kg. day 
Ismail & Malay/Chinese/ 59 mixed Multi-dose K,,, V,,,,,, K.: 3.66,0.77 mg/L 
Fatah 1994** Indian age retrospective V_: 
(Malaysia) 7.29,1.23 mg/kg. day 
-epileptics 
Rui et al Chinese 161 mixed multi-dose K,  V_ K.: 6.21,0.22 mg/L 1995* (China) age retrospective V.: 439,5.37 
-epileptics mg/day or 7.32,0.09 
mg/kg. day 
(60kg individual) 
Odani et al Japanese 116 Mixe Multi-dose K,,, V,,,,, K,: 9.19,1.08mg/L 
1996* (Japan) d age retrospective V.: 9.80,0.51 
-epileptics mg/kg. day 
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i. Km 
The reported Km values(95% confidence interval) in the mixed-age group of 
the Caucasian(5.29-6.12mg/L) and China-Chinese(5.78-6.64mg/L) was definitely 
higher than those of Japanese(3.12-4.22mg/L)), Black South African(2.90-3.96mg/L), 
Singapore-Chinese(2.23-2.38mgfL), and Malaysian mixed race(2.15-5.17mg/L) 
patients. These differences showed that interethnic differences could possibly exist. 
Similarly values for the paediatric Japanese(1.96-2.43mg/L) and Caucasian(2.71- 
3.69mglL) population showed further proof for interethnic difference. 
As for the adult population, the values for Caucasian(6.73-7.71mg/L) is at 
least 2 times higher than that of Chinese patients(2.23-2.38mg/L) obtained by Chan et 
al 1990. Although Chan et at (1990) reported no significant difference for Km 
between children and adult, a clear distinction was observed in Caucasians. Results by 
Voseh et at (1981) for adults(6.73-7.71mg/L) and Grasela et al (1983) for 
children(2.71-3.69mg/L) showed age can play an important factor among Caucasians. 
ii. Vmax (Maximum elimination rate) 
Population values of Vmax(mg/day) from mixed age group from mainland 
Chinese(428.87-449.52mg/day) was definitely higher than Caucasian(344.57- 
365.43mg/day) or Japanese(349.75-388.25mg/day). Vmax values in mg/kg. day 
similarly showed that there was no significant differences existed between mainland 
Chinese(7.14-7.50mg/kg. day), Black South African(5.95-7.05mg/kg. day) and 
multiethnic Malaysian population(4.88-9.70mg/kg. day). 
Vmax between Japanese and Caucasian paediatric population nevertheless 
displayed evidence for interethnic differences. Figures obtained for the Japanese 
population was about 33 percent lower than their Caucasian counterpart. The 
difference between adult and paediatric Caucasian could not be studied since the units 
used were incomparable. 
4.4 Carbamazepine 
Carbamazepine(CBZ) is first discovered in 1952 and currently considered as 
the first line treatment of both partial and generalized epilepsy [Wilder 1995]. 
Metabolism of carbamazepine has been studied both in-vivo and in-vitro [Eichelbaum 
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et al 1984,1985, Lertratanangkoon & Horning 1982, Tybring et al 1981]. The most 
important pathway is that describe by Eichelbaum (1985) where the active metabolite 
namely called carbamazepine-10,11-epoxide is formed. (figure 4-2). 
Figure 4-2: Major pathways of metabolism of carbamazepine in man(Eichelbaum et al 
1985). 
Carbamazepine 
hydroxylation epoxide-diol pathway 
CBZ epoxidase 
CBZ-10,11-e )oxide ......., 
epoxide 
hydrolase 
2-hydroxy-CBZ 9-hydroxymethyl- trans- 10,11 -dihydroxy- 
+ 10-carbamoyl f ..... 10,11-dihydroxy-CBZ 
30hydroxy-CBZ acridan 
Urinary excretion ... 
CBZ pharmacokinetics has been extensively reviewed and its autoinduction 
properties has been well documented in Caucasians [Eichelbaum et al 1985, Bertilsson 
et at 1986, Mikati et at 1989, Rapeport et al 1983]. The mechanism of autoinduction is 
reported by Rapeport et at (1983) and to be attributed to the activation of hepatic 
microsomal enzyme. 
The role of genetic factors in the interindividual variability in carbamazepine is 
little known although interethnic differences in drug metabolism among different 
population is often cited [Rodorfer et al 1985, Kalow et at 1984, Kalow 1982] and 
have been reported for other drugs. Eichelbaum et at (1985) investigated the 
possibility of this pharmacogenetic link upon eight Swedish volunteers who were then 
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subjected to seven metabolic reaction test that are associated for interindividual 
difference. These test which included debrisoquine 4-hydoxylation [Mahgoub et al 
1977], sparteine oxidation [Eichelbaum et al 1979], and antipyrine [Blain et at 1982, 
Vesell and Page 1968], examined carbamazepine clearance via its epoxide metabolite 
and found no significant relationship in any of the tests. They then concluded that the 
metabolism and clearance of carbamazepine were dependent on types of therapy and 
not to its pharmacogenetic aspects. 
Marley et al (1993) however found that the time course for anticonvulsant 
effect of carbamazepine on cocaine-induced seizures in rats depends on its genotype. 
The levels of carbamazepine and its active epoxide metabolite(CBZ- 10,11 -epoxide) in 
plasma and brain were dependent on strain-type which clearly indicates that there 
were genetic differences in its time course. These results showed the possible 
existence of interethnic differences in humans which has yet to be established. 
4.4.1 Individual-based studies 
Table 4-6 presented five published studies of healthy adult volunteers and a 
single study on epileptics which examined various carbamazepine pharmacokinetic 
parameters in single and chronic therapy. The most common parameter studied was 
the half-life of carbamazepine although several studies did measure parameters such 
as absorption rate constant(ka), elimination rate constant(ke) and volume of 
distribution(Vd). 
Results on the half-life of carbamazepine was obviously not affected by dose 
[Levy et at 1974] and half-lifer among healthy Caucasians was distinctly similar(Table 
4.6a). The reported half-lifes(95%, confidence interval, hours) for Caucasians in single 
dose studies on healthy volunteers were 27.15-38.05 hours [Levy et at 1974], 21.49- 
30.51 hours [Tomson et al 1983], 29.15-40.25 hours [Dalton et al 1985a], and 27.77- 
36.63 hours [Dalton et al 1985b] respectively. Results reported by Eichelbaum et at 
(1979) on epileptics patients although similar showed a wider range than in healthy 
volunteers(20.61-50.59 hours). 
Interethnic differences of half-lives between Koreans(44.13-52.44 hours) and 
Chinese(43.10-57.10 hours) were similarly small. No evidence of interethnic 
differences were also observed between healthy Caucasians from the United 
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States(27.15-38.05 hours, 29.15-40.25 hours, 27.77-36.63 hours) and Sweden(20.61- 
50.59 hours). However, the possibility of differences between Caucasians and Asians 
of Chinese and Korean nationalities might be present. 
Table 4-6: Carbamazepine pharmacokinetics in various ethnic groups 
Reference Ethnic(Country)/ Sample Age(years, mean, sd)/ Dose/ Route of Pharmacokinetic 
Patient-type size Ratio male: Female/ administration parameters 
Weight(mean, sd) 
Levy et al 
1974 
Tomson et al 
1983 
Hundt et al 
1983 
Caucasian 
(United States) 
-healthy volunteers 
Caucasian 
(Sweden) 
-healthy volunteers 
Blacks versus 
Caucasians 
(United States) 
6 -25 ± 3.8 yrs 
-3 :3 
-69.3 ± 18.8 kg 
4 -35.5 ± 10.1 yrs 
-2: 2 
-not stated 
single dose-6mg/kg 
P. O 
single dose-200 mg 
P. O 
half-Iife(tirz) 
Elimination rate 
constant(Ke), Half- 
live(t, 2), Volume of 
distribution(Vd), 
Clearance(CL) 
Eichelbaum et Caucasian 
a11985 (Germany) 
-epileptic 
Dalton et at Caucasian 
1985 (United States) 
-healthy volunteers 
Dalton et al Caucasian 
1985 (United States) 
-healthy volunteers 
451: na 
2225 
6 31.5 ± 3.7yrs 
-3 :2 
-66.6± 16.06kg 
8 24 - 35yrs 
-7: 0 
-81± 9.6kg 
8 23 - 36yrs 
-7: 0 
-81.0 ± 9.6kg 
multiple dose 
single-100 or 200 mg 
p. o + other AED's 
single- + cimetidine 
(600mg) 
single-600mg + 
rantidine 300mg/day 
mean serum 
concentration, 
CBZE/CBZ and 
CBZH/CBZ ratios 
half-life(tu7), Vd 
half-life(tin) 
half-life(tiR) 
Peiris et at Caucasian versus 47: 47 10-72yrs multiple dose serum level, relative 
1988 Sri Lankan wt-na serum 
concentration(1/CL) 
Lin et at 1991 Chinese(Taiwan) 12 -23.4 ± 3.1yrs a. Single dose(200mg) Vd, Ka, Ke and t, /2 
-healthy volunteers -7: 0 + 600mg 
-67.7 ± 11.2kg phenytoin(p. o) 
b. Multiple dose 
200mg tds X 7days, 
last dose + 600mg 
phenytoin(p. o) 
Yoon et at Koreans( South 139 22.6 t 1.3 a. Single dose-400mg Vd, Ka, Ke and tjn 1977 Korea) 
-67.5 f 5.7 kg b. Multiple dose 
-healthy volunteers 200/day X2 weeks 
Volume of distribution(Vd) of healthy Caucasian(0.64-1.11 L/kg) was lower 
than that reported by Korean(1.22-1.62 L/kg) and Taiwan-Chinese(1.01-1.29 L/kg). 
However, these differences were not significant but showed that Caucasian had 
higher inter-individual variation. Calculated Vd of Korean and Taiwanese Chinese 
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similarly showed the existence of differences in inter-individual variation between 
them. 
Table 4-6a : Summarised results of carbamazepine studies in various ethnic groups. 
Reference Ethnic groups Ilalf-lifes Elimination rate Volume of Serum Clearance 
(ti/2-hours) onstant(ke-L/hr) distribution level (mlkg. hr) 
Mean, se Mean, se (Vd-L/kg) (mg/L) Mean, se 
Mean. se Mean se 
Levy et at Caucasian single dose(3mg/kg) na na na na 
1974 (United States) -32.60,2.78 
-healthy volunteers single dose(6mg/kg) 
-30.60,1.88 
single dose(9mg/kg) 
. 32.60,5.02 
Hundt et al Blacks vs na na na Blacks> na 
1983 Caucasians Caucasian 
(United States) 
Tomson at Caucasian single dose(200mg) na 0.88 , 0.12 na 23.40,2.30 
at 1983 (Sweden) 26.00 , 2.30 
-healthy volunteers 
Eichelbaum Caucasian single dose(100mg) na single dose na single dose 
et at 1975 (Sweden) -35.60,7.65 -1.20,0.22 -30.4,9.90 
-disease multiple dose(200mg) multiple (ml/min) 
-20.90,2.50 dose multiple dose 
combine -not stated -not stated 
-8-20,1.17 combine combine 
-1.12,0.09 -114,9.44 
(ml/min) 
Dalton et at Caucasian single dose(600mg) na na na na 
1985a (United States) 34.7,2.83 
-healthy volunteers 
Dalton et at Caucasian single dose(600mg) na na na na 
1985b (United States) -32.20,2.26 
-healthy volunteers 
Peiris et at Holland na na na Caucasian RSC(mean, se 
1988 (Caucasian) -7.54,2.0 ) 
vs Sri Lankan S. Lankan Caucasian 
(Indians) . 7.45,3.22 -0.66,0.24 
SriLankan 
-0.67,0.52 
Lin et at Chinese(Taiwan) single dose(400mg) single dose single dose na Sngle dose 
1991 -healthy volunteers 50.1,3.57 -0.015 , 0.001 1.15,0.07 -16.40,1.17 
multiple dose(600mg) multiple dose multiple Multiple dose 
-26.10,1.48 -0.027,0.002 dose -45.30,8.27 
-1.64,0.24 Yoon et at Koreans( South Single dose(400mg) Single dose Single dose na Single dose 
1997 Korea) -48.29,2.12 -0.016,0.001 -1.42,0.10 -21.14,1.21 
-healthy volunteers Multiple dose(200mg) Multiple dose Multiple Multiple dose 
-26.97,1.41 -0.027,0.001 dose -35.08,1.53 
-1.36,0.08 
Hundt et al (1983) reported mean total carbamazepine, CBZ-epoxide, and 
CBZ-dihydroxy level of Black patients(n = 451) visiting the outpatients clinic and 
found them to be significantly lower(p<0.0005) than Caucasians(n = 2225). They also 
mentioned the difference between blacks and Caucasians could be due to Blacks 
having lower therapeutic window and elimination rate constant and the possibility that 
comedication tended to have greater impact on them. However, the prevalence of 
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higher incidences of noncompliance would raised the question of adequacy among 
Blacks. Peiris et al (1988) however compared dose and serum level relationship of 
Dutch and Sri Lankan patients and found no significant differences between them. 
They further noted that the wider variabilities in dose-serum concentration in Sri 
Lankan patients might possibly be due to noncompliance. 
Carbamazepine clearance although known to be dose dependent [Kudriakova 
et al 1992, Summers & Summers 1989], was observed to be higher in Caucasians than 
Korean or Taiwanese Chinese but no difference was observed between the latter two 
groups. This finding was obvious since clearances(95% confidence interval) for 
Caucasian after a single dose of 200mg(18.89-27.91 ml/kg. hr) were markedly higher 
than the 400 or 600 single dose taken by Taiwan-Chinese(14.11-18.69mg/kg. hr) or 
Korean(18.77-23.51 mg/kg. hr) volunteers. The determination of the elimination rate 
constant(ke), which is one of the two variables that has a direct relationship with 
clearance, again showed that no such relationship occurred between Chinese and 
Korean volunteers. 
4.4.2 Population-based studies on carbamazepine in epileptic patients from 
various ethnic groups. 
Studies on ethnic-based population pharmacokinetics of carbamazepine are 
again very few and until today it is not surprising that the relationship between dose 
and serum levels has yet to be concluded(Table 4-7). These studies tried to establish 
the influence of ethnicity to this undetermine relationship [Cereghino et at 1973, 
Summer & Summers 1989, Ismail & Rahman 1993] as well as investigating the 
relationship between parameters such as serum level-dose ratio [Yukawa et al 1985] 
to variables such as age, weight etc. To date, the most common population 
pharmacokinetic parameter examined by researchers was clearance [Yukawa 1995, 
Ismail & Rahman 1993, Summers & Summers 1989] and this determinant are used to 
compare differences among ethnic groups. 
The relationship between serum level and dose was observed to be linear in 
adult Caucasians [Cereghino et al 1973, Yukawa et al 1985], and curvilinear in 
paediatric Black South African patients [Summers & Summers 1989]. Ismail and 
Rahman (1993) however found no clear relationship between serum level and dose in 
Malaysian patients. 
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Table 4-7: Carbamazepine population pharmacokinetics of various ethnic groups 
Reference Ethnic(Country)/ 
Patient-type 
Sample size Age(years) 
Mean, sd/ 
range 
Dose/ Route of 
administration 
Pharmacokinetic 
parameters/Methods of 
analysis 
Yukawa 1995 Japanese 317 14.9,9.2 Multi-dose -CL 
(Japan) -retrospective -Non-linear mixed effect 
-epileptics model(NONMEM) using 
multiple peak approach 
Ismail & Rahman Malaysian 20 11-37 Multi-dose -Elimination constant(Ke), 
1993 (Malaysia) -prospectve Absorption rate 
-epileptics constant(Ka), Volume of 
distribution(Vd), t1n 
Clearance(CL), serum 
level and dose relationship 
-Bayesian(OPT) 
Yukawa et al 1985 Japanese 370 <18 Multi-dose -Serum level/Dose ratio, 
(Japan) -retrospective serum level and dose 
-epileptics relationship 
-linear regression 
Summers & Black African 262 <18 Multi-dose -CL, and serum level and 
Summers 1989 (South Africa) -retrospective dose relationship. 
-epileptics -Linear regression 
Cereghino et al Caucasian 8 21-48 Multi-dose -Serum level and dose 
1973 (United States) -prospective relationship 
-epileptics -Linear regression 
Population clearances estimated for Japanese and Malaysian were found to be 
significantly different. Their clearances range(mean, 95% confidence level) were 
68.10,66.47-69.72 ml/kg. hr and 60,55.53-64.47 mg/kg. hr showed that Malaysian 
patients values was about 10 percent lower than that of Japanese. Summers and 
Summers (1989) further reports that clearances in black paediatric patients decrease 
with increasing body mass, but increase with dose. Their correlation relationship for 
clearance, body mass and dose had an r value of 0.66 which they commented could be 
affected by other factors such as diet or genetic makeup. Delgrado Iribarnegaray 
(1997) also reported similar observations and mentioned that the nonlinearity 
relationship between clearance and age would mean that older children would have 
lower clearance with respect to total body weight. 
4.4 Sodium Vaiproate 
Valproic acid is a branched-chain fatty acid and is available in its parent 
compound, sodium salt, its amide derivative, and a combination of the parent 
compound and its sodium salt. It is eliminated mostly by metabolism and recovered 
less than 5% in the urine. Studies in mouse showed two active metabolites of valproic 
acid are the 2-En-valproic acid and 4-En-valproic acid [Loscher & Nau 1985]. 
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The pharmacokinetics of sodium valproate have been reviewed by various 
authors [Simon et al 1975, Pinder et al 1977, Lewis 1978, Bruni et al 1979, Koch 
Weser et al 1980, Gram et al 1985, Davis et al 1994] and its pharmacokinetic 
properties are well established. Its serum level and dose relationship at steady-state 
has been described as linear or dose dependent clearance [Hall et al 1985, Nutt & 
Kupferberg 1979], curvilinear [Gram et al 1979, May & Rambek 1985, Turnbull et al 
1983] and the serum level dose ratios decreases with dose [Tisdale et al 1992]. The 
reasons for the contradictory observations were explained by the drug saturated 
protein binding at high dosages [Davis et al 1994] resulting in increased clearance. 
Its pharmacokinetic properties in a variety of formulation [Chun et al 1980, 
Albright et al 1984, Barre and Berger 1989, Bailer et al 1985] have been studied in 
both paediatric and adult diseased patients and healthy volunteers. Predominantly 
pharmacokinetic parameters were significantly affected in patients in the paediatric 
and elderly age. Parameters such as t112, Vd and percentage of unbound were found to 
increase more in neonates than those in infants or children [Morselli et at 1980] while 
the older people has 2 fold prolongation of tl/2 and a higher Yd [Bryson et al 1983]. 
The effects of pregnancy, renal disease [Brewster & Muir 1980, Robson et al 
1980, Gugler & Mueller 1978], hepatic dysfunction [Klotz et al 1978] and disease 
such as diabetes mellitus [Gatti et al 1987] had also been assessed. All these diseases 
increased the unbound portion of the drug and this increased the risk of hepatotoxicity. 
Hence dosage adjustment based on the total plasma concentration should be made 
cautiously. 
All the above results have yet to ascertain interpatient variability due to ethnic 
differences. Comparison among ethnic groups were impossible since rarely was this 
factor mentioned. Until recently, a few studies did investigate the role and importance 
of intraindividual and interindividual variation [Chiba et al 1985, Botha et al 1995, 
Tisdale et al 1992] among population and their findings are discussed below. 
4.3.1 Ethnic-based studies 
Two studies of the paediatric population [Chiba et al 1985, Botha et al] using 
the individualised and population approach mentioned specific population or ethnic 
race in their trials(Table 4-8). Chiba et al 1985 compared Japanese children on 
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monotherapy and polytherapy and found that mean clearances of patients on 
polytherapy(0.023L/kg. hr) were significantly higher(p<0.001) than 
monotherapy(0.013L/kg. hr) patients. These differences were not observed by Botha et 
al 1995b who studied a mix of Black and Indian paediatric South African patients 
population. The clearances values(95% confidences, L/kg. hr) were 0.21(0.018,0.024) 
and 0.028(0.023,0.033) for patients on monotherapy and polytherapy respectively 
showed no such differences. This result was similarly obtained by Cloyd et al (1993) 
for both monotherapy(0.005-0.024L/kg. hr) and polytherapy(0.016-0.085L/kg. hr) 
paediatric patients. This study however had its drawback of not mentioning patients 
ethnic composition thus preventing a direct interethnic comparison among studies. 
Table 4-8: Sodium vaiproate population pharmacokinetics of various ethnic groups 
Reference Ethnic(Country)/ Sample size 
Patient-type 
Age(years)/ 
weight(kg) 
Mean, sd 
Dose/ Route of 
administration 
Pharmacokinetic 
parameters/Methods 
of analyssis 
Chiba et al 1985 Japanese 37 monotherapy multi-dose CL, t, n, Vd 
(Japan) age-9.4 , 2.9 P. O 
-epileptics polytherapy 
age-10.7,3.1 
wt-not stated 
Botha et al 1995 Indian/Blacks 52 mixed therapy multiple dose CL, Vd, Ka 
(South Africa) age-7.6 , 4.2 po 
-epileptics wt - 24.2 , 12.5 
Although clearances of polytherapy patients of both population showed no 
distinct differences, clearances(95% confidence interval) of Japanese(0.010- 
0.015LIkg. hr) and coloured South African(0.018-0.024L/kg. hr) monotherapy patients 
proved otherwise. Nevertheless, this difference was not visible between studies of 
Chiba et al (1985) and Cloyd et al (1993). 
4.4 Phenobarbitone 
This antiepileptic drug is the oldest drug used in generalised and partial 
seizures. It is currently more widely used in neonatal seizures and the prevention of 
neonatal hyperbilirubinaemia. For this reason pharmacokinetic data concerning 
neonates and younger children were more available than older children or adults. 
Phenobarbitone has not been reported to show ethnic differences in 
metabolism. However, Vessel and Page (1969) reported genetic control of 
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phenobarbital-induced shortening of plasma antipyrine halflifes in man. Their studies 
involved examining the effect of phenobarbitone on single dose of antipyrine in four 
sets each of identical and fraternal twins. Their results showed that after a2 week 
therapy of phenobarbitone(2 mg/kg) the half-lifes of antipyrine was reduced from 12.7 
hours to 8.0 hours. Further results revealed greater similarity of inductive responses 
for identical than fraternal twins which then implicates a genetic factor in the 
regulation of the hypothesized inductive process. Their findings reported the 
contribution of hereditary to trait to be 99% which could probably explain 
interindividual differences in the activities of hepatic microsomal enzymes among 
individuals. 
Table 4-9: Studies that examined the characteristic of neonatal phenobarbitone pharmacokinetics. 
Reference Neonates age group -no of patients Dose (mg/kg) t ., (h) C.., (g/L) tin 
route Mean, sd Mean, sd Mean, sd 
Jailing et al 1974 Term -10 
Term -8 
Royer et al 1976 Premature-12 
Dysmature Prem -3 
Dysmarure Term - 10 
Term -5 
5-13([M) 
6-21(PO) 
1 O(1M) 
10(1M) 
10(1M) 
1 O(IM) 
6.4,3.6 
8.6,4.2 
40.1,17. 
0 
7.0,5.7 
31.2,14. 
8 
26.6,7.7 
12.9,4.0 108,48 
14.0,5.3 96,32 
21.2,2.6 120,32 
18.3,2.4 74,40 
17.8,2.6 130,75 
16.0,3.3 93,31 
Heiman & Gladtke Term -14 
1977 2-3 months-16 
4-12months - 14 
1-5 year -7 
Pitlick et at 1978 Term/Premature-32 
Fischer et al 1981 Term (unasphyxiated) 
-5 
Term (asphyxiated) 
-10 
Gillman et al 1983 Term/Premature 
-16 
Kossman et al Term hyperb unasphyxiated-5 
1985 Premature hyperb unasphyxiated -15 
5-10(IV) 
10(IV) 
10(W) 
10(1V) 
20(1V) 
14-21(IM) 
13-20(IM) 
7-I5(1V) 
10(IM) 
- 119,16 
83,5 
63,4 
69,3 
- 67-115 
- 110,63 
100,44 
- 244,181 
0.5,0.3 12.4,1.3 
1.1,0.5 10.9,1.0 
The pharmacokinetics of phenobarbitone in neonates and young children has 
been reviewed by Battino et at (1995) and some of the findings are tabulated in table 
4-9. Their findings found that the elimination of phenobarbitone is delayed in 
neonates and can be explained by the slow metabolism, limited renal excretion and the 
more acidic urine. These conclusion are based on results obtained by Kossman et at 
(1985), Heiman and Gladtke (1977), and Pitlick et at (1978) where the terminal half- 
lifes of term and premature neonates range from 67 to 409 hours respectively. These 
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values are higher than that are observed for older children and adults of 37 to 73 and 
75 to 126 hours respectively [Levy et al 1991]. 
Factors that affect phenobarbitone elimination could also include duration of 
postnatal drug exposure, gestational age and neonatal asphyxia. However, the latter 
two factors were still inconclusive as results of other studies were found to be 
contradictory (table 4-9). 
The effect of postnatal drug exposure is clearly demonstrated by Kossman et al 
(1985) where they observed the terminal half-lifes in premature infants during the first 
4 to 5 days of life was low, but with an abrupt acceleration during the second week. 
Heiman and Galdtke (1977) observed the terminal half-lifes decreases from 119 ± 16 
hours in term babies to 69 ±3 hours in babies between the age of I to 5 years. 
The differences in results on the effect of gestational age on the elimination of 
phenobarbitone can be highlighted by comparing the studies of Kossman et al (1985) 
and Nahata et al (1988) to that of Royer et al (1976), Jailing (1974), Gillman et al 
(1983), and Pitlick et al (1978). The former two studies found the trend in elimination 
decreases with age while the latter four studies found the differences were 
insignificant (p > 0.05). 
The influence of neonatal asphyxia is also indecisive when the results by Gal 
et at 1984 showed the clearances of asphyxiated and non asphyxiated 
neonates(0.0041± 0.001 versus 0.0087 ± 0.0039 L/kg. hour) are significant while that 
Fischer et al (1981) found no such differences(0.0064 ± 0.0026 versus 0.0064 t 
0.0023 L/kg. hr) 
Painter (1989) reviewed the elimination of phenobarbitone and noted that the 
rate was higher in children than in adults. This observation was however inconclusive 
since the studies used were mainly from young children age(n=2772) ranging from 0- 
18 years while that of adults(n=72) [Svensmark & Buchthal 1964, Duran et al 1988, 
Suganuma et al 1981, Yukawa et al 1992, Rossi et al 1979, Suzuki et al 1980] in 
single dose trials. Nevertheless, the progressively increased concentrationldose(C/D) 
ratio with age in some of these studies showed the possibility of age-dependent 
elimination rate. 
The above results hypothesise that maturation changes in absorption lead to 
increase in C/D ratio but Rust and Dodson (1989) showed this was not true. Their 
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results showed that children and adults had in fact a similar absorption rate. C/D ratio 
was however affected by concomitant AED with the exception of valproic acid 
[Suganuma et al 1981, Yukawa et al 1992]. 
Reports on the correlation of dose and serum concentrations were highly 
variable and at times indecisive. This is partly due to the fact that some studies report 
the relationship is linear but not mentioning any statistical proof of its relationship. 
Nevertheless, Brachet-Liermain et al (1975) published result of a single dose study on 
infants and found the relationship is poorly related. Studies by Jailing (1974), Painter 
and Pippenger (1978) and Jailing (1975) on infants and neonates on chronic therapy 
showed the relationship is linear. Results on children showed the correlation is poor 
[Davis et al 1981, Mucklow et al 1981, Yukawa et al 1992] or significant [Melchior 
1965]. Findings in adult patients showed that the relationship is linear [Martin et al 
1979, Svensmark and Buchthal 1963]. Studies in mixed age population presented that 
the relationship is non-linear [Eadie et al 1977, Driessen and Hoppener 1977]. 
Table 4-10: Studies on the effect of age on serum concentration/Dose ratio in children 
Reference Age group(years) Child: adult Concurrent Dose(mg/kg) Final conclusion 
- sample size therapy 
Svensmark & 1-14(49) 49: 0 mixed 2-3 significant 
Buchthal 1964 
Suzuki et al 1980 <1-38 848: 24 mono/poly 1-10 significant between 
monotherapy and 
polytherapy 
Suganuma et at <3 -16 98: 0 mono/poly 2-3 monotherapy, 
1981 significant 
polytherapy-variable 
Rossi et al 1979 0-7 92: 0 mono - significant 
Duran et at 1988 <3 - 19 474: 62 mono 12 significant from <3-6, 
not significant from 7- 
19 
Yukawa et al <2 -15 1226: 0 mono/poly 2-6 Not significant with age 1992 
Abbreviation: Mono, monotherapy, Poly, polytherapy 
Although the above studies reported either linear or non-linear relationship 
between serum concentration and dose, Eadie et al (1977) also reported the possibility 
of a curvilinear relationship from a mixed age population group. They further stated 
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that serum level fell progressively with increased age. These results clearly indicates 
the presence of intraindividual and interindividual variations among population. 
4.4.1 Ethnic-based studies 
Although phenobarbitone pharmacokinetics have been well established, 
ethnic-based studies were rare. To date, only five population studies reported the 
ethnicity of patients used [Peiris et al 1988, Duran et al 1988, Botha et al 1995a, 
Yukawa et al 1992a, Yukawa et al 1992b]. Two of these were Japanese-based while 
the other three were from Sri Lanka, Spain and South Africa. A summary of these 
studies were presented in table 4-11. 
Table 4-11: Phenobarbitone population pharmacokinetics of various ethnic groups 
Reference Ethnic(Country)/ 
Patient-type 
Sample size Age(years) 
range or 
mean, se 
Dose/ Route of 
administration 
Pharmacokinetic 
parameters/Methods 
of analysis 
Duran et at 1988 Spain $36 1-73 Multiple dose level/dose ratio 
(Caucasian) -retrospective 
-epileptics 
Peiris et all 1988 Holland 47: 47 10-72 multiple dose serum concentration, 
(Caucasian) -prospective relative serum 
vs Sri Lankan concentration(RSC) 
Yukawa et al Japan 539 paediatric + Multiple dose level/dose ratio 
1992a (Japanese) adult -retrospective 
-epileptics 
Yukawa 1992b Japanese 539 paediatric + Multi-dose -Css, CL and serum 
(Japan) adult -retrospective level and dose 
-epileptics relationship 
-Non-linear mixed 
effect 
model(NONMEM) 
Botha et al 1995 Blacks/Indian 32 5.5 , 3.2 Multi-dose -Css, 
CL and serum 
(South Africa) -retrospective level and dose 
-epileptics relationship 
-Non-linear mixed 
effect 
model(NONMEM) 
Reports on level/dose ratios among the paediatric patients varied between 
population. Sagunuma et al (1981) and Yukawa E (1992a) observed significant 
level/dose ratios with age in the Japanese population in the age range of 0 to more 
than 15 years. Duran et al (1988) however found the same degree of significance only 
for the patients age less than 3 to 6 years old. The latter results were however similar 
to that reported by Rossi et al (1979), Guelen et al (1975), Benedetti et al (1979), 
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Minagawa et at (1981) and Davis et al (1981) which studied patients with undisclosed 
ethnic background between the age-group of 2 months to 6.5 years. These findings 
could possibly be due to interethnic differences in metabolism between paediatric 
Caucasian, Japanese and coloured South African children. 
Peiris et al (1988) however noted although the coefficient of variation for 
relative serum clearance for the Sri Lankan patients was higher than their Dutch 
counterparts, these differences did not reach any statistical significance. 
The studies by Yukawa (1992b) and Botha et al (1995a) estimate population 
clearance from routine data using the NONMEM method developed by Sheiner et al 
(1977) and Beal and Sheiner (1980). Both Botha et al (1995a) and Yukawa et al 
(1992b) also showed that clearance was significantly affected by weight. The latter 
further concluded that this relationship was most affected by patients on polytherapy 
with other AED's than those combined with sodium valproate. 
Although the population ages of Yukawa (1992b) and Botha et al (1995a) 
were distinctly different, their clearances(95% confidence interval) were similar; 
monotherapy(5.5-7.6L/kg. hr and 6.2-9. OL/kg. hr), polytherapy with valproate(3.7- 
4.7L/kg. hr and 4.0-6. OL/kg. hr) and polytherapy with other AED's(5.0-6. OL/kg. hr and 
5.6-8. OL/kg. hr) patients group(table 3.12). Their mean intraindividual(18.65%, 18.1%) 
and interindividual(20.07%, 18.0%) variation were almost identical. These findings 
must still be examined further because of the different population age-groups studied. 
Botha et al (1995a) also noted the possibility of no interethnic differences of 
paediatric Indians and Black patients in South Africa as their mean clearances were 
significantly similar.. 
Significant clearance and age relationship had actually been observed earlier 
by Grasela and Donn (1985) on neonatal patients between the ages of 24 to 42 weeks. 
Their results showed that mean clearances values of neonatal patients were more than 
10 times lower(0.0047L/kg. hr) than those in the paediatric or adults age. 
4.6 Review limitations 
This review suffers from the lack of published ethnic-based studies. This 
problem mainly arise from researchers who find that describing the racial or ethnic 
composition of patients being assumed as clinically unimportant or possibly 
11%, 
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discriminatory. Reports from the developing or third world countries are also too few 
for a full assessment of clinical applicability and relevance in all ethnic groups. 
Although evidence about interethnic differences of certain drugs such as 
phenytoin had already been mentioned and reviewed, for drugs such as 
carbamazepine, valproic acid and phenobarbitone, where this relationship has yet to be 
determined, the problems of establishing evidence is almost impossible. Hence to 
substantiate or dissaprove the influence of ethnicity on the pharmacokinetic of these 
three establish antiepileptic drugs are made difficult by the scarcity of published data. 
The limited number of studies cited were again restricted due to problems of 
inter-study variations. Inter-study variations can be broadly categorised into three 
main types. First was the age group; paediatric(0-18 years), adult(>18 years) and 
mixed(all ages), second the type of pharmacokinetic model employed and finally the 
type of computer software(OPT and NONMEM) used to estimate the population 
pharmacokinetics. These inter-study variations reduced the number of studies for 
comparison which makes any conclusion indecisive. 
4.7 Conclusion 
Establishing ethnic-based population pharmacokinetics for established 
antiepileptic drugs may prove important in optimizing drug therapy. Inter-ethnic 
differences are evident in drugs such as phenytoin and carbamazepine but these 
differences are less clear cut for valproic acid and phenobarbitone. 
Pharmacokinetic parameters which are associated with phenytoin inter-ethnic 
differences are its metabolic rate constant(Km), maximum metabolic rate(Vmax), half- 
lifes(tlr2) and clearance(CL). Half-lifes and clearance were the two main 
pharmacokinetics parameters linked to inter-ethnic differences in carbamazepine, 
valproic acid and phenobarbitone. 
Reliability of conclusions made in this review was however restricted by the 
limited numbers of published ethnic-based literatures and inter-study variations. These 
findings otherwise showed inter-ethnic differences could be present for established 
antiepileptic drugs and more research is needed to verify their importance. 
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Part 2 
Data extraction 
Chapter 5 
Methods and material 
5.1 Background information 
Data on epileptic patients were gathered retrospectively from government 
hospitals in Malaysia. The population data consisted of both paediatric and adult patients. 
The patients were mainly of Malay, Chinese and Indian origins which form the three most 
dominant ethnic groups in Malaysia. 
Malays are called as the `bumiputera's or original native of the land and this 
include other indigenous groups(such as Iban, Melanau) from Sabah and Sarawak(East 
Malaysia) from the island of Borneo. The Chinese population which came to Malaysia 
during the British colonisation period are mostly from the southern part of mainland 
China. Similarly, Indians are from the highly populated and heterogenous continent of 
India. A brief outline of the composition. of the Malaysian multi-ethnic population and 
health system is described below. 
5.1.1 Malaysia the country 
Malaysia is a tropical country situated 7 degrees north of the equator in the heart 
of South-east Asia. It comprises Peninsula Malaysia and the two states of Sabah and 
Sarawak on the island of Borneo. Together it covers a total area of 329,758 square 
kilometers(figure 5-1). 
Malaysia comprises of thirteen states and two federal territories. The two federal 
territories are namely the capital city of Kuala Lumpur and the Island of Labuan. Nine of 
the states have a hereditary ruler respectively from which the Supreme head of State, the 
Yang Di-Pertuan Agong(King) is elected every five years [Malaysian Tourism Agency 
1996]. 
Malaysia is a multiracial country with a population of approximately 19.9 million. 
This consists of the main ethnic groups of Malays(61.28%), Chinese(27.56%) and 
Indians(7.83°%0) and a very diverse group of indigenous people in Sabah and Sarawak. 
Table 5.1 and table 5.2 presented the population distribution by race and sex as in the year 
of 1994. 
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Table 5-2: Mid-year population estimates by sex and state, 1994a 
Sex 
State Total(, 000) Male(, 000) Female(, 000) 
Malaysia 19,657 9,975.90 9,682.00 
Johor 2,310.6 1,181.0 1,129.6 
Kedah 1,453.3 719.0 733.6 
Kelantan 1,313.2 648.8 664.4 
Melaka 562.7 277.2 285.5 
Negeri Sembilan 764.0 385.5 378.5 
Pahang 1,154.7 598.3 556.4 
Perak 2,018.6 1,033.7 1,047.9 
Perlis 201.4 101.0 100.4 
Pulau Pinang 1,171.2 582.3 588.9 
Sabah 1,977.0 1,040.6 936.4 
Sarawak 1,837.8 944.2 893.6 
Selangor 2,591.4 1,317.4 1,274.0 
Terengganu 874.9 445.3 429.6 
Federal Territory 
(Kuala Lumpur) 1,304.5 669.0 635.5 
Federal Territory 
(Labuan) 59.6 31.9 27.7 
a As at 30th June, 1994. The figures are estimated using the 1991 census data as the base and adding the annual natural 
increase, that is, the excess of births over deaths 
States in bold signify where the hospitals are situated and used in this study 
5.1.2 The Health System 
Each of the thirteen states and two federal territories provide both inpatient and 
outpatient care programs which form a vital part of the medical care program of the 
Malaysian Ministry of Health. This program is provided through a network of sixteen 
general hospitals, eighty-nine district hospitals and four mental institutions throughout the 
country [Annual Report, Ministry of Health, Malaysia 1991]. Table 5-3 showed the 
distribution of hospitals and special institutions by state and bed strength. 
5.2 Research protocol 
The protocol involved visits to hospitals with a special emphasis on hospitals 
which provide therapeutic drug monitoring services on the four antiepileptic drugs. 
Approval from the Director General of Health, Ministry of Health, Malaysia, was 
initiated. Upon approval, patients profiles were obtained from case-notes dated to the time 
when drug monitoring was first initiated. Only complete case-notes were taken and lost 
notes were omitted. Summary of the proposed research protocol in figure 5-2. 
81 
Figure 5-2: Research protocol for the multi-centre retrospective study. 
1. Hospitals : 
(a) General Hospitals 
(b) Psychiatric Hospitals 
u 
2. Patient selection 
4 
3. Data collection: 
(a) Pharmacy department 
( b) Biochemistry Department 
(c)Outpatient's clinics 
(d) Records Department 
u 
4. Organisation of Data 
u 
5. Data analysis 
5.3 Data retrieval 
The period allocated for data collection was approximately three months. The 
dates for hospital visits were from the 30 September to the 20 December 1997. Detailed 
outline of dates for each hospital visit is in appendix 5-1. Since patients' files were kept in 
the record office, the relevant clearance from the proper department was obtained. The 
departments involved were the pharmacy department, biochemistry department, record 
office, and the neurology, medical or psychiatric units. All collected data were transferred 
to the standardised worksheet (appendix 5-2) and were kept confidential and no name of 
patients were recorded. 
Data from the years of 1993 - 1996 were retrieved from five government hospitals 
which offer therapeutic drug monitoring services for these drugs. The hospitals selected 
are those where monitoring of the drugs is done routinely by the pharmacy department 
where control, recording, accessibility and retrieval of patient's data are better organised. 
The protocol for therapeutic blood monitoring(appendix 5-3a, 5-3b) is similar to the 
guidelines outline in the Ministry of Health Handbook 1996. 
5.4 The Hospitals 
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The five selected hospitals selected were Hospital Sultanah Aminah Johor Bahru, 
Hospital Ampuan Rahimah Kelang, Hospital Ipoh and Hospital Pulau Pinang which are 
general hospitals, and Hospital Permai Johor Bahru which is a mental institution dealing 
mainly with psychiatric cases. These hospitals spread out all over the peninsula of Malaya 
and were specifically identified because of several reasons. The first is that these hospitals 
are situated in four of the most populated states(bold letters) of Malaysia and the 
demographic statistic of the four states is in table 5-1. The four states concern were Johor, 
Selangor, Perak and Penang. Together these states constitute approximately 41.5% of the 
total population. However the inter-ethnic distribution were slightly different. Malays 
were more prominent in Johor, Chinese in Pulau Pinang, while Indians was highest in 
Selangor. Population estimates by sex is in table 5-2 [ State Data Bank, Department of 
Statistic 1994, Social Statistic Bulletin, Department of Statistic 1974 ]. Overall, the ratio 
per 100 of male to female of the four selected states was almost equivalent, i. e., 50.3: 49.7. 
This is similar to the national ratio of 50.7: 49.3. 
Secondly the combined bed capacity of the five hospitals of about 6260 would 
provide enough patient data during the screening procedure. Types of services offered 
were similar for all hospitals with the exception of Hospital Permai which is an institution 
specialised in mental health. A summary of the services that are available in each of the 
five hospitals is in Table 5-4 [Annual report Hospital Sultanah Aminah, JB, Hospital 
Permai, Hospital Klang, Hospital Ipoh, Hospital Penang ] 
Thirdly, the hospitals selected are all classified as either regional or specialised 
hospitals. Regional Hospitals are hospitals where patients come for treatment and review 
from several catchment areas. Specialised hospitals are institutions where treatment are 
specific towards certain disease condition such as epilepsy. Regional Hospitals are referral 
hospitals with medical consultants of various specialities providing services for patients 
coming from smaller district hospitals. District hospitals are hospitals with only a few or 
no medical consultants managing the hospitals. These hospitals usually have a bed 
capacity ranging from 100 to 400 beds. Each regional hospital services at least five district 
hospitals. An example of a regional hospital is Hospital Sultanah Aminah Johor Bahru 
which services six district hospitals in the state of Johor. Other than Hospital Sultanah 
Aminah, therapeutic drug monitoring is practiced quite extensively in Hospital Tengku 
Ampuan Rahimah, Selangor, Hospital Ipoh, Perak, Hospital Alor Star, Kedah, Hospital 
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Kota Bahru, Kelantan, Hospital Besar Kuala Terengganu, Terengganu, Hospital Kuantan, 
Pahang, Hospital Queen Elizabeth, Sabah and Hospital Kuching Sarawak. 
There are currently four specialised hospitals in Malaysia. All four hospitals are 
hospitals which handles mainly mental health care. Two of the hospitals are based in West 
Malaysia and one each are situated in Sabah and Sarawak in East Malaysia. Therapeutic 
drug monitoring is routinely practiced in two of the hospitals, Hospital Permai and 
Bahagia in West Malaysia. 
These hospitals were also selected due to all patients were treated and reviewed by 
qualified physician. These hospitals follow stringent guidelines(based on Ministry of 
Health instruction) for blood sampling with experienced paramedical staffs managing the 
department. 
Finally, the period and cost of study had limited the number of hospitals to be 
visited. It should be mentioned that the period of study is limited to three months only and 
these hospitals are situated from the southernmost state(Johor) of the Malay peninsula to 
the northern state of Penang. The distance between these two states is already about 1120 
kilometers and if hospitals from the States of Sabah or Sarawak(Borneo Island) were to be 
included(more than 1600 kilometers from Johor), the time is surely inadequate and 
substantial extra cost would have been incurred which could not be met from within the 
study budget. 
5.5 Selection of patients 
Patients were initially screened from data recorded at the Therapeutic Drug 
Monitoring Unit of the Pharmacy Department. This was then cross-checked at the 
department concerned, i. e. medical, neurology etc. The fmal list of patients recruited was 
selected on the basis that there were complete written records and they were taking the 
drugs orally for at least one month. Complete written record were notes made by the 
physician concerning patient history, biodata, examination, observation, and conclusion. 
Patients with missed but retrievable records were included. The criteria for selection of 
population sample were as follows: 
a. Inclusion criteria: 
i. Patients who must be diagnosed and confirmed to be epileptics. 
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ii. Patients receiving at least one of the study drugs. 
iii. All laboratory results for serum levels must use a known appropriate analytical 
methodology 
iv. Patients must be on the studied drugs for at least a month before any monitoring 
is done 
b. Exclusion criteria: 
i. Patients which were non-compliant 
ii. Patients with incomplete records 
iii. Etiology of seizure is neoplastic, progressive degenerative, metabolic, 
demyelinating, or active infection. ( Patients with a previously resected 
tumor that is not recurrent are accepted) 
iv. Seizures due to acute medical disorders such as hypoglycemia, uremia etc are not 
considered 
v. Seizures due to alcohol abuse or alcohol withdrawal 
vi. Seizures due to neurologic disorder or any kind of serious medical disorder or 
active infection. 
Due to the distance between hospitals and the short study period only five hospitals were 
visited although seven hospitals were initially targeted. Retrieval of data was often tedious 
and time consuming since none of the hospitals were computerised and data had to be 
searched by hand. Details of data collected were summarised by the format in appendix 5- 
4. 
Patients were selected only if they were on antiepileptic drug therapy for at least a 
month and were confirmed epileptics with no known metabolic or neurological disorder. 
These were checked for non-compliance based on the written notes or comments made in 
the therapeutic request forms. However, no formal interview with patients were made to 
confirm the findings. 
No age limit was set and patients were grouped in their respective ethnic 
background. Patients were categorised as adults if their age is 18 years or more and those 
below this age limit are considered in the children group. 
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The number of patients screened and selected were 696,134,397,180 and 461 
for hospital Johor Bahru, Hospital Permai, Hospital Kelang, Hospital Ipoh, and Hospital 
Penang respectively. However, the number of suitable data were 1,215 or 65.04 percent of 
the total number shortlisted. The number of adult to children was 874 and 341 with the 
most number of patients(394) selected coming from Hospital Johor Bahru. Reasons for 
exclusion for about 34.96% of the shortlisted patients were inadequate patient's data, non- 
compliance and lost files. Inadequate patient's data means that patients notes were 
incomplete for a full compilation as that is listed in appendix 5-4. 
Table 5-4 and 5-8 highlighted the demographic and clinical data of children and 
adult epileptic patients of each individual hospital visited. Patients were categorised into 
epilepsy types namely generalised( code 1), partial(code 2) or others(code 3). Epilepsy 
categorised as others include specific epileptic syndromes and unclassified epilepsies. 
Examples of specific epileptic syndromes are febrile convulsions, reflex epilepsies and 
seizure induced seizures while unclassified epilepsies are neonatal seizures and nocturnal 
tonic-clonic seizures. 
Table 5-4 : Patients' characteristic of Hospital Sultanah Aminah, Johor 
Variables Malay Chinese Indian 
Sample size 194 117 83 
Sex(M: F) 80: 114 70: 47 37: 46 
Age group 73: 121 63: 54 51: 20 
(Children: Adult) 
Mean Age(years), sd 24.52,14.59 21.42,13.49 26.08,12.48 
Range 2-67 2-53 2-55 
Mean Weight(kg), sd 48.27,19.23 45.87,19.22 13.14,17.82 
Range 7.90-84 9.60-81.75 9.50-79 
Length of disease(years), sd 
Range 9.88,9.15 9.61,8.35 9.66,8.12 
0.25-33 0.50-39 0.75-40 
Epilepsy types(1: 2: 3) 120: 26: 48 71: 15: 31 53: 15: 15 
Therapy 
. mono: poly 126: 68 70: 47 57: 26 
Abbreviation: mono=monopoly, poly-polytherapy 
Seizure index was the indicator and the common metric used for outcome 
measurement of seizure control. Seizure index was calculated by dividing the number of 
seizures per day. The record of seizures were obtained from the written notes on the day 
of hospital visit. For example, if a patient has a history of 5 seizure per three months; 
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number of seizures 
seizure index == 5/90 =0.0555(seizures/day) 
period of observations 
Patients were then grouped into controlled or uncontrolled groups. 
Table 5-5 : Patients' characteristic of Hospital Permai, Johor 
Variables Malay Chinese Indian 
Sample size 51 59 29 
Sex(M: F) 30: 21 27: 32 23: 6 
Age group 51: 0 59: 0 29: 0 
(Children: Adult) 
Mean Age(years), sd 41.00,12.43 39.85,12.05 42.99,15.61 
Range 21-71 17-69 19-81 
Mean Weight(kg), sd 60.92,9.10 59.06,9.14 59.01,8.35 
Range 46-75 41-75 50-72 
Length of disease(years), sd 
Range 10.26,8.29 9.97,8.09 11.64,10.96 
1-34 0.50-42 0.25-42 
Epilepsy types(1: 2: 3) 47: 4: 0 55: 4: 0 26: 3: 0 
Therapy 
-monopoly 12: 39 20: 39 9: 20 
Abbreviation: mono=monopoly, poly=polytherapy 
Table 5-6: Patients' characteristic of Hospital Klang, Selangor 
Variables Malay Chinese Indian 
Sample size 86 48 115 
Sex(M: F) 44: 42 19: 29 48: 67 
Age group 38: 46 7: 37 43: 72 
(Children: Adult) 
Mean Age(years), sd 26.52,18.11 33.09,14.93 25.37,12.91 
Range 1-73 2.60-62 2.75-50 
Mean Weight(kg), sd 44.26,18.39 52.15,15.73 48.13,15.72 
Range 5.10-84 11-87 13-89 
Length of disease(years), sd 
Range 8.60,8.94 16.52,11.80 10.96,9.45 
1-36 2-50 1.50-33 
Epilepsy types(1: 2: 3) 61: 22: 3 40: 8: 0 102: 12: 1 
Therapy 
-mono: poly 52: 34 10: 38 67: 48 
Abbreviation: mono=monopoly, poly=polytherapy 
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Table 5-7 : Patients' characteristic of Hospital Ipoh, Perak 
Variables Malay Chinese Indian 
Sample size 57 26 51 
Sex(M: F) 28: 29 16: 10 21: 29 
Age group 25: 32 6: 20 15: 36 
(Children: Adult) 
Mean Age(years), sd 21.59,15.39 28.71,13.17 24.43,13.02 
Range 3-61 4-55 3-58 
Mean Weight(kg), sd 44.88,20.56 53.65,14.72 47.98,15.77 
Range 11-80 16-80 13-82 
Length of disease(years), sd 
Range 10.61,6.86 13.24,8.52 12.67,8.94 
2.50-30 3-32 1.50-40 
Epilepsy types(1: 2: 3) 53: 4: 0 23: 3: 0 44: 7: 0 
Therapy 
-mono: poly 28: 29 10: 16 38: 13 
Abbreviation: mono=monopoly, poly=polytherapy 
Table 5-8 : Patients' characteristic of Hospital Penang, Penang 
Variables Malay Chinese Indian 
Sample size 82 173 44 
Sex(M: F) 40: 42 91: 82 26: 18 
Age group 15: 57 28: 145 30: 6 
(Children: Adult) 
Mean Age(years), sd 29.33,12.95 34.06,15.83 33.82,13.24 
Range 2-55 6-94 9-55 
Mean Weight(kg), sd 53.57,16.92 55.97,12.40 54.41,16.18 
Range 12-90 16-80 23-82 
Length of disease(years), sd 
Range 15.11,11.86 13.65,11.83 18.05,10.83 
1.75-46 1-61 2-39 
Epilepsy types(1: 2: 3) 53: 24: 5 125: 43: 5 29: 14: 1 
Therapy 
-mono: poly 34: 48 60: 113 18: 26 
Abbreviation: mono=monopoly, poly-polytherapy 
5.6 Therapeutic Drug Monitoring 
Therapeutic Drug monitoring is one of the activities of the Clinical 
Pharmacokinetics Services [Pharmaceutical Services Division, Ministry of Health 
Malaysia, 1996]. It was first started in the mid-eighties by Hospital Pulau Pinang and upto 
1995, more than forty hospitals had started the service. The range of therapeutic blood 
monitoring depends largely on the hospital needs and financial capabilities. This service is 
of clinical importance as demonstrated by the many departments utilising its services. ( 
table 5- 9) 
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i. Guidelines for Therapeutic Drug Monitoring. 
A standard guideline is used for all routine blood sampling [ Pharmaceutical 
Services Division, Ministry of Health 1996 ]. Requests for therapeutic blood monitoring 
are restricted to patients reviewed by either consultants or senior medical officers. These 
guidelines stress the importance that hospitals should follow stringent rules for blood 
sampling with experienced paramedical staff managing the department. 
The guideline outlines that patients must be informed of the specified date upon 
which blood sample will be taken. This is usually a week before the next review date. 
This would ensure that the result(s) can be made available on the schedule date of review. 
Table 5-9 : Summary statistic of Therapeutic Drug Monitoring services in 
five main hospitals in Malaysia (1995) 
Facility 
Hospital 
J. Bahru Permai Kelang lpoh Penang 
Bed 
TDM unit 
Test/year 
test/year(AED 
test/year 
(antibiotics) 
Others 
Departments 
-Surgery 
-Medical 
-O&G 
-Paediatric 
-Anaesthiology 
-Opthalmology 
-Psychiatric 
-ICU 
-CCU 
-Outpatient 
-A&E 
989 2080 811 990 1390 
y n y y y 
4898 700 1838 1221 5234 
45 95 43 27 46 
46 <1 32 46 43 
9 4 25 27 11 
y n y y y 
y n y y y 
y n y y y 
y n y y y 
y n y y y 
Y n y y y 
y y y y y 
y n y y y 
y n y y y 
Y y y y y 
y n y y y 
Abbreviation: 
ys yes, n- no, 0&G- Obstetric & Gynaecology, ICU- Intensive Care unit, CCU = Coronary Care Unit, A&E= 
Accident & Emergency Department 
Antibiotics, are the aminoglycosides i. e. gentamicin, amikacin, netilmicin, vancomycin 
Others, include theophylline, digoxin, cyclosporin 
Blood sample was taken between 10.00am and 12.00am where 3-5 milliliters of 
blood are extracted by venuspuncture and placed into a 10 ml test-tube. The test-tube was 
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then labeled and sent to the Pharmacy department with an accompanying request form 
about details of patient biodata and drug therapy(appendix 5-5). The samples were sent on 
the same afternoon to be analysed. Results of the assays were obtained either on the same 
or following day. 
ii. Analytical procedures 
The fluorescent polarization immunoassay(FPIA) is used to determine serum 
concentration. The coefficient of variation for the four analysed drugs is between 2 to 4%. 
FPIA is ranked between good and excellent for all drug tests and with a high work rate. 
However, its usefulness is limited to tests involving plasma or serum sample only. A 
summary of the relative advantages and disadvantages of FPIA over the other analytical 
methods are in appendix 5-6 to 5-9 [Winter & Tozer 1991, Levy et at 1991]. 
iii. Drugs Assay 
The two most common groups of drugs monitored are the aminoglycoside 
antibiotics and antiepileptics such as phenytoin, carbamazepine, valproic acid and 
phenobarbitone [unpublished report from the Ministry of Health, Pharmacy Division, 
Malaysia 1995]. Table 5-9 summarised the range and extent of therapeutic drug 
monitoring activities of these four drugs in Hospital Sultanah Aminah, Johor Bahru, 
Hospital Pulau Pinang, Penang, Hospital Ampuan Rahimah, Kelang, Hospital Ipoh, 
Perak, and Hospital Permai, Johor for the year 1995. Therapeutic drug monitoring 
services is offered for both in and outpatient in all hospitals with the only exception of 
Hospital Ipoh where patients are hospitalised whenever therapeutic drug monitoring is 
initiated. 
5.7 Pharmacokinetics Models and statistical analysis 
5.7.1 Individual patient data 
The three main variables investigated were dose, serum concentration and 
clearance. Dose can either be in milligrams per day or milligrams per kilogram body 
weight. Serum concentration are converted to milligram per litres. 
Since many patients with one or more doses having several measured serum 
concentrations, the average of the measured levels and the subsequent treatment 
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response(seizure index, i. e, controlled or uncontrolled) for each dose were taken. Many 
patients were also on two or more different dosage regimens on all three antiepileptic 
drugs(table 5-10). 
Table 5-10 : Summary of dose serum level pairs of patients on phenytoin, carbamazepine, valproic acid 
and phenobarbitone 
Dose-serum level pairs Phenytoin(n) Carbamazepine(n) Valproic acid(n) Phenobarbitone(n) 
-child: adult -child: adult -child: adult -child: adult 
1 17: 259 51: 210 70: 99 28: 67 
2 35: 277 79: 139 129: 115 19: 55 
3 12: 80 10: 37 31: 22 7: 11 
4 2: 19 0: 6 12: 14 0: 3 
5 0: 8 0: 2 1: 1 - 
6-0: 1 -- 
The efficacy of the therapeutic or target range of phenytoin, carbamazepine, 
valproic acid and phenobarbitone was determined by the used of odd-ratios between 
seizure controlled and uncontrolled patients. The method essentially utilised only one 
single dose and serum concentration data from each patient and the details will be 
described in chapter 6. Random selection of a single dose/serum concentration pair from 
patients with more than one dose and serum concentration pairs were computer generated( 
appendix 5-10). This method of systematic selection was mainly employed to avoid inter- 
patient bias. 
The same set of data was used to establish relationship between dose with either 
serum concentration or clearance of carbamazepine, valproic acid and phenobarbitone. 
However, two dose and serum concentration pairs were randomly selected from each 
individual during the determination of the Michealis-Menten constants for phenytoin. The 
computer based selection is described and presented in appendix 5-11. The formula used 
in calculating clearance and the Michealis-Menten constant are describe in section 5.7.2. 
Both linear and multiple regression technique was used for analysis. Linear 
regression was appropriate because of its characteristic of being able to recognise the 
relationship of an dependent and independent variable. This relationship was summarised 
by the regression equation consisting of the slope and the intercept. The method also 
enable the test of significance and confidence intervals of hypothesis and make 
assumptions on the underlying errors on the test of significance. Multiple regression 
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methodology is also used in looking for relationship between continuous variables, and 
allowing for a third variable. It is also important when adjustment may need to be made 
for differences in confounding factors between groups. Data was analysed using the 
software available in the Minitab Statistical package, version 10.2. 
5.7.2 Pharmacokinetic variables 
Carbamazepine, sodium valproate, and phenobarbitone clearance was calculated 
on the assumption that at steady state( at equilibrium) the ratio of change is proportionate 
to the ratio of change of serum concentrations. Clearance is usually measured in liters per 
day (L/day) or liters per kilogram per day. (L/kg. day) The formula and assumptions by 
Wagner (1965) and is described in chapter 1, section 1.5.5 was used in calculating the 
clearance; 
F. D 
Css = 
Vd. Ke r 
where Css is the average asymptomatic blood concentration, D is the dose, r is the length 
of the dosage interval, Ke is the first-order rate constant for overall loss of drug from the 
blood, F is the fraction of each dose which is absorbed( bioavailibility factor ), and Vd is 
the apparent volume of distribution. 
Since clearance ( CL, Liters/day) is equal to Vd multiplied by Ke , the formula 
can be rewritten as; 
ED 
Clearance(CL) 
G. T 
rcan be in minutes or hours per day. For simplicity, F is taken as equal to 1. 
ED 
or Css 
Cl. r 
The regression equation was obtained by plotting the relationship of steady-state 
serum concentration(Css) and dose( D ). For simplicity, F is taken as equal to 1 and i is 
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taken as per day. This assumption is also based on the reason that the drugs taken by all 
patients were the same since the drugs came from a single government body. 
As for phenytoin, assuming steady-state condition, the following linearised 
Michealis-Menten relationship( as described in chapter 1, section 1.5.5) was used to 
obtain clearance, Vmax and Km. 
(S. F. R)er - Vmax - Km. [S. F. R. J 
Css 
where (S. F. R) is the final expected rate of absorption, which is dependent on the salt 
factor(S) form and is equal to 1, F is the bioavailibility while R is the rate of 
administration(dose/day) [equal = 1]. For this study, bioavailibility was assumed to similar 
to all patients for all patients and this omitted. Vmaz is defined as the maximum rate of 
metabolism (metabolic capacity) and Km is a constant with a value equal to the plasma 
concentration at which the rate of metabolism is one-half the maximum. 
As describe in chapter 1, section 1.5.5, Vmax and Km can be estimated by plotting 
clearance[S. F. R/Css] against R(dose/day). The point of intercept on the y-axis is the value 
for Vmax (mg/day) while the slope is the negative value for Km(mg/1). Thus, at least two 
dose-level pairs are needed in plotting the desired graph. The equation of y=a+ bx is 
defined as the regression equation, where a is the intercept ( equal to Vmax) and b is the 
regression coefficient or gradient and is equal to Km . Similarly, multivariate regression 
was also employed to ascertain the relationship of continuous variables with the earlier 
equation. 
5.8 Statistical tests 
Data was stratified according to ethnic and age group. Analysis of 
variance(ANOVA) is used in investigating differences between continous data(age, 
weight, length of disease years, dose, serum concentration, clearance) in each ethnic 
groups. Degree of significance is set at p: 5 0.05. 
The method proposed by Greenland (1971) in estimating trend from the slope(ß) 
of the regression equation was employed in determining difference between groups(eg. 
ethnic, age). Detailed outline of the formulas used was described in chapter 3, section 
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3.3.3b Multivariate regression equation was later used for modeling if the relation is 
suspected to be linear. (Chapter 3, section 3.2.4 ). Similarly, variances of slope( ß) or 
mean values of parameters(eg. clearances, Km, Vmax( constants ( a, 6)) was calculated 
by the formulas described by Armitage and Berry (1997) and described in chapter 3. 
These variances (ß a) were used to calculate the summary estimate, Q statistic ( chi 
square statistic) and correlation values for homogeneity, and the 95% confidence interval 
and summary estimate of each individual groups. The degree of significance is also set at 
p: 5 0.05. All confidence intervals are 95%. 
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Part 3 
Data analysis and outcome 
Chapter 6 
Therapeutic Drug Monitoring of antiepileptic drugs 
6.1 Introduction: 
Therapeutic drug monitoring or clinical pharmacokinetics is defined by the 
process of using drug concentrations, pharmacokinetic principles, and 
pharmacodynamic criteria to optimize therapy [Evans 1991]. Optimizing therapy of 
AED drugs by therapeutic drug monitoring is accomplished by minimizing the 
probability of toxicity or by increasing the probability of the desired therapeutic effect. 
The desired therapeutic effect or the occurrences of toxicity are usually associated 
with a certain concentration range. These concentration ranges are termed the 
therapeutic range or therapeutic window. Therapeutic range is defined as a range of 
drug concentration within which the drug is effective and the probability of 
unacceptable toxicity is low. Currently, the value and reasons for therapeutic drug 
monitoring have been well established for the aminoglycosides class of antibiotics, 
digoxin, theophylline and for established antiepileptic drugs(AED) such as phenytoin, 
carbamazepine, sodium valproate and phenobarbitone [Evans et al 1991]. 
Other than the phenomena of narrow therapeutic range, these AEDs are also 
associated with high intra and inter-individual variation between patients[Welty et al 
1983]. This then led to the use of these AEDs being individualised to suit to patient's 
needs. Individualisation in therapy can be best established by proper monitoring or 
titration of these drugs. 
Studies on therapeutic drug monitoring of AEDs [Frewin et al 1982, Larkin et 
al 1991, Karande et al 1992, Mckee et al 1993, Eadie 1994] had all shown the benefits 
of antiepileptic drug monitoring for chronic epileptics. The reports of higher number 
of serum levels in target range, improvement in therapeutic response and reduced 
hospital visits had indicated the advantage and the critical nature of this service for 
patient care. However, interpretation of a single measurement of serum level is often 
difficult and sometimes impractical unless the drug pharmacokinetics and time of 
sampling are known [Chadwick 1994]. Currently, therapeutic drug monitoring is 
warranted when certain conditions and disease states led to changes of the 
pharmacokinetics of these drugs. These include suspected non-compliance, signs of 
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toxicity, drug-drug interactions, pregnancy and diseases of the kidney and liver 
[Commission on AEDs, International League Against Epilepsy 1993]. The 
pharmacokinetic changes are often complicated and monitoring of plasma 
concentration helps to identify and rectify problems in treatment. These 
recommendations for monitoring were later upheld by the British Epilepsy Association 
(1994) and they stressed that therapeutic drug monitoring should function as a tool to 
improve pharmacotherapy only if clinical judgment failed in its role in the use of these 
AED in epilepsy. 
The above recommendation however prompted two questions pertaining to its 
validity. The first question is the method used to derive the above recommendations. It 
should be mentioned that most studies on established AEDs have been noted to be 
poorly designed [Coatsworth 1971] and systematic reviews to provide evidence 
towards these recommendations are yet to be published. The second is the problem in 
applying these recommendation to epileptic patients worldwide when inter-ethnic 
differences in metabolism have been reviewed for phenytoin [Edeki & Brase 1995] 
and reported for carbamazepine [Lin et al 1991, Yoon et at 1997]. Inter-ethnic 
differences have been shown to be significantly important from published European, 
American or Japanese based studies and extending these recommendations to all 
populations might be inappropriate. 
The current therapeutic ranges of antiepileptic drugs such as phenytoin, 
carbamazepine, valproic acid and phenobarbitone are well established [Brodie & 
Dichter 1997]. Studies that showed their importance are plentiful but reports of their 
use in patients from the Malaysian society were rather limited [Ismail & Rahman 
1990, Ismail & Rahman 1993]. These studies came mainly from the predominantly 
Malay population and failed to mention the therapeutic outcome of treated patients 
within the desired therapeutic range. Evidence towards the benefits of therapeutic 
drug monitoring of established antiepileptic drugs in the multi-ethnic society of 
Malaysia is thus the main objective of this study. The benefits will be measured as the 
ratio of seizure control between controlled to uncontrolled patients within the 
specified therapeutic range. 
This study will nevertheless have three main objectives. Firstly, to determine 
the importance of the therapeutic or target range to attain maximum therapeutic 
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response of established AEDs, secondly, to investigate whether therapeutic response 
is affected by inter-ethnic differences, and finally, to establish if age is an important 
determinant for optimum therapeutic response. 
6.2 Methodology 
The total of 874 and 341 adult and paediatric patients were selected. Patients were 
selected only if they were on antiepileptic drug therapy for at least a month and were 
confirmed epileptics with no known metabolic or other neurological disorder. They were 
checked for non-compliance to the prescribed drug(s) based on the written notes or 
comments made in the therapeutic request forms. Patients were grouped in their 
respective ethnic background. No age limit was set and patients were categorised as adults 
or children. The age range for children is set from zero to less than 18 years while patients 
age higher than the set limit(18 years old) are referred as adults. 
Table 6-1 and 6-4 highlighted the demographic and clinical data of paediatric and 
adult epileptic patients of each individual hospital visited. Patients were categorised into 
epilepsy types namely generalised( code 1), partial(code 2) or others(code 3). Epilepsy 
categorised as others include specific epileptic syndromes and unclassified epilepsies. 
Examples of specific epileptic syndromes are febrile convulsions, reflex epilepsies and 
seizure induced seizures while unclassified epilepsies are neonatal seizures and nocturnal 
tonic-clonic seizures. 
To evaluate the effectiveness of these documented therapeutic ranges of the four 
studied drugs on the control of seizures, the Mantel-Haenszel fixed effect model method 
for pooling across data was employed. This method basically measures the ratio of effect 
on two different treatment, typically known as odds ratio. This involved arrangement of 
data into 2X2 table as described in chapter 3. This provides a mathematical relationship 
of the effect estimate with the summary estimate or the pooled estimate. Radhakrishna 
1965 also reported that Mantel-Haenszel chi-square has good statistical properties and is a 
powerful test. To compare heterogeneity across groups, the chi-square statistic [Mantel 
1963], variance of the summary effect measure [Robins, Greenland, Breslow 1986], and a 
test for homogeneity of effect size across data [Mantel, Brown, Byar 1977] were also 
used. 
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Since most patients were on two or more different dosage regimens, only one dose 
and serum level pair and the corresponding treatment response from each patient was 
randomly taken. Treatment response was defined as the number of seizures recorded by 
patients and were broadly classified either controlled or non-controlled. Records for 
seizures were obtained from patients' record book where seizures were noted down by 
each patient's carers. Record for seizures for hospitalised patients were gathered from 
seizure charts. Randomisation was based on computer selected set of numbers for each 
dose-serum level pair(Appendix 6-1). This method of randomisation was used as to avoid 
bias in selection all dose-serum level pairs. 
No attempts were made to separate monotherapy and polytherapy patients since 
this study was aimed to examine the effectiveness of the defined therapeutic ranges of 
phenytoin(1O-20mgfL), carbamazepine(4-12mg/L), valproic acid(50-100mg/L) and 
phenobarbitone(15-40mg/L). The hypothesis of this study is thus to test the difference in 
odds ratio(W) of controlled and uncontrolled epileptic patients in the so-called therapeutic 
ranges between Malay(yrm), Chinese(y. ) and Indian(y) patients, for example, Ho ; yam = 
yf, and Hi ;%# Wm . yam 
denotes odds ratio of Malay epileptic patients while yrc is odds 
ratio of Chinese epileptic patients. 
ANOVA one way analysis of variances and t-test were used for comparison of 
age, weight, disease years and dose per kilogram among ethnic groups. P value equal or 
less than 0.05 was considered significant in determining homogeneity, difference in odds 
ratio and ANOVA one way analysis of variances. The parameter used in the analysis were 
the mean dose per kilogram and serum levels in which levels were expressed in mg/L. 
6.3 Results 
6.3.1 Phenytoin 
Table 6-5 details clinical data and odds ratio of patients on phenytoin either on 
monotherapy or polytherapy. Test of one-way analysis of variance(ANOVA) on age(p = 
0.08), weight(p = 0.07) and disease years(p = 0.27) showed no significant difference was 
found to exist on the population sample of Malay, Chinese and Indian patients. Mean 
doses(p = 0.42) and serum levels(p = 0.06) were found to be similar for all three ethnic 
groups. 
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Figure 6-1: Phenytoin dose and serum level in 
controlled epileptic patients 
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Figure 6-2: Phenytoin dose and serum level in 
uncontrolled epileptic patients 
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Figure 6-1 and 6-2 presented the distribution of doses and serum levels in 
controlled and uncontrolled patients of the three ethnic groups respectively. Serum levels 
of controlled patients were well scattered with only 42.92% falling within the desired 
therapeutic range as compared to 39.07% of uncontrolled patients. Odds ratio(95%, C. I) 
for the probability of serum levels falling within the desired therapeutic range were found 
to be 1.29(0.74-2.23), 0.98(0.56-1.70), and 1.28(0.65-2.53) in Malays, Chinese and 
Indian. The 95% confidence limits however showed that the relationship between the 
desired therapeutic range and seizure controlled were insignificant for all ethnic groups. 
Test of homogeneity found that the summary odds ratio of 1.16(0.74-1.83) was not 
effected by inter-ethnic diferences(p= 0.37). 
Inter-individual variation between ethnic groups which was measured by the 
variances of odds ratio, showed Indian(0.12) had the most variation than either 
Chinese(O. 08) or Malays(0.08). This observation is possibly due to the fact that the Indian 
population of Malaysia came from various regions of the highly populated country of 
India where the diversity and differences in genetic, culture and language is most 
prominent. 
6.3.2 Carbamazepine 
Table 6-6 presented the results of paediatric and adult patients of different ethnic 
groups on carbamazepine therapy. Age(p = 0.003), weight(p = 0.003) and dose(p = 0.008) 
were the variables found to be distinctly different between adults patients. Age and dose 
were found to be highest in Chinese while Indian patients had the lowest body weight. 
Indian and Malay patients were similar in age(p > 0.05) and dose(p >0.05 ) while no 
differences was observed between the body weight(p > 0.05) of Malay and Chinese 
patients. 
None of the above confounder variables were found to be different in paediatric 
patients. Mean doses and serum levels between ethnic groups also showed no significant 
differences. 
Figure 6-3, and 6-4 graphically highlighted the distribution of serum levels of 
controlled and uncontrolled paediatric patients in all ethnic groups. The high number of 
serum levels within the desired therapeutic range of 4-l2mg/L in both controlled and 
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uncontrolled patients demonstrated the lack of significant relationship between serum 
level and therapeutic outcome. 
Table 6-6 showed that the odds ratio of controlled to uncontrolled patients is 
highest for Malay paediatric patients. This clearly signifies that serum levels of controlled 
Malay patients showed the highest probability of falling within the therapeutic range 
when compared to Chinese or Indian patients. Homogeneity test of the 95% confidence 
limit of these observed odds ratio nevertheless showed there was no significant difference 
between ethnic groups (p=0.40) although Malays had the widest range. 
The lower confidence limit of the odds ratio being less than 1 in all ethnic groups 
further proved that therapeutic range was statistically unimportant for control of seizures. 
These findings also demonstrated that the observed differences in age, weight and dose 
between the three ethnic groups had no significant effect on the pooled odds ratio of 
efficacy for the target range of carbamazepine. 
Figure 6-5 and figure 6-6 presented the pattern of observed serum levels between 
ethnic groups in both controlled and uncontrolled adult patients. Odds ratio of all three 
ethnic groups showed values higher than 1 but their 95% confidence limits showed that 
these findings were not conclusive for the desired range of 4-12mg/L. Pooled odds 
ratio(95%, C. I) of 1.58(0.59-5.23) subsequently confirmed these fmdings(p=0.25). 
Inter-patient variability among ethnic groups is measured by their variances. 
Variances of Malays, Chinese and Indians paediatric patients were found to be between 
0.39 and 0.42 These clearly showed that high inter-individual variation between patients 
do exist in all ethnic groups. The inter-individual differences between ethnic groups were 
however very small and possibly insignificant. 
Test of homogeneity for the odds ratio between paediatric and adult patients in all 
ethnic groups were insignificant. Pooled odds ratio of 1.07(0.40-2.87) and the 
corresponding p value of 0.13 clearly demonstrated that the use of target range to 
ascertain the best therapeutic response is inaccurate and could be related to the high inter 
and intraindividual differences between individuals. 
Variances for adult patients showed that large inter-individual differences do exist 
in all ethnic groups. Inter-individual differences were however highest in Chinese(1.00), 
Indians(0.99), and Malay(0.42). These findings can be demonstrated by the wide range of 
odds ratio of each ethnic groups. The differences in adults were more pronounced where 
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Figure 6-3: Carbanrazepine dose and serum level 
in controlled paediatric epileptic patients 
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Figure 6-4 : Carbanrazepine dose and serum level in 
uncontrolled paediatric epileptic children 
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Figure 6-5: Carbamazepine dose and serum level 
in controlled adult epileptic patients 
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Figure 6 -6: Carbamazepine dose and serum level 
in uncontrolled adult epileptic patients 
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the upper confidence limit odds ratio value of 12.06,10.80 and 4.85 were observed for 
Indians, Chinese and Malays. However, these observations could also be affected by the 
differences in sample sizes as the number of controlled patients were smaller than 
uncontrolled patients in both age and ethnic groups. The lower limit were however very 
similar in all groups. 
6.3.3 Valproic acid 
Table 6-7 summarised the mean clinical data of paediatric and adult patients on 
valproic acid therapy. The studied population were found to be homogenous as none of 
the variables and covariables tested showed a clear distinction in either age or ethnic 
groups. 
Scatter plot of serum levels against dose in both controlled and uncontrolled 
paediatric patients highlighted that serum levels were mostly within the desired 
therapeutic range of 50-100mg/L(figure 6-7 and 6-8). However the lower percentage of 
serum levels within the therapeutic range for controlled(69.74%) patients than 
uncontrolled(79.04%) patients showed that determining of serum levels for optimising 
therapeutic efficacy was still questionable. 
The percentage of serum levels outside the target range for uncontrolled and 
controlled patients were 26.52% and this showed that the determination of serum 
concentration for non-compliance or toxicity may be useful since evidence of serum levels 
outside the designated therapeutic range is more notable in uncontrolled patients. 
Odds ratios(95%, confidence interval) of paediatric patients from different ethnic 
groups showed that Chinese(1.28,0.21-7.77) had a wider range than that of Malay(0.55, 
0.25-1.18) or Indian(0.49,0.18-1.31). These findings also showed that the incidence of 
serum levels falling inside the desired therapeutic range 50-100mg/L were similar in both 
controlled and uncontrolled paediatric patients. The pooled odds-ratio(95%, C. I ) of 
0.60(0.30-1.22) showed no significant difference existed between ethnic groups(p=0.14). 
Figure 6-9 and 6-10 showed the distribution of serum levels to dose in controlled 
and uncontrolled adult epileptics. Serum levels of adults showed a high number of 
patients having levels below the desired range in both controlled(52.24%) and 
uncontrolled(55.65%) patient groups. Number of serum levels above the desired 
therapeutic range were few and only observed in uncontrolled patients. This was expected 
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Figure 6-7: Valproic acid dose and serum level in 
controlled paediatric epileptic patients 
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Figure 6 -8: Valproic acid dose and serum level in 
uncontrolled paediatric epileptic patients 
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Figure 6- 9: Valproic acid dose and serum level in 
controlled adult epileptic patients 
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Figure 6-10 : Valproic acid dose and serum level in 
uncontrolled adult epileptic patients 
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since the mean dose used in all ethnic groups were on the lower end of the recommended 
dose of 20-30mg/kg/day [BNF 1996]. 
The percentage of serum levels inside the therapeutic range is 16.67% in adult 
Chinese controlled patients as compared to 52.63% and 46.94% in Malays and Indians 
indicate the dose used for Chinese was probably ineffective. This might also indicate that 
Chinese patients need a bigger dose in order to attain a similar serum level so as to 
achieve control of seizures. 
95% confidence interval of odds ratio for Chinese adult patients which ranged 
between 0.08-0.47 is well below the significant level of 1(baseline for test of odds ratio). 
The findings showed a statistically significant probability for uncontrolled Chinese 
patients to fall inside the therapeutic range than those of controlled patients. The 
probability of serum levels being inside the therapeutic range for Malay(0.37-2.83) and 
Indian(0.90-2.51) patients were found to be no different in controlled or uncontrolled 
patients as these values fell below and above the value of 1. Pooled odds-ratio(0.70,0.30- 
1.60) of the observed differences for three ethnic groups however revealed homogeneity 
with the degree of significance value of 0.20. This result indicates that the use of 
therapeutic drug monitoring of valproic acid is highly inconsistent and displayed large 
inter-patient variation. 
Pooled odds ratio of children and adults showed a value of 0.65(0.30-1.60) and a 
p value of 0.15. This confirmed that that the target range has no significant impact in both 
age groups. 
Variances obtained for paediatric and adult patients showed the existence of high 
inter-individual variation among Malay, Chinese and Indian ethnic groups. Inter- 
individual variation was prominent in paediatric patients with Indians displayed the 
highest variance of 0.85. There was also large differences(0.10) in inter-individual 
differences between Chinese(0.25) and Malay patients(0.15). Similar inter-individual 
variation were however observed in adults of all ethnic groups. 
6.3.4 Phenobarbitone 
Patients data on phenobarbitone therapy showed that the difference in age, weight 
and disease years between ethnic groups were insignificant(table 6-8). No significant 
difference in mean doses and serum levels were noted between ethnic groups. 
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Figure 6-11 : Phenobarbitone dose and serum level 
in controlled epileptic patients 
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Figure 6-12 : Phenobarbitone dose and serum level 
in uncontrolled epileptic patients 
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Figure 6-11 and 6-12 presented scatter plot of serum levels and dose for 
controlled and uncontrolled patients of the main ethnic groups. The plots depicted a wide 
scatter of serum levels in all ethnic groups. Most of these levels were either 
below(53.56%) or within the therapeutic range(42.68%) but occurrences of potential toxic 
levels(3.76%) were more prominent in uncontrolled patients. The percentage of toxic 
levels(above the desired range) in controlled and uncontrolled patients were 0.66% and 
10.34%. 
Differences between the odds ratios of 2.05,1.40 and 0.66 obtained for Indian, 
Chinese and Malay patients were observed to be statistically insignificant(1.36(0.87-2.14), 
p=0.11). The trend for inter-individual variation however showed that Indian patients 
have a two fold and four fold higher differences to that of Chinese or Malay patients. This 
clearly demonstrated that although serial monitoring of serum concentration might not be 
important, the relationship between serum concentration and therapeutic response may be 
affected by interindividual differences. 
These results showed that monitoring of phenobarbitone serum levels are 
unimportant and irrelevant. Its used in the determination of compliance and suspected 
toxicity may be of clinical importance. These findings showed that the therapeutic range 
of 15-40mg/L of phenobarbitone had little or no effect in ensuring adequate therapeutic 
response. 
6.4 Discussion 
Several studies of patients on chronic therapy have suggested that measuring drug 
concentrations may enhance seizure control [Wing & Duff 1989] while others indicated 
that their routine use may not improve the treatment of epilepsy [Woo et al 1988]. Based 
on these contradictory observation, this study utilised data from both chronic outpatient 
and inpatients registered from hospitals in Malaysia to confirm these findings. In this 
study the method to measure treatment effect by Mantel-Haenszel (1959) was applied. 
The method was found suitable since it essentially estimate the difference in rates of 
disease between exposed and unexposed group as the odds ratio and allows the estimation 
of sampling variance and confidence interval. The sampling variance and confidence 
interval is important in assessing the degree of significance and homogeneity among 
treatment groups. 
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In this study, the two treatment patient groups were referred to as 
controlled(responsive) and uncontrolled(non-responsive) group. The groups were tested 
on the number of positive responses(no seizures) at a defined therapeutic range of each 
antiepileptic drug. Odds ratios and the corresponding 95% confidence interval allows 
significance test for the hypothesis and provide a measure of precision. 
Pooled odds ratios of controlled and uncontrolled patients on each of the studied 
drug revealed that monitoring serum levels at the defined therapeutic range was 
inadequate and clinical assessment is still the crucial factor for the best therapeutic 
outcome. These findings were further strengthened by the high incidences of inter- 
individual variation observed in each ethnic groups. Similar reports of poor correlation by 
studies between serum levels and seizure control for phenytoin [Dawson & Jamieson 
1971], carbamazepine [Callaghan et al 1978, Shorvon et al 1978], phenobarbitone 
[Buchanan & Allen 1971], and valproic acid[McQueen et al 1982] showed that inter- 
individual variation is an important factor that restricts the use of target therapeutic range 
across all individuals. These results thus distinctly validate the current guidelines for 
monitoring of these established antiepileptic drugs. 
The present study was not only aimed to verify the current recommendation but 
also to examine the impact of inter-ethnic differences to treatment. Odds ratio of Malays, 
Chinese and Indians epileptic patients on phenytoin, carbamazepine, valproic acid and 
phenobarbitone therapy revealed that the difference between controlled patients within 
and outside the defined therapeutic range was statistically insignificant. Results from this 
multiethnic Malaysian patients although similar to earlier reports[Froescher et al 1981, 
Beardsley et al 1983, Bussey & Hoffman 1983] had furnished further evidence for control 
on the seemingly important request for serial serum concentration of these drugs. These 
findings also showed that without appropriate indication for monitoring, the use of these 
therapeutic ranges would not be beneficial for optimising therapy[Schoenenberger et al 
1995]. 
High inter-individual variations for all four AEDs had been reported[Schmidt & 
Haenel 1984, Strandford & Johannessen 1980, Bruni et at 1978] and had clearly 
demonstrated that individualised therapy is crucial in therapy. Although similar inter- 
individual variations for all three ethnic groups were also observed in the present study, 
the rate of variation for Chinese and Indian patients were more pronounced than Malay 
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patients. These differences are an indication that the Chinese and Indian population of 
Malaysia are a diverse group of people and the use of a single population 
pharmacokinetics for all groups of patients is not appropriate. 
Age had not been reported to have any correlation with the variation in response 
with respect to the desired therapeutic range of carbamazepine [Schmidt & Haenel 1984, 
Strandjord & Johannessen 1980, Semah et al 1994] and valproic acid [Turnbull et al 
1983, Haigh D et al 1975, Jeavons et al 1975]. These findings were similarly 
demonstrated in this study by the pooled odds ratios(95%, C. I ) where the observed 
differences in controlled and uncontrolled adult and paediatric patients(all ethnic groups) 
on carbamazepine, 1.07(-0.49 to 1.64) and valproic acid, 0.65(-0.25 to 1.05) had ap 
value of greater than 0.05. This again showed the universal trend at which the association 
of seizure control and therapeutic range at different age groups. 
Although the Commission on AEDs, International league against epilepsy (1993) 
had already listed three common pitfalls in therapeutic monitoring as high intra and inter- 
individual variation on the degree of control to similar serum concentration, discrepancies 
in sampling time and accuracy in measurement, the above results could also be explained 
by the following practices. First, although monitoring of antiepileptic drug concentrations 
can be helpful in optimising therapy, rigorous adhering to the narrow concentration can 
result to medical practitioners treating blood level and not the patient [Dodson 1989]. 
Secondly, therapeutic or target range should be regarded as an approximation 
obtained from population data and restriction to these so-called target range can lead to 
treatment failure. These practices are definitely inappropriate since studies reporting of 
patients being well-controlled at serum concentrations below the lower limit [Woo et at 
1988] or requiring concentration well above the range to become seizure free [Gannaway 
et at 1981] had certainly provided proof of the extent to which these target ranges are 
helpful in ensuring appropriate therapeutic response. 
Finally, the act of reducing dose due to "toxic level" for well maintained patients 
or sustaining the present dose for uncontrolled patients because of the threat of 
overstepping the target range is not proper and certainly would not improve outcome. It 
should be stressed that outcome for the treatment of epilepsy is complete seizure control 
with no or minimal side-effects [Brodie & Dichter 1997] and the above treatment methods 
would eventually defeat the purpose and effectiveness of therapy. 
119 
6.5 Limitation of study 
The present study design analyses routine data for the determination of therapeutic 
efficacy on the therapeutic range of phenytoin, carbamazepine, valproic acid and 
phenobarbitone. This method of data collection is however controversial and did not 
follow the recommendation by Mattson et at (1982) for prospective evaluation study of 
efficacy and toxicity of antiepileptic drugs or that for population base studies 
recommended by Pledger & Schmidt (1994) and can restrict the final conclusions of this 
study. 
Studies using routine patient data that were collected retrospectively have often 
been stated to be inferior to the traditional study design (prospective, comparative, 
randomised controlled study etc). The disadvantage of routine data is its reliability and the 
possibility of being highly biased. The high possibility of bias is mainly due to the effects 
of unknown concomitant variables that are correlated with included variables. Another 
problem associated from routine data methodology is data cannot be deliberately 
constructed as it can in a controlled study design. Questions that are often asked of studies 
on routine data are those that concern the way data was gathered and whether any control 
procedures were instituted. Thus, these weaknesses can result in mistakenly concluding 
that variables do correlate. 
It should also be pointed that data that are collected retrospectively do have its 
advantages. Among the reasons quoted are the absence of restriction for study admittance 
of patients groups, cheapness, and most importantly it provides a data base of a true 
patient population that include data on extreme and atypical as well as on well-controlled 
patients. These atypical cases might be less useful for analysis since it constitute the 
extraneous factor namely called as `noise', but the defects in fit serve to suggest further 
exploration [Sheiner et al 1977]. 
The weaknesses of routine data collection can also be controlled by a study design 
that detailed certain restriction for admittance of data [CRD report 4 1996]. For this study, 
the above limitations were controlled by having inclusion and exclusion criteria for 
selection of data. Full particulars of patients selected were essential and patients with 
incomplete or undefined characteristic were omitted. However, the problems of reliability 
concerning the completeness of recorded information obtained from patients files might 
be the confounding factor that obstructs the validity of results. 
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Statistical insufficiency in this study was complemented by the use of odds ratio 
as a tool to measure effect. Odds ratio is used to observe the difference between controlled 
and uncontrolled patients within the target range. This ratio is also applicable when 
pooling data across strata(between ethnic groups) and where the summary effect provide 
statistical evidence of their relationship. The method offers strength in statistical power by 
the method of pooling weighted data and the use of Q chi-square statistic to ascertain the 
relationship between ethnic group and efficiency. 
The present study is however not devoid from limitations. One crucial factor that 
limits its used is it fails to take into account the variation between patient groups. This is 
clearly evident for adult patient groups on carbamazepine therapy which are unmatched 
for confounders such as age, weight, or dose. This is another example of a problem that 
usually beseiged routine data for it is almost impossible to clearly construct a controlled 
study where matching for either age, weight or dose would defmitely lead to a better and a 
much refined findings. This weaknesses can nevertheless be resolved by the method of 
stratification where it is essential to ascertain which of the three confounding variables 
could have contributed to the observed difference. 
These difference were however found irrelevant since the pooled odds ratio 
among the three groups were statistically insignificant. Thus, the results of this study has 
in fact managed to answer questions raised earlier by defming the 95% confidence 
interval of each conclusions which is then used in determining its statistical significance. 
6.6 Conclusion 
This study had managed to verify the current views in the used of therapeutic 
blood monitoring and the concept of target range of established AEDs for chronic 
epileptics. The recommendations made by the Commission of AEDs, International 
League Against Epilepsy (1993) on the guidelines for therapeutic monitoring on 
established AEDs such as phenytoin, carbamazepine, valproic acid and 
phenobarbitone was demonstrated to be applicable in the multi-ethnic society of 
Malaysia. 
The above results was confirmed as the differences observed between Malays, 
Chinese and Indians pooled odds ratio were proven to be statistically insignificant. 
This finding clearly showed that therapeutic response were no different for all ethnic 
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groups in the defined therapeutic range. Observed inter-individual variation in all 
ethnic groups treated with the studied AEDs also proved that treatment should be 
individualised. This study however could not verify for intra-individual variations. 
Age was not found to be an important factor for the association between 
therapeutic response and the target therapeutic range. This was confirmed by the 
pooled odds ratio of carbamazepine and valproic acid. Similar observation were not 
conclusive for phenytoin and phenobarbitone due to inadequacy of data. 
It should be mentioned that the results of this study are unique in that no other 
study had ever reported or compared effectiveness of the current therapeutic range 
between ethnic groups. This study nevertheless does suffer from certain limitations 
associated with data commonly gathered from retrospective studies and the use of the 
odds ratio to measure effect. These weaknesses were however complemented by the 
introduction of set criteria for data selection and matching groups for confounders to 
improve accuracy. 
Finally, these findings had managed to conclude that routine monitoring of 
established antiepileptic drugs to that of their target ranges is unimportant and had 
little bearing to good therapeutic response. Therapeutic response which was measured 
to the degree of seizure control was not dependent on either age or inter-ethnic 
differences. These observation is thus in-line with the recommendation outlined by the 
Commission on Antiepileptic drugs, International League Against Epilepsy (1993). 
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Chapter 7: 
Carbamazepine: Steady-state pharmacokinetics in multi- 
ethnic epileptic population 
7.1 Introduction 
Carbamazepine (5H-dibenzo[b, flazepine-5-carboxamide) was introduced in the 
early 1960's and is an effective agent for the control of epileptic seizures. It is now used 
widely in the treatment of both partial and generalized epilepsy [Troupin et al 1977 and 
trigeminal neuralgia [Tomson et al 1980]. 
Data on pharmacokinetic relationship between dose and serum level are currently 
inconclusive either in monotherapy or polytherapy. In chronically treated patients, a poor 
relationship between dose and serum level has often been reported [Nolen et al 1988, 
Bertilsson 1978, Morselli 1977, Pynnonen et al 1977, Johannessen and Strandjord 1975, 
Mihaly et al 1977, Christiansen and Dam 1977] while Perruca et al observed a linear 
relationship. Others reported a curvilinear relationship [Kudriakova et al 1992, Eadie and 
Tyrer 1980, Rambeck et al 1987] and this finding was associated with the induction by 
carbamazepine of its own metabolism(autoinduction) [Cloyd et al 1980, Levy and Kerr 
1988]. 
The controversy on the non-linear relationship between clearances and dose has 
been supported by several authors [Huf & Schain 1980, Rane et al 1978, Schain et al 
1977]. Nevertheless, Summers and Summers (1989) and Kudriakova et al (1992) found 
apparent clearances of carbamazepine to be linearly related to dose. Summers and 
Summers (1989) further mentioned the probability that the genetic makeup could affect 
the clearance and dose relationship. 
Inter-ethnic differences in carbamazepine metabolising capacity have yet to be 
accounted for in its pharmacokinetic interindividual variations. Recently, studies by Lin et 
al (1991) and Yoon et al (1996) reported that the half-lives of carbamazepine in Chinese 
and Koreans were in fact significantly different from Caucasians. Lin et at (1991) further 
concluded that the time course for autoinduction for Chinese is about 46 days and this 
duration is higher than the 21 to 30 days reported by Bertilsson et al (1986) and Mikati et 
al (1989) for European based patients. 
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Objectively, this study has three main goals. Firstly, it aims to investigate the 
relationship between carbamazepine daily dose and serum level. The second objective is 
to determine the correlation between apparent clearance and dose (dose-dependent 
relationship). Finally, to examine the influence of ethnicity on the two earlier relationship 
in the multiethnic Malaysian society. 
7.2 Methods 
i. Patients 
The data used for this study were obtained retrospectively from outpatients and 
inpatients treated for epilepsy in five hospitals on the Western Peninsula of Malaysia. A 
total of 549 randomly selected dose and serum concentration pairs from 410 adult and 139 
paediatric epileptic patients were included in the study. The method of random selection 
of dose and serum pairs is decribed in appendix 5-10. 
Table 7-1: Summary data of adult patients 
Characteristic Malays Chinese Indians 
No. of patients 130 165 115 
Ratio of malelfemale 55: 77 92: 83 56: 59 
Age) 
Mean, sd 3321,9.69 36.85,12.25 33.09,10.47 
Range 18.00-63.00 18.00-72.00 18.00-62.00 
Weight 
Mean, sd 58.23,10.49 58.98,10.82 54.59,10.84 
Range 34.00-90.00 36.00-87.00 31.00-78.00 
Disease duration(yr) 
Mean, sd 13.38,10.49 14.54,12.14 14.23,10.64 
Range 0.75-44.00 1.00-61.00 0.75-40.00 
Epilepsy Types 
Generalised 93 126 106 
Partial 23 38 8 
Others 14 11 1 
Dose(mg/kg/day) 
Mean, sd 10.94,6.30 12.76,5.92 13.21,6.45 
Range 1.25-32.50 2.53-32.00 3.23-34.88 
Css(mg/L) 
Mean, sd 6.42,2.18 6.63,2.03 6.68,1.91 
Range 1.42-12.24 2.60-13.65 3.00-11.25 
CL(ml/min/kg) 
Mean, sd 1.17,0.54 1.32,0.46 1.42,0.60 
Range 0.23-2.76 0.28-3.10 0.46-3.06 
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These patients were divided into groups according to age and ethnicity. The three 
ethnic groups studied were Malay, Chinese and Indian and these patients were subdivided 
further according to age. Patients were categorised as paediatric or adult based on the age 
limit of 18 years old. The clinical characteristics of the patients pertinent to the study are 
presented in table 7-1 and 7-2. 
Table 7-2: Summary data of paediatric patients 
Characteristic Malays Chinese All patients 
No. of patients 62 43 34 
Ratio of male/female 38: 24 24: 19 13: 21 
Age(yr) 
Mean, sd 10.61,4.57 11.52,4.21 1232,337 
Range 1.00-17.00 4-17.00 5.00-17.00 
Weight 
Mean, sd 30.67,12.13 37.15,14.77 35.71,11.65 
Range 5.10-58.00 16.00-80.00 10.30-57.00 
Disease duration(yr) 
Mean, sd 6.57,4.50 5.13,3.65 6.21,3.15 
Range 0.50-16.00 0.50-14.00 2.00-12.00 
Epilepsy Types 
Generalised 41 27 21 
Partial 9 10 11 
Others 12 6 2 
Dose(m¬/kg/day) 
Mean, sd 15.69.12.73 14.80,8.50 16.28,6.57 
Range 2.86-75.00 2.50-40.00 7.02-33.33 
Css(mg/L) 
Mean, sd 5.84,2.16 5.53,2.12 6.70,1.86 
Range 1.98-13.02 1.71-10.05 2.35-10.70 
CL(ml/min/kg) 
Mean, sd 1.89,1.40 1.85,0.91 1.75,0.72 
Range 0.65-8.39 0.46-5.27 0.74-3.94 
The patients received carbamazepine alone or in combination with other 
antiepileptics. Non-compliant patients were determined from patient notes and plasma 
concentration request forms and were excluded. Details pertaining to each dose and serum 
concentration selected were checked from patient notes for confirmation. Only serum 
concentration after at least 30 days of therapy were taken by which time steady state could 
be assumed and autoinduction was stabilised [Bertillson et al 1980, Browne et al 1987, 
McNamara et al 1978]. The serum level was measured by the fluorescence polarization 
immunoassay(FPIA) method. The coefficient of variation of this assay was less than 10%. 
The retrospective study was approved by the Head Director of Health, Ministry of Health 
with the cooperation of Chief Director of Pharmaceutical Services and Director of all 
125 
hospitals involved. Further details of the retrospective study are described in chapter 5 of 
this thesis. 
ii. Analysis 
Relationship between dose and serum level was determined by linear regression 
analysis. Regression lines were calculated by least square regression and correlation 
coefficients were calculated. To ease calculation, MINITAB version 10 were used for all 
calculation. AP value less than or equal to 0.05 was considered significant. The 
parameter used for analysis was dose, serum level, and apparent clearance. Doses were 
expressed in either milligram per day(mg/day) or per kilogram(mg/kg), serum levels in 
milligram per liter(mg/L) and clearance in Liters per kg per day(L/kg. day). 
The formula by Wagner (1965) was used to calculate apparent clearance and is 
described in chapter 1, section 1.5.5, i. e, 
F. D, j 
CssY _ (equation 7.1) 
J% 14 r 
where Cssy is the steady state blood concentration, D;; is the dose, r is the length of the 
dosage interval, Ky is the first-order rate constant for overall loss of drug from the blood, 
F is the fraction of each dose which is absorbed( bioavailability factor ), and V is the 
apparent volume of distribution. Plotting Css and DJ would be a straight line with the y 
intersect of 0 and the assumption that the other variables remains constant. 
Since clearance (CL, Liters/day) is equal to Vj multiplied by Ky , the formula 
can be rewritten as; 
F. Dij 
Clearance(CLij) 
Css#. r 
(equation 7.2) 
r can be in minutes or hours per day. Ismail & Rahman (1993) had earlier reported the F 
value for Malaysian epileptic to be 0.96. For simplicity in calculation, F is however taken 
as equal to 1. 
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Carbamazepine clearance was calculated on the assumption that at steady state 
(at equilibrium) the ratio of change in dose is proportionate to the ratio of change of serum 
concentrations. Clearance is measured in liters per kg. hour (L/kg. hr). Correlation of 
clearance and dose were evaluated by linear regression. 
To ascertain inter-ethnic differences, the method proposed by Greenland (1971) in 
estimating trend from the slope of regression equation was employed. Detailed outline of 
the formulas used was described in chapter 3, section 3.3.3(b). Differences in age, sex, 
disease duration and epilepsy types in each group were evaluated by one way analysis of 
variance(ANOVA) while the coefficient of variation(CV) between serum level/dose ratios 
was used to differentiate for inter-individual variation. The formula to calculate 
coefficient of variation(CV, %) = (SD = Mean) X 100, where SD denotes standard 
deviation. 
7.3 Results 
Analysis of variance of variables of adult patients found that age( p<0.01), 
weight(p<0.01) and dose(p<0.01) differed significantly between ethnic groups. Mean 
length of disease years and serum concentration were similar. Mean dose(p<0.05), 
serum level(p<0.05) and weight(p<0.05) were significantly different in paediatric 
patients. Length of disease years and age did not show any statistical differences 
(Table 7-3). 
7.3.1 Relationship between dose and serum level 
Table 7-4 shows the correlation between dose in mg/day and mg/kg with 
serum levels in adult and paediatric patients. Overall, there was evidence of a rather 
weak linear relationship between dose in mg/day and serum level being better 
correlated than dose expressed in mg/kg for all ethnic groups. These differences was 
more visible in the paediatric than in adults patients where all three ethnic group 
showed a higher correlation coefficient for dose prescribed in milligram per day. The 
possible reason for this observation could be due to all of the paediatric patients were 
on long term carbamazepine therapy where dosing is based on therapeutic response 
rather than weight. 
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Table 7-3: Analysis of variances of variables 
Variables Malay 
(mean, sd) 
Chinese 
(mean, sd) 
Indian 
(mean, sd) 
p-value 
(mean, sd) 
1. Adult 
-Age(years) 33.21,9.69 36.85,12.25 33.09,10.48 0.003 
-Weight(kg) 58.23,11.63 58.98,10.82 54.59,10.84 0.003 
-Length of disease 13.38,10.49 14.54,12.14 14.23,10.65 0.666 
years(years) 
-Dose(mg/day) 605.40,295.00 718.30,293.40 690.40,304.60 0.004 
-Serum 6.42,2.18 6.63,2.03 6.68,1.91 0.553 
concentration(mg/L) 
2. Children 
-Age(years) 2.81,0.72 2.95,0.82 2.94,0.69 0.538 
-Weight(kg) 30.67,12.13 37.15,14.77 35.71,11.65 0.029 
-Length of disease 6.57,4.50 5.13,3.65 6.21,3.16 0.179 
years(years) 
-Dose(mg/day) 421.80,263.90 499.50,248.40 552.90,218.80 0.040 
-Serum 5.84,2.16 5.52,2.12 6.70,1.86 0.044 
concentration(mg/L) 
Table 7-4: Dose and serum level(SL) relationship in adult paediatric patients 
Predictors Malays Chinese Indians 
I. Adults 
a) Regression equation SL=4.29 + 0.194Dose SL=3.74 + 0.226Dose SL=4.66 + 0.153Dose 
(dose, mg/kg) 
R-square(adj) 31.6% 43.6% 26.6% 
F value 59.23 133.59 40.99 
p-value 0.00 0.00 0.00 
b) Regression equation SL=3.71 + 0.0045Dose SL=3.35 + 0.0046Dose SL=4.50 + 0.0031 Dose 
(dose, mg/day) 
R-square(adj) 36.8% 43.7% 25.3% 
F-value 74.40 134.32 3835 
p-value 0.00 0.00 0.00 
II. Children 
a) Regression equation SL=4.94 + 0.057 SL=3.44 +0.141 Dose SL=4.81 +0.116Dose 
(dose, mg/kg) 
R-square 11.5% 31.8% 16.9% 
F-square 7.81 19.15 6.51 
p-value 0.01 0.00 0.02 
b) Regression equation SL=4.14 +0.0040Dose SL-2.65 + 0.00S7Dose SL=3.91 + 0.0050Dose 
(dose, mg/day) 
R-square 24.3% 45.6% 35.5% 
F-value 1924 34.34 17.56 
p-value 0.00 0.00 0.00 
Dose and serum level relationship also displayed a wide scatter in data points 
along the regression line(figure 7-1 to 7-6). This relationship can implies that there is 
high inter-individual variation and can be clearly demonstrated by the observed 
coefficient of variation of serum level/dose ratios for paediatric and adult Malay, 
Chinese and Indian of 54.45%, 45.41%, 47.19% and 50.06%, 56.48%, 37.83% 
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Figure 7-1: Carbamazepine dose and serum level relationship in 
Malay paediatric patients 
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Figure 7-2: Carbamazepine dose and serum level relationship 
in Chinese paediatric patients 
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Figure 3: Carbamazepine dose and serum level relationship in 
Indian paediatric patients 
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Figure 7-4: Carbamazepine dose and serum level relationship in 
adult Malay patients 
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Figure 7-5: Carbamazepine dose and serum level relationship 
in adult Chinese patients 
14 
12 
10 
4 "f 2 
0 
05 10 15 20 25 30 35 
Dose(m g/kg) 
Figure 7-6 : Carbamazepine dose and serum level relationship 
in adult Indian patients 
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respectively. These results also suggest that prediction of serum levels based solely 
on either daily dose or dose per kilogram is not possible. 
7.3.3 Dose and clearance relationship 
Table 7-5 shows the correlation of clearance with respect to dose in all groups 
of epileptic patients. Dose in mg/kg or mg/day had similar significant relationship 
with clearance in adult patients. However, in paediatric patients dose in milligram per 
kilogram had better correlation with clearance than dose in milligram per day. 
Table 7-5: Dose and clearance(CL) relationship in adult paediatric patients 
Predictors Malays 
I. Adults 
a) Regression equation CL=0.02 + 0.004Dose 
(dose, mg/kg) 
R-square(adj) 68.6% 
F value 279.53 
p-value 0.00 
b) Regression equation CL=0.022+ 0.0001 Dose 
(dose, mg/day) 
R-square(adj) 54.2% 
F-value 151.27 
p-value 0.00 
II. Children 
a) Regression equation CL-0.021 +0.006Dose 
(dose, mg/kg) 
R-square(adj) 78.6% 
F-square 225.43 
p-value 0.00 
Chinese Indians 
CLO. 03 + 0.004Dose CL=0.025+ 0.004Dose 
61.2% 65.8% 
272.91 217.38 
0.00 0.00 
CL=0.03 + 0.0001 Dose CLO. 025+ 0.00001 Dose 
45.6% 
145.21 
0.00 
CL=0.036 +. 0.005Dose 
61.6% 
68.36 
0.00 
53.0% 
127.55 
0.00 
CL=0.028 +0.005Dose 
49.7% 
33.64 
0.00 
b) Regression equation CL-0.038+0.0002Dose CL=0.075+ 0.000 1 Dose CLO. 077+0.00005Dose 
(dose, mg/day) 
R-square(adj) 31.5% 9.1% 3.3% 
F-value 27.60 5.22 2.12 
p-value 0.00 0.03 0.15 
This observation highlights the probable importance of the body weight-factor 
in dosing of carbamazepine in the paediatric population. The importance of weight 
can be highlighted by employing multiple regression plot of clearance as a function of 
dose(mg/kg) and weight(appendix 7-1). The resultant correlation displayed an 
increase of about 2% in correlation(radj square = 73.3%, p =0.00 ) than clearance and 
dose(radj square = 71.6%, p=0.00) alone. However, the smaller value of S (standard 
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deviation to the regression line) and F( F-ratio ) of the latter to that of the former 
could be due to disparities in study design rather than a real relationship. 
Table 7-6: Summary estimate of slope of dose and clearance relationship 
in various ethnic groups 
Age-group Malay Chinese 
0.00435 0.00367 
0.0041 0.00370 
243.90 270.27 
Indian 
0.00423 
0.0049 
204.08 
Final results 
I. Adult 
-slope 
-variance 
-weights 
-Summary slope 
-Q statistic 
-df 
-P 
-95% C. 1 
ü. Paediatric 
-slope 
-variance 
-weights 
0.00588 0.00506 
0.0081 0.0017 
123.46 588.23 
0.00473 
0.0084 
119.05 
0.0041 
0.0001 
2 
0.50 
-0.07-0.08 
-Summary slope - --0.0051 
-Q-statistic 0.0001 
-df 2 
-p 0.50 
-95% C. I -0.06-0.07 
iii. All 
-Summary slope - --0.0046 
-Q statistic 0.0006 
-df 5 
-p <0.000 
-95% C. I -0.045 - 0.054 
The highly correlated relationship between clearance and dose per kilogram 
distinctly showed that clearance increases proportionally with increase dose. This 
observation confirmed that carbamazepine exhibited dose-dependent properties(figure 
7-7 to figure 7-12). 
7.3.3 Influence of age 
Pooled summary estimate of slope obtained from the relationship between 
clearance and dose among paediatric and adult patients (table 7-5) showed that there 
existed a definite and significant difference(p >0.001). These observations 
demonstrate that age had a significant influence on carbamazepine clearance. Pooled 
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Figure 7-7: Cart mazepine dose and clearance relationship in 
Malay paediatric patients 
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Figure 7-8: Carbamazepine dose and clearance relationship in 
Chinese paediatric patients 
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Figure 7-9 : Carbamazepine dose and clearance relationship in 
Indian patients 
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Figure 7-10: Carbamazepine dose and clearance relationship in 
adult Malay patients 
0.2 
r 0.15 ý" N 
0.1 
0.05 
Cý " 
0 
05 10 15 20 25 30 35 
Dose(mg/kg) 
Figure 7-11: Carbamazepine dose and clearance relationship in 
adult Chinese patients 
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Figure 7-12: Carbamazepine dose and clearance relations hip in 
adult Indian patients 
0.2 
0.15 f" 
0.05 
fM 
0 
05 10 15 20 25 30 35 
Dose(mg/kg) 
134 
Figure 7-13: Carhamazepine dose and clearance relationship in 
paediatric patients 
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Figure 7-14: Carbamazepine dose and clearance relationship in 
adult patients 
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estimate of slope of children and adults showed that the clearance of paediatric 
patients was significantly higher than adult patients(figure 7-13, figure 7-14). 
7.3.4 Influence of ethnicity 
The method described by Greenland (1987) requires essentially a linear 
relationship between two variables and used the slope to estimate trend of measured 
effect. Since there were inconsistencies in the relationship of plots between clearance 
and dose(mg/day) among paediatric patients(table 7-6), the use of these regression 
equations to establish inter-ethnic differences was not statistically appropriate and was 
unjustified. Effect of ethnicity was thus determined by comparing the trend from the 
more reliable and significant linear relationship of clearance and dose in milligram per 
kilogram body weight. 
Figures 7-15 and 7-16 demonstrate the linear relationship between 
clearance(L/kg. hour) and dose(mg/kg) in paediatric and adult patients of the three 
ethnic groups. Summary estimate of the slope and 95% confidence interval in adults 
and paediatric patients revealed that the slopes were homogenous. These findings 
distinctly signifies that there is no association between ethnicity and slope in both age 
groups. 
7.3.5 Predicted dose and serum level relationship 
The linear regression equation of carbamazepine clearance(CL) and dose(D) 
for adults(figure 7-13) and paediatric(figure 7-14) patients were as follows; 
Adults CL = 0.0272 + 0.0041D (equation 7-3) 
Paediatrics ; CL = 0.0241 + 0.0056D (equation 7-4) 
The units used for clearance was liters per kilogram per hour and dose in milligram 
per kilogram body weight. 
Relationship of dose(D) and serum levels at steady-state(Css) can be derived 
by combining equation 7-1 and equations 7-3 or 7-4. The latter two equations had to 
be transform to litres per kg per day by a multiple of 24. The final equations for 
paediatric and adult were; 
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Figure 7-17: Predicted carbamazepine dose and 
serum level relationship in adult patients 
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Figure 7-18: Predicted carbamazepine dose and 
serum level in paediatric patients 
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Adults Css = 10.16D (equation 6-4) 
6.53 +D 
Paediatric ; Css = 7.69D (equation 6-5) 
4.46+D 
These equations theoretically resemble a hyperbolic association and thus a 
non-linear relationship. The curves reflecting these equations are presented in figures 
7-17 and 7-18. 
7.4 Discussion 
The design of this retrospective study is not at all the best suited to determine 
population-based relationship between dose and serum levels of any drug. Although a 
prospectively designed study with frequent drug level analysis would be more 
desirable, problems of cost, time, study size and unspecific selection of patients 
groups are the hindering factors for any population studies [Sheiner et al 1977]. 
Reports of carbamazepine population based studies employing both retrospective 
[Summers & Summers 1989] and prospective [Kudriakova et al 1992, Bernus et al 
1996] patients data are few and only the recent introduction of sophisticated statistical 
software such as NONMEM [Sheiner & Beal 1981] has led to more studies being 
reported [Odani et al 1996, Yukawa 1995, Delgado Iribarnegaray et al 1997]. 
These earlier population base studies pooled data from patients with unequal 
number of dose and, serum level pairs in investigating the relationship. This method is 
commonly known as the naive pooled approach and did not allow for inter-individual 
variability [Sheiner & Beal 1980], and hence the degree of accuracy of the final results 
is doubtful. It should be mentioned that during regression, patients with more dose and 
serum level pairs have higher influence on the overall conclusion. 
However, the present study used a random selection of a single dose-serum 
level pair from each patient, being more appropriate in determining relationship. By 
this method, similar numbers of data points from each patient provide an equal 
contribution during regression analysis and the final results are freer of any possibility 
of being biased. This method would thus enhance the statistical validity of the overall 
relationship. Similar studies using single set of dose/serum level pairs of either the 
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first or latest data sets had also been published earlier [ McKauge et al 1981, Suzuki et 
al 1991]. 
Studies of the correlation between dose and serum level have been 
contradictory since both linear and non-linear had been reported(table 7-7). The 
present results are in-line with the latter observation. The current results are also 
similar to a prospective study on Malaysian patients by Ismail & Rahman 1993 where 
no such relationship was reported. This observation is in fact contradicting the theory 
that at steady-state conditions, the relationship between dose and steady-state serum 
level is linear [Wagner 1965]. This current result clearly validates that carbamazepine 
is not among the group of drugs characteristic of this behaviour. 
Table 7-7: Studies that reported either linear or non-linear relationship between dose and serum 
level of carbamazepine 
Final conclusion 
-Authors 
Therapy Sample 
size 
Patient's type Dose 
given 
Ethnicity 
1. Non-linear relationship 
-Rane et at 1976 Polytherapy 20 Paediatric patients mg/kg. day - 
-Eichelbaum et al 1976 Polytherapy 13 Not defined mg/kg. day 
-Strandjord & Johannessen 1977 Mixed 28 Mixed age patients mg/kg. day 
-Mihaly et al 1977 Not mentioned 35 Mixed age patients mg/day - 
-Schain et al 1977 Mixed 37 Paediatric patients mg/kg. day 
-Sato et al 1979 Monotherapy 27 Paediatric patients mg/kg. day - 
"Pynnonen et al 1980 Not mentioned 35 Adult patients mg/kg. day 
-Strandjord & Johannessen 1977 Mixed 62 Mixed age patients mg/kg. day - 
-McKauge et al 1981 * Mixed 295 Mixed age epileptics mg/kg. day 
-Bourgeois & Wad 1984 Polytherapy 33 Mixed age epileptics ma/kg. day - 
-Elyas et al 1986 Mixed 68 Paediatric patients mg/kg. day 
-Belle & Friel 1986 Mixed 24 Adult patients mg/kg. day - 
-Tomson et al 1989 Mixed 13 Adult patients mg/day - 
-Irfan et al 1989* Monotherapy 183 Mixed age patients mg/m. sq - 
-Wang et al 1990 Mixed 135 Mixed age epileptics mg/kg. day - 
-Ichikou et at 1990 Mixed 27 Adult patients mg/kg. day - 
-Wang et al 1990 Mixed 135 Mixed patients mg/kg. day 
-Suzuki et al 1991 * Polytherapy 107 Paediatric patients mg/kg. day - 
-Yukawa et al 1992* Polytherapy 370 Paediatric patients mg/kg. day Japanese 
-Ismail & Rahman 1993 Monotherapy 14 Mixed age epileptics mg/day Malaysian 
(mostly 
Liu & Delgado 1994 Not mentioned 55 Paediatric patients mg/kg. day 
) Malays) 
11. Linear relationship 
-Cereghino et al 1973 Polytherapy 8 Adult patients mg/day 
-Rane et al 1976 Monotherapy 23 Paediatric patients mg/kg. day - 
-Perucca et al 1978 Mixed 80 Adult patients mg/kg. day 
-Huf & Schain 1980 Mixed 61 Paediatric patients mg/kg. day 
-Rylance & Moreland 1981# Mixed 35 Paediatric patients mg/m2 - 
-Kumps AH 1981 Mixed 24 Adult epileptics mgfkg. day 
-Kumps AH 1981 Mixed 26 Paediatric epileptics mg/kg. day - 
-Bourgeois & Wad 1984 Monotherapy 14 Adult patients ma/kg. day - 
-Hartley et al 1990 Monotherapy 21 Paediatric patients - mg/kg. day 
-Larkin et al 1991 " Mixed 106 Not defined mg/day - 
*: Retrospective studies, otherwise prospective, #: Measurement by saliva, if not plasma/serum 
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This non-linear relationship is linked to the autoinduction properties of 
carbamazepine [Tomson et al 1989,. Bernus et al 1996]. Autoinduction in 
carbamazepine was originally observed by Eichelbaum et al (1974) as they reported 
the half-life was shorter and steady-state serum level lower in multiple dose compared 
to single dose patients. They further commented that carbamazepine induces its own 
metabolism during repeated administration and this characteristic is called 
autoinduction. 
Autoinduction in carbamazepine leads to the reputed dose-dependent kinetics 
of the drug. Dose-dependent pharmacokinetics is the phenomenon where a high 
increase in dose lead to small increase in serum level. The small increase in serum 
level is directly proportional to increased clearance where relationship between dose 
and clearance had been reported to be linear [Kudriakova et al 1992]. Tomson et al 
(1989) relates this observation by the higher ratios of carbamazepine metabolite to 
total carbamazepine, i. e. trans-CBZ -diol/CBZ ratios. They further explained the 
increased in ratio led to lower serum concentration and this is characteristic for the 
dose-dependent pharmacokinetic relationship. 
Bernus et al (1996) also proposed the possibility of the dose-dependent 
relation being explained by incomplete oral bioavailability. Since bioavailability has 
been reported to be both affected [Levy et al 1975] and unaffected [Tedeshi et al 
1981] by food, the extent to which it affected the present study is unknown. Also, 
since the studied patient groups were of different ethnic groups, the possibility of 
differences in bioavailability cannot be discounted. This is clearly important in this 
study where the bioavailability factor( F) used was equated to one in all ethnic 
groups. Bioavailability factor might contribute to interindividual and possibly 
interethnic variation during the estimation of apparent clearance which can lead to the 
final predicted serum concentration being lower than it should be. 
The better correlation of dose in mg/day than mg/kg to serum concentration 
observed in the present study has similarly been reported by Bernus et al (1996). 
Results for paediatric patients showed that the correlation values for dose in mg/day 
had a better overall relationship (radj square = 32.4%) than dose in mg/kg (radj square 
= 16.1% ). Results from adult patients however similarly showed higher correlation 
values for dose in mg/day (radj square = 36.0%) than mg/kg (radj square = 34.6% ) 
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but the differences were not entirely distinctive. These findings verify the present 
recommendation that carbamazepine dosing guidelines [BNF 1996] is based on 
therapeutic response rather than body weight. Bernus et al (1996) contributed the 
reasons for carbamazepine non-linearity behavior reported in earlier studies to the 
common expectation that allowance for body weight would provide better measure of 
serum concentration. 
The results from this study are in accord with the many earlier authors that the 
relationship between dose and clearance is linear where an increase in dose lead to a 
proportionate increase in clearance [Sadie & Tyrer 1980, Meinardi 1975, Rambeck et 
al 1987, Schneider 1975). The current result nevertheless contradicts prospective 
studies by Sanchez et al (1986) and Ismail & Rahman (1993). Sanchez et al (1986) 
reported this relationship is true for children but not for adult but noted problems of 
compliance might have affected their findings. Ismail & Rahman (1993) however 
reported no such relationship. Their anomalous finding may be explained by a 
population size of only 14 patients and a limited dose range between 400 to 600 
mg/day which might restrict the chance of demonstrating a similar relationship 
[Hartley et al 1990, Perucca et al 1980]. 
The results showed that the difference in clearance of paediatric patients 
significantly faster than adults and is expected. Similar findings on the rate of 
elimination of paediatric patients has long been reported to be considerably higher 
than adults by Rey et at (1979), Moreland et at (1982), Pynnonen et at (1977) and 
Rylance et at (1979). 
The impact of inter-ethnic differences on the linear relationship between dose 
and clearance were found to be statistically insignificant in both adult and paediatric 
patients of Malay, Chinese and Indian origin. These results showed that the effect of 
differences in age, weight, dose and serum level in either adult or paediatric patients 
have no significant influence on inter-ethnic differences. 
Comparing the final regression equation(table 7-7) for the paediatric 
Malaysian population to Black Africans reported by Summers & Summers (1989) 
suggested that inter-ethnic differences were clearly absent. As for adult patients, no 
confounding differences were also observed between Malaysians, Australians [Bernus 
et al 1996], and Germans [Kudriakova et al 1992] population. These findings 
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decisively showed that inter-ethnic differences have no influence on the dose- 
dependent pharmacokinetics of carbamazepine in chronically treated patients. 
Table 7-7: Comparison of clearance(CL) and dose(D) relationship with publish studies 
Studies Correlation r-1 t-ratio SE- variance Homogeneity 
equation value -slope test-p value 
1. Paediatric 
-current study CL 0.02+0.006D(mg/kg) 0.72 18.80 0.1128 0.0127 
-Summers & CL-0.03+ 0.002D(mglkg) 0.49 9.19 0.0184 0.0003 
Summers 
1989 
Pooled 
2(a). Adults 
-current study CL=29.5 + 0.06D(mg/day) 0.53 
-Bernus et al CL=28.98 + 0.55 
1996 7.58D(mg/day) 
. Kudriakova et CL-252 + 0.07D(mg/day) 0.90 
al 1992 
0.49 
21.87 131 1.72 
4.28 32.45 1053.18 
28.02 1.82 3.32 
Pooled 0.49 
The predicted curvilinear dose and serum level relationship observed in this 
study was similar to that concluded by Kudriakova et al (1992) and Summers & 
Summers (1989). A similar curvilinear relationship was reported by Yukawa et al 
(1992) where they derived similar relationship from the significantly related 
dose/serum level ratios to dose. However, the presence of wide scatter signify a 
considerably large inter-individual variation. 
This relationship is highly likely from the many reports of carbamazepine 
dose-dependent kinetics. In current perspective, the non-linear relationship has been 
widely used and accepted in studies to determine carbamazepine population 
pharmacokinetics using retrospective population pharmacokinetic data. 
7.5 Limitations of study 
Difficulties in the current retrospective study have been discussed in chapter 5. 
However, the present study has two limitations which may affect the overall findings. 
The first is the factor for bioavailability( F) which was assumed to equal to 
one for estimating apparent clearance. Although, the estimated bioavailability factor 
by Ismail & Rahman (1993) had showed that its value is close to one, no studies have 
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yet been initiated to accurately measure population values specific for Malaysian 
multi-ethnic epileptic population. Therapeutic bioequivalency studies of 
carbamazepine have been shown to vary between products [Bhatia et al 1988] while 
Jumao et al (1989), Hartley et al (1990) and Oles et al (1992) had all shown no 
significant differences. Comparative studies between chewable [Patsalos et al 1990, 
Cornaggia et al 1993], slow release [Reunanen et al 1990] and conventional 
carbamazepine similarly showed no significant differences in bioequivalence although 
the latter had been reported to be less efficacious and have more frequent occurrences 
of side-effects [Reunanen et al 1990]. Carbamazepine bioavailibility was also reported 
to be increased by food [Levy et al 1975] and this could also contribute to variation in 
serum concentration. 
Secondly, the minimum period of therapy is linked to the time of 
autoinduction. Time for autoinduction to stabilise has been noted to be between 21 to 
30 days [ Browne et al 1989, Mikati et al 19, Bertilsson 1980] and 30 days was 
assumed for the minimum period of therapy during selection of patients in Malaysian 
patients. However, reports on Chinese [Lin et al 1992] and Koreans [Yoon et al 1996] 
healthy volunteers time for autoinduction of approximately 46 days showed that there 
is the possibility of inter-ethnic differences in carbamazepine rate of metabolism. 
Critically, inter-ethnic differences in the time for autoinduction to complete could well 
be present in Malays, Chinese and Indians. Thus, 30 days might not be sufficient for 
all ethnic groups. 
7.6 Conclusion 
The exact relationship between dose and serum level for carbamazepine has 
yet to be confirmed although it has been 25 years after the earliest report in 1973 was 
first published. Linear relationship were mostly observed in the earlier year of 1970 
and 1980 while lately most of the published reports tend to favour the non-linear 
relationship. The present study showed a weak and a statistically insignificant 
relationship between dose and serum level. High inter-individual variation was also 
observed in all ethnic groups with Indian and Chinese patients displaying values much 
higher than their Malay counterparts. 
145 
Large population-based studies [Yukawa et al 1992, Summers & Summers 
1989] and evidence of dose-dependent pharmacokinetics of carbamazepine [Kumps 
AH 1981] has strengthened the latter claim and reduce the former claim of linearity 
now believed to be due to study faults or inappropriate study design [Bernus et at 
1996]. However, authors of reported linear relationship [Perucca et al 1978, Huf & 
Schain 1980] had similarly found the presence of a wide scatter around the regression 
line to be related to high inter-individual variations. They also mentioned that high 
inter-individual variation makes estimating serum level directly from the prescribed 
dose unpredictable. 
The true nature of the non-linear relationship is still unconfirmed. To date, 
reports by Eadie & Tyrer (1980), Rambeck et al (1987), Summers & Summers (1989), 
and Kudriakova et al (1992) had all reported the curvilinear relationship between dose 
and serum level but no consensus has yet been reached. The result of this study 
nevertheless substantiated the possibility of the curvilinear theory although further 
investigation may need to be initiated to confirm this fording. 
Evidence of inter-ethnic differences in the dose-dependent kinetics of 
carbamazepine among Malay, Chinese and Indian epileptic population in Malaysia 
was found to be statistically unlikely. Comparison with published reports on Blacks, 
Australian and German patients on chronic carbamazepine therapy showed similar 
results. 
The possibility of ethnic differences may however be detected by investigating 
population pharmacokinetic parameters such as half-lifes(related to time of 
autoinduction), clearance etc, and intra and interindividual differences among patient 
groups. This finding may prove conclusive since reports of single and multi-dose 
studies has shown significant inter-ethnic differences in the half-lifes of 
carbamazepine between Orientals (Korean and Chinese) [ Yoon et at 1996 and Lin et 
at 1991] and Caucasian. 
Finally, the present study presented the first ever relationship between dose 
and serum level in both paediatric and adult Malaysian epileptics. This formula might 
proved useful for estimating serum level especially in hospitals where therapeutic drug 
monitoring services are not provided. However, it should be stressed that this formula 
should act as a basic guideline in carbamazepine therapy and its practical use may 
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need to be restricted to determining suspected non-compliance and toxicity only. 
Clinical judgment is still crucial for optimum therapeutic outcome because of well- 
known high inter-individual variation in carbamazepine kinetics. 
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Chapter 8: 
Valproic acid: Steady-state pharmacokinetics in a multi- 
ethnic epileptic population 
8.1 Introduction 
Valproic acid or the salt form sodium valproate(sodium dipropylacetate) is 
currently used as an anticonvulsant agent in the treatment of generalized tonic-clonic and 
absence seizures [Chadwick DW 1987]. Although, this drug has been used for more than 
20 years after it was first discovered in 1963, the relationship between valproic acid dose 
and serum concentration has yet to be defined. 
Monitoring of total serum level of valproic acid is complicated by valproic acid 
exhibiting the phenomenon called concentration-dependent serum protein binding 
[Bowdle et al 1980]. This is a condition where increase of serum level is dependent on 
serum albumin binding sites. At saturation of binding sites, serum levels of unbound 
valproic acid fraction will increase disproportionately, which consequently leads to 
increase in the rate of elimination but decrease in total serum level. Therefore, as total 
serum level increases, theoretically the relationship between dose and serum levels 
becomes curvilinear, that is, incremental increase in dose produces less elevation of total 
serum valproic acid concentrations [Levy eta! 1986]. 
Secondly, valproic acid is known to display high interindividual variation, which 
leads to the consistently poor relationship between dose and serum levels among patients 
[Cloyd et al 1983, Dodson & Tasch 1981, Bruni et al 1978]. This has made dosage 
determination and adjustment complicated. 
Poor correlation between dose and serum level has been attributed to differences 
in valproic acid clearance. Evidence which suggests clearance changes with age and/or 
polytherapy have been reported to be responsible for interindividual variation [Levy RH 
1984]. All these factors are however linked to the way in which valproic acid is 
metabolised and eliminated. 
Valproic acid is primarily metabolised and eliminated by the liver [Levy et al 
1986]. Since liver function changes with maturity(age), steady-state serum levels could be 
expected to vary among 
individuals with different metabolic capabilities. This is clearly 
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demonstrated where clearance of adults has been showed to be higher than children 
[Dodson & Tasch 1981, Cloyd et al 1983]. The inconsistent relationship between dose 
and serum levels observed in several studies might have been due to the inclusion of both 
paediatric and adult age groups. 
Clearance of valproic acid has been shown to be higher when taken with other 
antipeileptic drugs [Henriksen & Johannessen 1982]. An increase in enzyme induction 
activities induced by concomitant antiepileptic drugs leads to an increased clearance of 
valproic acid [Sackellares et al 1981]. This factor may also contribute to the lack of 
correlation between dose and steady-state serum level of valproic acid. 
Enzymes responsible for the hepatic metabolism of antiepileptic drugs have been 
known to be genetically controlled [Kalow et al 1982]. By contrast to valproic acid, 
differences in inter-ethnic rates of metabolism have been published for phenytoin [Grasela 
et al 1983] and several studies [Chan et at 1990, Rui et al 1995] have reported on its 
ethnic-specific population pharmacokinetics. Evidence on carbamazepine has yet to be 
established although differences have been reported [Yoon et al 1996, Lin et al 1991]. 
Nevertheless, comparative studies examining for inter-ethnic differences for valproic acid 
has been reported by Botha et al (1995) and their results showed that valproic acid mean 
clearances in South Africa Black and Indian paediatric patients were within the normal 
quoted range. However, more studies of this nature are needed to disapprove this 
assumption of inter-et hic differences in valproic acid metabolism. 
Based on above information concerning valproic acid, this study aims to 
determine the relationship between valproic acid dose and serum concentration 
relationship among both paediatric and adult patients groups of Malay, Chinese and 
Indian ethnic origin. Differences in treatment strategy(monotherapy and polytherapy) and 
interindividual variation will be the other main focus of study. Essentially, this study hope 
to establish evidence to prove that there are inter-ethnic differences in valproic acid 
metabolism. 
8.2 Methods 
Patient data were obtained retrospectively using the method described in detail in 
chapter in chapter 5. A total of 473 steady-state dose and serum data pairs were selected 
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utilising the randomisation strategy described in chapter 5.236 adult and 237 paediatric 
epileptic patients were included in the study. 
Patients were divided into groups according to type of therapy(monotherapy or 
polytherapy), age and ethnicity. The ethnic groups studied were Malay, Chinese and 
Indian and were subdivided further according to age. Patients were categorised as 
paediatric or adult based on the age limit of 18 years old. The clinical characteristics of the 
patients pertinent to the study are presented in table 8-1 and 8-2. 
Table 8.1: Summary data of adult patients 
Characteristic Malays Chinese Indians 
No. of patients 89 75 72 
Ratio ofmale/female 45: 43 32: 43 38: 34 
Age(yr) 
Mean, sd 33.60,11.00 33.15,12.07 30.37,1124 
Range 18.00-64.00 18.00.69.00 18.00-54.00 
Weight 
Mean, sd 56.85,10.93 56.63,8.51 56.01,11.55 
Range 34.00-80.00 37.00-74.20 31.00-89.00 
Disease duratlon(yr) 
Mean, sd 12.97,9.60 13.87,8.91 13.87,10.88 
Range 1.00-38.00 1.0045.00 1.00-40.00 
Epilepsy Types 
Generalised 65 56 64 
partial 11 12 11 
Others 12 7 12 
Tberapy(M: P) 32: 56 16: 59 24: 46 
Dose(mg/day) 
Mean, sd 879.50,421.90 813.30,359.90 750.00,352.10 
Range 200-2000 200-1900 200-1600 
Dose(m8/kg) 
Mean, sd 16.47,9.77 14.71,7.14 14.18,8.20 
Range 3.33-51.28 3.28,41.86 3.03-38.46 
Css(mg'L) 
Mean, sd 43.16,20.40 37.25,17.85 41.30,17.67 
Range 3.33-125.34 7.71-82.11 3.60-74.79 
CL(LIkg day) 
Mean, sd 0.48,0.49 0.46,033 0.39.0.30 
Range 0.15-3.03 0.19-2.67 0.10-2.18 
Abbreviation: M- monotherapy, P- polytherapy 
Non-compliant patients were determined from patient notes and plasma 
concentration request forms and were excluded. Details pertaining to each dose and serum 
concentration selected were checked from patient notes for confirmation. The serum level 
was measured by the fluorescence polarization immunoassay(FPIA) method. Patients 
were only included if they were on valproic acid therapy for a minimum period of 30 
days. 
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The relationship between dose and serum level was determined by linear 
regression analysis and Pearsons correlation coefficient and the significance of correlation 
was determined using Student's t test [Daniel WW 1987]. To ease calculation, MINITAB 
version 10 were used for all calculation. AP value less than or equal 0.05 was considered 
significant. 
Table 8.2: Summary data of paediatric patients 
Characteristic Malays Chinese Indian 
No. of patients 116 64 60 
Ratio of male/female 65: 51 36: 28 35: 25 
Age(yr) 
Mean, sd 8.65,4.47 8.18,4.00 10.12,4.36 
Range 1.00-17.00 4-17.00 5.00-17.00 
Weight 
Mean, sd 2722,14.07 27.09,13.30 30.35,12.91 
Range 5.10-58.00 16.00-80.00 10.30-57.00 
Disease duration(yr) 
Mean, sd 5.63,3.87 6.29,3.95 5.91,3.51 
Range 050-16.00 0.50-14.00 2.00-12.00 
Epilepsy Types 
Generalised 84 36 36 
Partial 13 11 21 
Others 19 17 3 
Therapy(M: P) 48: 16 
Dose(mpf kg) 
Mean, sd 23.83,20.54 23.86,11.74 2129,1254 
Range 
Dose(mg/day) 
Mean, sd 545.10,362.40 616.10,353.10 629.20,414.30 
Range 100-1500 90-2000 150-2000 
Css(mg/L) 
Mean, sd 56.62,31.61 67.13,30.78 65.12,38.87 
Range 4.06-197.19 10.69-141.56 8.71-174.01 
CL<lA8"day) 
Mean, sd 0.51,0.46 0.40,0.25 0.44,0.36 
Range 0.11-3.43 0.13-1.50 0.09.2.39 
Abbreviation: M-monotherapy, P-poiytberapy 
The variables used for analysis was dose, serum level, and apparent clearance. 
Doses were expressed in either milligram per day(mgiday) or per kilogram(mg/kg), 
serum levels in milligram per liters(mg/L) and clearance in Liters per kg per 
day(L/kg. day). The formula by Wagner (1965) and is described in chapter 1, section 1.5.5, 
was used to calculate apparent clearance, 
Clearance(CLij) = F. Dy (equation 7-1) 
C 
where Cssy is the steady state blood concentration, Dy is the dose, r is the length of the 
dosage interval, F is the fraction of each dose which is absorbed( bioavailibility factor ). 
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Plotting Css and D# would be a straight line with the y intercept of 0 and the assumption 
that the other variables remains constant. F has been reported to be between 0.85 to 1 in 
various oral dosage forms [Perucca et at 1978, Johannessen & Henriksen 1980]. For 
simplicity, F was taken as equal to 1. The formula assumes that at steady state (at 
equilibrium) the ratio of change is proportionate to the ratio of change of serum 
concentrations. Clearance is measured in liters per kg. day (L/kg. day). Correlation of 
clearance and dose were evaluated by linear regression [Daniel 1987]. 
The method proposed by Greenland 1971 was used to determine for inter-ethnic 
differences. Detail outlining the formulas were described in chapter 3, section 3.3.3(b). 
Differences in age, sex, disease duration and epilepsy types in each group were evaluated 
by one way analysis of variance(ANOVA). Coefficient of variation(CV) for 
interindividual variation was calculated using the following formula: CV(%) = (SD 
Mean) x 100, where `SD'denotes standard deviation. 
8.3 Results 
Analysis of variance of in adult patients found that there were significant 
differences among adult patients for the variables such as age, weight, length of 
disease years, dose and serum concentration. Significant differences between ethnic 
groups were found for serum concentration(p<0.05) in paediatric patients. (Table 8-3). 
Table 8-3: Analysis of variances of variables 
Variables Malay Chinese Indian p-value (mean, sd) (mean, sd) (mean, sd) (mean, sd) 
1. Adult-n 
-Age(yeffs) 
33.60,11.00 33.15,12.07 30.37,11.24 0.171 
. Weight(kg) 
56.85,10.93 56.63,8.51 56.01,11.55 0.874 
-length of 
disease 12.97,9.60 13.88,8.91 13.87,10.88 0.792 
years(years) 
. Dose(mglday) 
879.50,421.90 813.30,359.90 750.00,352.10 0.104 
-Serum 
43.16,20.40 37.25,17.85 41.30,17.67 0.131 
concentration(mWL) 
2. Children-n 
-Age(years) 
8.65,4.47 8.18,4.00 
-Weight(kg) 
27.22,14.07 27.09,13.30 
-Length of 
disease 5.63,3.87 6.30,3.95 
-ose(mg/d 
day) mg 545.10,362.40 616.10,353.10 
-Serum eru 
56.62,31.61 67.13,30.78 
concentration(mg/L) 
10.12,4.36 0.032 
30.35,12.91 0.292 
5.91,3.51 0.530 
629.20,414.30 0.274 
65.12,38.87 0.084 
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8.3.1 Relationship between dose and serum level 
Plots of dose and serum level in paediatric and adult patients(irrespective of 
therapy) showed that a rather weak linear relationship existed for both dose in mg/day 
or mg/kg(figure 8-1 to 8-4). The corresponding correlation coefficient( radj ) values for 
dose in mg/day and mg/kg in paediatric and adult patients were 0.47(p < 0.01) and 
0.17(p < 0.01) and 0.32(p < 0.01) and 0.29(p < 0.01) respectively. 
Table 8-4: Dose and serum level(SL) relationship in paediatric and adult patients 
Predictors Malays Chinese Indite 
I. Paediatric 
a) Regression equation SL 42.5 + 0.59Dose SL=33.7 + 1.40Dose SL-28.2 + 1.73 Dose 
(dose, mg/kg) 
R-square(adj) 14.2% 27.2% 31.3% 
F value 20.02 24.57 26.45 
p-value 0.00 0.00 0.00 
C. V(serum level/dose) 61.74 48.41 65.56 
b) Regression equation 
(dose, mg/day) 
R-square(adj) 
F-value 
p-value 
C. V(serum level/dose) 
II. Adult 
a) Regression equation 
(dose, mg/kg) 
R-square(adi) 
F-square 
p-value 
C. V(seram level/dose) 
SL=27.3 + 0.0538Dose 
38.1% 
70.13 
0.00 
57.85 
SL=24.4+ 1.14Dose 
29.0% 
36.60 
0.00 
50.45 
SL=30.6 + 0.0593Dose 
45.5% 
53.50 
0.00 
45.91 
SL-13.6 + 1.61 Dose 
40.7% 
51.76 
0.00 
43.03 
SL-19.1 + 0.0732Dose 
60.2% 
90.24 
0.00 
54.66 
SL-23.7 + 1.04 Dose 
23.5% 
22.81 
0.00 
53.09 
SL-18.5 + 0.0293Doso 
35.1% 
39.31 
0.00 
49.13 
b) Regression equation 
(dose, mg/daY) 
R-square(adi) 
F-value 
p-value 
C. V(serum levelldose) 
SL=19.4 +0.0271Dose SL- 11.8 + 0.0313Dose 
30.5% 38.9% 
39.19 48.19 
0.00 0,00 
45.09 42.87 
Abbrcvt don: C. Vs ooemc e. t of voriotb.. 
Figures 8-1 to 8-4 are also characterised by a wide scatter of data points about 
the regression line which is an indicator for high interindividual variation. The mean 
serum level: dose ratio(sd) for dose given in mg/day and mg/kg in paediatric patients 
was 0.1238(0.0665) and 3.213(1.917) and the calculated coefficient of variation(CV) 
was 53.71% and 61.38%. The corresponding serum level: dose ratios for adults were 
0.0557(0,0294) and 3.133(1.625). The coefficient of variation for adults were 52.78% 
and 51.87%. These high values of coefficient of variation noted in both paediatric and 
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Figure 8-1: Valproic acid dose and serum level relationship in 
paediatric patients 
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Figure 8-2: Valproic acid dose and serum level relationship in 
paediatric patients 
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Figure 8-3: Valproic acid dose and serum level relationship in 
adult patients 
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Figure 8-4: Valproic acid dose and serum level relationship in 
adult patients 
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Figure 8-5: Valproic acid dose and serum level relationship in 
Malay paediatric patients 
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Figure 8-6: Valproic acid dose and serum level relationship in 
Chinese paediatric patients 
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Figure 8-7: Valproic acid dose and serum level relationship in 
Indian paediatric patients 
200 
150 
100 
ff 
2 50 
0 500 1000 1500 2000 
Dose(mg/day) 
156 
is r i 'ýý R 
Figure 8-8: Valproic acid dose and serum level relationship in 
adult Malay patients 
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Figure 8-9: Valproic acid dose and serum level relationship in 
Chinese adult patients 
100 
80 " 
E 60 f"" d" 
40 fZ 
E" 
- 
0 
0 500 1000 1500 2000 
Dose(mg/day) 
Figure 8-10: Valproic acid dose and serum level relationship in 
adult Indian patients 
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adult patients showed a considerably high degree of interindividual variation in the 
studied population. 
Table 8-4 shows the correlation between dose in mg/day and mg/kg with 
serum levels in adult and paediatric patients according to ethnicity. Overall, dose and 
serum level relationship in all patient groups were found to be statistically 
insignificant. However, the only exception was observed for Indian paediatric patients 
which clearly showed a significant relationship(radj = 0.60, p=0.00) between daily 
dose(mg/day) and serum level. 
Poor correlation between dose and serum level can be associated with high 
interindividual variation. Interindividual variation was clearly demonstrated by the 
wide scatter of data points from the plots of dose and serum levels in all ethnic 
groups(figure 8-5 to 8-10). Evidence about the scale of interindividual variation was 
highlighted by the coefficient of variation(mean serum level: dose(mg/day)) ranging 
between 48.41% - 57.85% and 42.87% - 49.13% for paediatric and adult patients. 
8.3.2 Dose and clearance relationship 
The regression equations that determined the linear relationship between 
clearance(CL) and dose(mg/kg) or dose(mg/day) for the paediatric and adult 
population were as follows; 
I. Paediatric population 
CL(L/day) _ 
CL(L/kg. day) = 
ii. Adult population 
C1(L/day) 
CL(L/kg. day) = 
7.84 + 0.0055Dose(mg/day) 
(rjj= 0.06, p<0.005) 
0.237 + 0.0098Dose(mg/kg) 
(r. di=0.17, p<0.005) 
17.0 + 0.0091 D(mg/day) 
(radj =0.02, p=0.01 ) 
0.274 + 0.0115Dose(mg/kg) 
( rdj = 0.06, p<0.005 ) 
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The above equations showed no significant linear relationship existed between 
clearance and dose in either population. 
Table 8-5 shows the correlation of clearance with respect to dose according to 
age and ethnic groups. A non-significant linear relationship was observed all groups. 
These findings demonstrate that the poor correlation between valproic acid clearance 
and dose is not characteristic of a dose-dependent relationship. 
Table 8-5: Dose and clearance(CL) relationship in adult and paediatric patients 
Predictors Malays Chinese Indians 
L Paediatric 
a) Regression equation 
(dose, mg/kg) 
R-square(adj) 
F value 
p-value 
CL-7.10+0.0077Dose 
13.3% 
17.55 
0.00 
CL 5.70+0.0068Dose CIr10.1+0.0311Dose 
b) Regression equation 
(dose, mgfday) 
R-square(adi) 
F-value 
p-value 
11. Adults 
a) Regression equation 
(dose, mg/kg) 
R-square(adj) 
F-square 
p-value 
b) Regression equation 
(dose, mg/daY) 
R-square(adi) 
F-value 
p-value 
14.6% 
11.74 
0.00 
CL-0.25+ 0.0110Dose CL-0.24 +0.0098Dose 
23.0% 
35.28 
0.00 
16.90/a 
49.67 
0.00 
CL=-0.30 +O. OlO8Dose CL-0.32 +. 0.009SDose 
3.6% 
4.24 
0.04 
CL=18.2+ 0.0088Dose 
1.0% 
1.05 
0.18 
8.3.3 Influence of therapy 
2.8% 
3.14 
0.08 
CL-18.8+ 0.0091Dose 
1.7% 
2.30 
0.13 
0.0% 
0.86 
0.36 
CL-0.37+ 0.0035Dose 
0.0% 
0.86 
0.36 
CL-0.21 +0.0132Dose 
11.9°/0 
10.61 
0.00 
CL-15.3+ 0.0078Dose 
2.3% 
2.69 
0.10 
The relationship between monotherapy and polytherapy is presented in figures 
8-11 , 
8-12,8-13 and 8-14. Significant correlations were present in both adult( ragU _ 
0.58, p < 0.005 ) and paediatric( rdj = 0.60, p<0.005) patients on valproic acid 
monotherapy. Polytherapy treated adult(radj = 0.38, p<0.005) and paediatric(radj _ 
0.35, p<0.005) patients however showed a weak but statistically not significant 
relationship. 
The mean serum level: dose ratios(sd) for monotherapy and polytherapy treated 
paediatric patients were 0.13(0.05) and 0.11(0.07) while the corresponding coefficient 
of variation were 50.98% and 61.99%. Values obtained for adults on monotherapy and 
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polytherapy were 0.07(0.03) and 0.05(0.02) with a coefficient of variation of 38.41% 
and 45.52%. These results showed that interindividual variations were highly 
distinctive in both monotherapy and polytherapy treated patients. Adults patients 
however were observed to display lower interindividual variations than paediatric 
patients. 
8.3.4 Influence of ethnicity 
The method described by Greenland (1987) requires essentially a linear 
relationship between two variables and uses the slope to estimate the trend of 
measured effect. The effect of ethnicity was determined by comparing the trend from 
the more reliable linear relationship of dose(mg/day) and serum level in monotherapy 
treated patients. The final result of analysis is presented in table 8-6. 
Table 8-6: Summary estimate of slope of dose and serum level relationship In various ethnic groups 
Age-group Malay Chinese Indian Final results 
I. Paediatric 87 48 44 
_n 
0.0851 0.0679 0.0835 
-slope 
-variance 
0.00006 0.00008 0.00008 
-weights 
16666.7 12500 12500 
-Summary slope - - 0.0795 
.Q statistic 2.4046 
-df 2 
-p 0.15 
. 95% C. I 0.07-0.09 
ILAdult 
-n 
32 16 24 
-slope 
0.0476 0.0384 0.0346 
. variance 
0.00004 0.0001 0.00003 
. weights 
25000 8333.3 33333.3 
-Summary slope - 0.0399 
_Q-statistic 2.4372 
-df 2 
-p 0.15 
. 95% C. I 0.03-0.05 
iii. All patients 
_n 
119 64 68 
. summary slope - - 0.0359 
. Q-statistic 24.9640 
-df 5 
-p <0.00 
-95% C. I 0.05-0.06 
Abbreviation: (C-1, confidence interval 
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Figure 8-15: Valproic acid dose and serum level relationship in 
monotherapy treated Malay paediatric patients 
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Figure 8-16: Valproic acid dose and serum level relationship in 
monotherapy treated Chinese paediatric patients 
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Figure 8-17: Valproic acid dose and serum level relationship in 
monotherapy treated Indian paediatric patients 
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Figure 8-11: Valproic acid dose and serum level relationship in 
monotherapv treated paediatric patients 
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Figure 8-12: Valproic acid dose and serum level relations hip in 
polytherapy treated paediatric patients 
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Figure 8-14: Valproic acid dose and serum level relationship in 
polytherapy treated adult patients 
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Figure 8-19: Valproic acid dose and serum level relations hip in 
monotherapy treated adult Chinese patients 
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Figure 8-20: Valproic acid dose and serum level relationship in 
monotherapy treated adult Indian patients 
70 
.. 60 
el 50 
40 
30 
E 20 
10 
0 
0 200 400 600 800 1000 1200 
Dose(mg/day) 
- ----- --- -- - 
/V 
r, 60 
50 
40 
30 
E 20 
10 
0 
164 
I. Paediatric patients 
The relationship of dose(mg/day) and serum level of monotherapy treated 
paediatric patients(figure 8-15 to 8-17) showed that the correlation coefficient for 
Indians (raaj = 0.67, p<0.005 ), Malays( raij = 0.56, p<0.005 ) and Chinese patients( 
rj; = 0.533, p<0.005 ) were statistically significant and suggestive of a linear 
relationship. Test of homogeneity showed that the difference in slope of regression 
lines between ethnic groups was statistically insignificant. This finding clearly 
indicate that there is no inter-ethnic difference in the relationship between dose and 
serum level in all patient's groups. 
Mean serum level: dose ratio(sd) obtained for Malays, Chinese and Indians 
were 0.1311(0.0717), 0.1283(0.0534) and 0.1230(0.0654) respectively. Corresponding 
coefficient of variation values of 54.69%(Malays), 41.62%(Chinese), 53.21(Indians) 
showed that interindividual variation was prominent in all ethnic groups. However, 
Chinese displayed lower interindividual variation than either Malays or Indians. 
II, Adult patients 
A significant linear relationship between dose and serum level was observed in 
all ethnic groups(figure 8-18 to 8-20). The strength of correlation coefficient(rdj) was 
however highest in Malays(0.63, p<0.005), with Indians(0.57, p<0.005) and 
Chinese(O. 42, p<0.005) coming second and third respectively. Summary effect on 
slope of regression lines in all ethnic groups again showed the relationship between 
dose and serum level was homogenous and indicating the absence of any inter-ethnic 
differences(table 8-6). 
The mean serum level: dose ratios(sd) for Malay, Indian and Chinese patients 
were 0.07(0.02), 0.07(0.04) and 0.07(0.01) respectively. The coefficients of variation 
in Malay(34.03%), Indian(44.80%), and Chinese(21.67%) patients demonstrate that 
interindividual variation do differ considerably between ethnic groups. 
8.4 Discussion 
Interindividual variation observed at similar doses has been reported by 
various authors [ Levy RH 1984, Wulff et al 1977, Schobben et al 1975, Loiseau et al 
1975, Baruzzi et al 1977]. The occurrences of high interindividual variation had led to 
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contradicting reports on the relationship between valproic acid dose and serum level 
relationship(table 8-6). Dosage selection and subsequent dosage adjustment based on 
this relationship is rather difficult and at most times inappropriate. Previously reported 
studies most often differed not only in the inclusion of different patients age groups 
but also as to the type of therapy. This study examined the influence of inter-ethnic 
differences on both of these factors in determining the probable relationship of 
valproic acid dose and serum level. 
In the present study, the correlation between dose in either mg/day or mg/kg 
and serum level in mixed therapy(monotherapy and polytherapy) adult and paediatric 
patients of all ethnic groups showed either weak or insignificant linear relationships. 
These observations are in agreement with the study by McQueen et al (1982) and 
Haigh & Forsythe (1975). Although McQueen et al (1982) mentioned the lack of 
correlation was not related to irregular compliance, concomitant therapy, sampling 
time, dosage changes, age and weight, the probable explanation could be related to 
the observed high interindividual variation among patients. In this study, 
interindividual variation for dose in mg/day and mg/kg were 52.60% and 59.66% in 
paediatric patients and 52.69% to 51.87% in adult groups. 
Interindividual variation has been clearly presented by Dodson et al (1981). 
Their results showed that although a significant relationship between dose and serum 
level( r value between 0.519 to 0.997 ) was noted for individual patients, a similar 
high degree of correlation was not observed when all patients' data were pooled (r= 
0.42 ). Their report again proved that valproic acid should be individualised and that 
population parameters may be used as guidelines during initiating of therapy. 
The present study also showed that the correlation between dose and serum 
level was closely dependent on the type of therapy. Patients on valproic acid 
monotherapy had a statistically significant linear relationship while those with 
concomitant therapy showed a weak and insignificant relationship. These findings 
were clearly in agreement with most of the earlier reported studies in table 8-7. 
The influence of associated therapy on valproic acid dose and serum level 
relationship has been 
demonstrated by Sackellares et al (1981) and Henriksen & 
Johannessen (1982). Both of these studies showed the level of relationship of dose and 
serum concentration 
is affected by concomitant therapy in both adult and children. 
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Sackellares et al (1981) further compared the influence of associated therapy by 
observing a significant relationship( r=0.64) in 11 patients on monotherapy and a 
poor insignificant correlation (r = 0.22) in 22 patients on polytherapy. 
Two earlier studies by Hassan et al (1976) and Redenbaugh et al (1977) 
however reported a linear relationship between valproic acid dose and serum level in 
polytherapy treated patients. Unfortunately neither study reports the correlation 
coefficient of the observed linear relationship. Moreover, the plot of dose and serum 
levels by Rodenbaugh et al (1977) showed a wide scatter which clearly demonstrate a 
high degree of interindividual variation which could possibly denote a weak and 
statistically insignificant relationship. 
Table 8-7: Studies that reported either linear or non-linear relationship between dose and serum level of valproic acid 
Study Age group Therapy Dose r-value 
I. No linear relationship 
Schobben at al 1975 paed + adult polytherapy mg/day 0.43 
Johannessen SI 1977 paed + adult polytherapy mg/day 
Bruni et al 1977 paed + adult polytherapy mg/day 0 26 
Coulter at at 1980 peed polytherapy mg/kg . 0 44 
Johannessen paed monotherapy mfg . 
& Henriksen 1980 
Loscher W 1981 paed + adult mixed therapy mg/kg <0.5 
Henriksen paed monotherapy mg/day 
& Johannessen 1982 polytherapy mg/day 
McQueen at al 1982 paed mixed mg/kg 0 1 
McQueen et al 1982 paed mixed mg/day . 0 2 
Sackellares et al 1981 paed polytherapy mg/kg . 0 2 
Mesdjian et al 1984 paed + adult polytherapy mg/kg . 
ii. Linear relationship 
Hassan et al 1976 paed + adult polytherapy mg/day 
Klotz 1977 paed + adult monotherapy 0 88 
Bodenburg at at 1977 paed + adult polytherapy mg/kg . 
Sackellares at al 1981 paed monotherapy mg/kg 0 64 
Turnbull et al 1983 adult monotherapy my . 64 0 
Mesdjian et al 1984 paed + adult monotherapy g mg/kg . 0 50 
Tisdale at al 1992 adult monotherapy mg/kg . 0.63 
The relationship between dose and serum level has been reported to be 
dependent on time of blood sampling although trough levels(pre-dose) are commonly 
recommended [Chadwick 1994, Welty et al 1983]. However, several studies have 
shown that following the recommended time of blood sampling is not always 
appropriate. Baruzzi et al (1977) studied a total of 106 patients and used 
concentrations at both trough(pre-dose) and 5 hour post dose in determining 
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association. Their results showed that the correlation was poor(r = 0.10) based on 
trough concentrations and marginally better(r = 0.40) on concentration obtained 5 
hours post dose. Bruni and colleagues similarly followed the same sampling times and 
found a poor correlation (r = 0.26) between dose and serum levels in 25 patients. 
Tisdale et al (1992) however utilised trough serum concentrations and found a 
significant relationship( r=0.64). These findings clearly demonstrate the many 
problems in establishing valproic acid dose and serum level relationship in any 
population group. In this study, although serum concentration was monitored between 
10.00 am to 12.00 noon for all patients irrespective of pre or post dose, a significant 
linear relationship was observed only on monotherapy treated patients. 
Controversy over the true relationship between clearance and dose has yet to 
be resolved. In the present study, a poor correlation between clearance and dose was 
observed in all age and ethnic groups. The relationship between clearance and dose 
has been reported to be a non-linear exponential curve [Dodson et al 1981]. This 
finding has been similarly reported by Gram et al (1980) and Vadja et al (1978) and is 
attributed to valproic acid concentration-dependent protein binding properties. Tisdale 
et al (1992) however reported that the relationship is linear. They commented that 
their observed dose-dependent relationship is a consequence of the saturation of 
binding sites of the concentration-dependent protein binding properties of valproic 
acid. 
These studies however differed in two important areas that are known to have 
a significant influence in the outcome of their studies, i. e, age and therapy. Dodson et 
al (1981) used paediatric patients on polytherapy while Tisdale et al (1992) employed 
adult patients on valproic acid monotherapy. These findings indicate that the 
relationship is probably 
dependent on patient's age and the type of therapy. The 
influence of age was moreover demonstrated by Hall et al (1981) where a similar 
exponential curve 
is reported for the association between clearance and age in 
paediatric patients. 
The clearance of valproic acid has been reported to be affected by concomitant 
therapy with phenytoin, carbamazepine and phenobarbitone. The effect of phenytoin 
has been reported by several studies. Coulthard (1975) reported the removal of 
phenytoin was associated with 
improved in seizure control and increased serum levels. 
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De Wolff et al (1982) reported that the serum level/dose ratios of valproic acid were 
decreased by 50% in children receiving valproic acid-phenytoin combination and 
Henrikssen and Johannessen (1982) reported patients on this combination had an 
increase of 122% in serum concentration when phenytoin is withdrawn. The effect of 
carbamazepine and phenobarbitone withdrawal has been reported by Henriksen and 
Johannessen 1982 to be between 50% and 67% in serum concentration. These studies 
clearly demonstrate the effect of concomitant therapy on valproic acid clearance and 
on the relationship between dose and serum concentration. 
This current study(table 8-6) showed that there was no significant inter-ethnic 
differences between dose and serum levels linear relationship in adult( p=0.15 ) and 
paediatric( p=0.15 ) monotherapy treated patients(p = 0.50). However, high 
interindividual variation with a mean coefficient of variation of 50.98% and 38.42% 
for paediatric and adults patients indicate a high degree of diversity among individual 
patients in handling valproic acid therapy. Interindividual variation of adults on 
valproic acid monotherapy of 38.42% was also higher than the 28.86% reported by 
Tisdale et al (1992). This again highlight the degree of diversity of Malaysian 
epileptic patients thus indicating that blood monitoring is crucial during initiation of 
valproic therapy for epileptic patients. 
The above observations clearly showed that the relationship between dose and 
serum level was distinctly related to interindividual variation rather than to inter- 
ethnic differences. However, the influence of ethnicity on interindividual variation 
between patients on valproic acid monotherapy in adults showed a trend where Indian 
patients(44.80%) having the highest coefficient of variation with Malays(34.03%) 
being the intermediate and Chinese(21.67%) the least. Interindividual variation for 
paediatric patients similarly showed that Chinese(41.62%) had the least coefficient of 
variation with Malay(54.69%) and Indian(53.21%) showing almost equal values. 
These findings showed that interindividual variation does differ between ethnic and 
age groups. 
Evidence about the influence of age on interindividual variation is also 
observed in the study. Test of homogeneity between adult and paediatric patients 
showed that there were heterogeneity between the two groups(table 8-6). Pooled 
slope(mean, 95% C. I) of regression lines in paediatric(0.0795,0.0698-0.0891) and 
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adult(O. 0399,0.0323-0.0475) patients showed the rate of elimination is slower in 
younger individuals. 
The effect of age in the rate of elimination of valproic acid is expected since 
valproic acid is primarily metabolised in the liver and hepatic function improves with 
maturity. Thus, higher interindividual variation observed in paediatric patients(age 
range 1-17 years old) is due to differing metabolic capacity between individuals. 
8.5 Limitation of study 
Other than problems on the design of study already discussed in chapter 5 and 
6, one further limitation of this study should be mentioned. Blood samples as 
mentioned earlier were routinely taken between 10.00am to 12.00 noon. Since 
valproic acid has a short half-life of 9-15 hours [Davis et al 1994], the period of two 
hours may have a significant affect on the serum concentration level at the time of 
monitoring. The difference on the time of sampling may contribute to the variation in 
serum concentrations of individuals and this could affect the reliability and accuracy 
of the overall results although it should not have led to a systematic bias. This is 
especially important since establishing relationships between dose and serum levels 
and dose and clearance among patients groups needs both accuracy in blood sampling 
and drug assaying. 
8.6 Conclusion 
The relationship between valproic acid dose and serum level is highly variable 
and is dependent on patient age-group( adults and paediatric patients ) and therapy. 
Dose given in milligram per day or milligram per kilogram body weight had no 
significant influence on the above relationship. The correlation between dose and 
serum level was however 
found to be highly significant in patients on valproic acid 
monotherapy but not 
for patients in polytherapy or mixed therapy(monotherapy + 
polytherapy). 
The results of this study clearly showed that the main reason for the observed 
poor correlation was 
due to the high interindividual variation among patients. The 
coefficient of variation of the studied population of adult and paediatric 
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patients(Malay, Indian, Chinese) on valproic acid monotherapy were 54.69%, 53.21 %, 
41.62% and 34.03%, 44.80%, 21.67% respectively. Test of homogeneity showed that 
inter-ethnic differences had no significant effect on the relationship between dose and 
serum levels. 
The relationship between clearance and dose showed no significant correlation 
in both monotherapy and polytherapy treated patients of all ages and ethnic groups. 
These results showed that the non-existence of linear relationship being not 
dependent on the type of therapy, age group or inter-ethnic differences. Although the 
true nature of its relationship is not determined, these findings disproved the claim by 
Tisdale et al (1992) valproic acid exhibiting dose-dependent properties although 
further study need to be initiated. 
Finally, this study showed the clinical importance of monitoring serum 
concentration of valproic acid. High interindividual variation and drug-drug 
interaction are the two main determinants that might affect serum levels. These 
findings showed that individualised approach strategy is important if valproic acid is 
used for the treatment of epilepsy. 
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Chapter 9: 
Phenobarbitone: Dose and serum level relationship in a 
multiethnic epileptic population 
9.1 Introduction 
Phenobarbitone was first shown to have anticonvulsant properties in 1912 by Dr 
Alfred Hauptmann [Hauptmann 1912]. Currently, phenobarbitone is used in partial and 
generalised seizures [Mattson et al 19851. It is widely used as a sole anticonvulsant in 
infants and children, but in adolescent and adults, it is more commonly used as an adjunct 
in combination with one of the other major antiepileptic drugs. 
Phenobarbitone is a classic example of a drug causing induction of hepatic 
microsomal enzymes [Conney 1967, Patsalos et al 1988, Wilensky et al 1982]. It 
increases clearances and thus decreases serum levels of other antiepileptic drugs such as 
carbamazepine [Welty et al 1983] and valproic acid [Bruni et al 1980, Patel et al 1980, 
yukawa et al 1989]. However, drugs such valproic acid also decrease elimination of 
phenobarbital mainly through a direct competition for hepatic enzymes binding sites 
which consequently lead to elevated serum concentration [Kapetanovic et al 19811. The 
drug interaction with phenytoin is complex [Patsalos & Duncan 1993]. 
The pharmacokinetics of phenobarbitone are well established [Evan et al 1991, 
Battino et al 1995]. Elimination of phenobarbitone is prolonged and the half-lives varies 
with age. Adults half-lives ranges from 3-5 days and in children, from 2-3 days. 
Therefore, steady state can only be accurately measured after a minimum of 20 days after 
adequate doses was given [Welty et al 1985, Patsalos & Duncan 1993]. 
The relationship between steady-state serum concentration and dose is reported to 
be linear in both adults [Svensmark & Buchthal 1963, Buchthal et al 1972, Strandjord & 
Johannessen 1977] and children [ Jailing 1974, Heimann & Gladtke 1977, Painter et al 
1978, Martin et al 1979]. Eadie at al (1977), however, found in a mixed age population 
that the relationship was curvilinear(r = 0.453). Studies by Yukawa et al (1992) in 
Japanese paediatric population showed that the relationship was poor(r = 0.330). They 
further accounted for their observation by high interindividual variation caused mainly by 
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age-dependent variations in drug disposition [Ehrnebo et al 1970] and drug-drug 
interactions [Patsalos & Duncan 1993]. 
The influence of factors such as age, sex, and concurrent therapy on dose and 
serum level relationship of phenobarbitone have been reported for younger patients. 
However, the effects of these factors were mostly investigated by examining its 
relationship on the ratio of serum level: dose. Rossi et al (1979) (r = 0.72) reported a 
strong association with age while Suganuma et al (1981) (r = 0.81 and Yukawa et al 
(1992) (r = 0.59 ) showed similar significant relationship on polytherapy treated patients. 
Duran et al (1988) observed that sex has no such effect. 
Relationship between phenobarbitone clearance and dose have been reported as 
being non-linear by various authors by using semilog plots of serum concentration versus 
time [Viswanathan et al 1979, Butler et al 1954, Lous 1954, Svensmark & Buchthal 
1963, Raven-Jonsen et al 1967]. However, a systematic study on individual epileptic 
patients found the relationship is non-linear in adults on monotherapy [Browne et al 
1985]. Similar fmdings were also reported in mixed population epileptics [Duran et al 
1988]. The relationship to age in children less than 15 years has been reported as being 
curvilinear [Yukawa et a! 1992]. 
The above findings on the relationship between dose and serum concentration or 
factors that affect its relationship such as age, although important has not mentioned the 
effect of ethnic differences on phenobarbitone pharmacokinetics. However, 
phenobarbitone has been shown to display large variation( 0- 69%) in metabolism of 
antipyrine in identical and fraternal twins [ Vessel & Page 1969]. The findings showed 
that the existence of a genetically controlled factor on the rate of enzyme induction 
properties ofphenobarbitone. 
The relationship between clearance and dose however suffers from lack of 
published reports both in children [Battino et at 1995] and adults [Browne et at 1985]. 
However, studies on the relationship between serum level and dose ratios (inverse to 
apparent clearance) showed that clearance is linear in children [Yukawa et at 1992, 
Suganuma et al 1981, Rossi et al 1979] and curvilinear in mixed populations [Duran et at 
1988]. Both of these relationship will however be investigated in the present study on 
epileptic patients of Malay, Chinese and Indian origin. 
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This main hypothesis of this study is to prove that phenobarbitone 
pharmacokinetics is affected by inter-ethnic differences. Thus, this study aims to 
investigate the relationship of phenobarbitone dose and serum concentration in epileptic 
patients with different ethnic backgrounds. Determination of the relationship between 
clearance and dose in the three ethnic groups will be the second objective of this study. 
Interindividual variation and the trend of slope in the relationship between dose and serum 
concentration will be the main determinants to differentiate the influence of ethnicity. 
Finally, this study aims to propose pharmacokinetic models on which the use of 
phenobarbitone tailored for the multi-ethnic Malaysian population. 
9.2 Methods 
Patient data were obtained retrospectively using the method described in chapter 
5. A total of 190 adult epileptic steady-state dose and serum data pairs were randomly 
selected utilising the randomisation strategy mentioned in chapter 5. Patients were divided 
into ethnic groups of Malay, Chinese and Indian. Their clinical characteristics are 
presented in table 9-1. 
Non-compliant patients were determined from patients notes and plasma 
concentration request forms and were excluded. Details pertaining to each dose and the 
serum concentration selected were checked from patient notes for confumation. The 
serum level was measured by the fluorescence polarization immunoassay(FPIA) method. 
Patients were included if they were on phenobarbitone therapy for a minimum period of 
30 days. 
The relationship between dose and serum level was determined by linear 
regression analysis and Pearsons correlation coefficient and the significance of corre lation 
was determined using Student's t test [Daniel 1987]. To ease calculation, MINITAB 
version 10 were used for all calculation. AP value equal or less than 0.05 was considered 
significant. The parameter used 
for analysis was dose, serum level, and apparent 
clearance. Doses were expressed 
in either milligram per day(mg/day) or per 
kilogram(mgI'kg), serum levels in milligram per liters(mg/L) and clearance in Liters per 
kg per day(Ukg. day). The formula to calculate apparent clearance by Wagner 1965 (as 
described in chapter 1, section 1.5.5 ) was used, 
Clearance(CLU) _ F. ä 
Cssq. T 
(equation 7-1) 
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where Css# is the steady state blood concentration, Du is the dose, r is the length of the 
dosage interval, F is the fraction of each dose which is absorbed (bioavailability factor ). 
Plotting Css and D; j would be a straight line with they intersect of 0 and the assumption 
that the other variables remains constant. F has been reported to be between 0.95 to 1 in 
various oral dosage forms [Nelson et al 1982, Wilensky et al 1982, Strandjord & 
Johannessen 1977]. For simplicity, F was taken as equal to 1. The formula assumes that at 
steady state (at equilibrium) the ratio of change in dose is proportionate to the ratio of 
change of serum concentrations. Clearance is measured in liters per kg. day (L/kg. day). 
Correlation of clearance and dose were evaluated by linear regression [Daniel 1987]. 
Table 9.1: Summary data of patients according to ethnicity 
Characteristic Malays Indians Chinese 
Na of patients 67 38 82 
Ratio of malelfemale 26: 41 26: 12 39: 43 
Age(yr) 
Mean, sd 3828,11.46 39.73,14.23 37.93.11.00 
Range 20.00-71.00 19.00-81.00 20.00.69.00 
Weight 
6133,10.55 59.78,9.31 60.32,937 
Range 40.00-83.00 39.00-78.00 40.00-79.00 
Disease duration(Yr) 
Mewysd 15.16,11.27 14.24-10.14 14.37,9.59 
Range 1.00-44.00 2.0042.00 2.0042.00 
Epilepsy TYPes 
Generalised 51 32 67 
padw 13 5 14 
Others 3 1 1 
Therapy(MP) 1: 66 2: 36 13: 69 
Dose(mg/daY) 
Meae, ad 85.52,46.12 90.40,63.10 98.11.44.12 
Range 15.00-210.00 15.00-270.00 15-00-210.00 
Dose(mg/W 
Mean, sd 1.41,0.71 1.61.1.35 1.48,0.76 
Range 0.29-3.15 0.19-6.92 0.24-4.29 
Mean, sd 16.26,9.86 20.38,13.21 14.78,8.65 
Range 0.95-48.24 337-45.89 1.13-400 
ýy) 
Me 0.12,0.10 0.09,0.05 0.12,0.09 
Range 0.04-0.63 0.02-0.24 0.044.67 
Abb on: M. monotherapy, P- polytherapy 
9.3 Results 
Analysis of variance between ethnic group with respect to age( p=0.74 , 
weight (p = 0.70), 
disease duration (p = 0.87), and dose in mg/kg (p = 0.54 ) 
showed no significant 
difference. Serum level (p = 0.02) and clearance (p < 0.005) 
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showed significant difference exist between Malays, Chinese and Indians. Mean 
serum level(sd) in mg/L of Malay, Chinese and Indian patients were 16.26(9.86), 
14.78(8.65)mg/L and 20.38(13.21) respectively. Their mean clearances(sd) estimate 
in liters/kg. day were 6.99(5.65)L/kg. day, 4.79(2.97)L/kg. day and 3.42(1.50)L/kg. day. 
9.3.1 Relationship between dose and serum level 
Plot of dose and serum level showed that a linear relationship existed in both 
dose in mg/day or mg/kg(figure 9-1 to 9-2). The corresponding correlation coefficient( 
radj ) values for dose in mg/day and mg/kg are 0.57 and 0.54. The similarities in rd j 
values indicated the guidelines for phenobarbitone dosing in mg/kg is useful during 
the initial therapy and to prevent intoxication. In establishing optimum serum 
concentration for seizure control, dose in mg/day is sufficient. 
Figures 9-1 to 9-2 are also characterised by a wide scatter of data points along 
the regression line which is an indicator for high interindividual variation. The mean 
serum level: dose ratio(sd) for dose given in mg/day and mg/kg. day for all patients 
was 0.20(0.10) and 11.96(5.93) and the range between 0.03-0.68 and 1.50-40.60 
respectively. The calculated coefficient of variation(CV) were 50.00% and 49.58%. 
These high values of coefficient of variation showed a considerably high degree of 
interindividual variation in the studied population. 
Table 9.2: Dose and serum level(SL) relationship of patients according to ethnicity 
Predictors Malays Chinese Indians 
I. Adult 
a) Regression equation 
SL=2.08 + 10.1Dose SL-1.24 + 9.16 Dose 
(dose, mg/kg) 
R-square(adi) 52.6% 63.9% 
F-square 74.37 144.63 
p-value 
0.00 0.00 
Serum level: dose ratio, sd 12.19,5.92 10.30,3.66 
Range 1.58-28.22 1.50-23.00 
C. V(serum level/dose) 48.56% 35.53% 
b) Regression equation SL=3.38 + 0.151Dose SL'0.74 + 0.159Dose 
(dose, mgtdaY) 
R-squate(adi) 48.8% 65.7% 
F-value 63.99 156.03 
p-value 
0.00 0.00 
Serum level: dose ratio 0.20,0.10 0.17,0.06 
Range 0.03-0.50 0.03-0.04 
C. V(serum level/dose) 50.00% 35.38% 
SL-9.95 + 7.11 Dose 
31.7% 
40.66 
0.00 
15.13,8.28 
4.96-40.60 
54.73% 
SL-3.47 + 0.16SDose 
61.0% 
58.92 
0.00 
0.25,0.13 
0.10-0.68 
52.00% 
Abbrevf"tO° GV. Offlckst of vorfýtioo. 
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Figure 9-1: Phenobarbitone dose and serum level relationship in 
adult patients 
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Figure 9-2: Phenobarbitone dose and serum level relationship 
in adult patients 
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Figure 9-3: Phenobarbitone dose and serum level relationship 
in adult Malay patients 
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Figure 9-4: Phenobarbitone dose and serum level relationship 
in adult Chinese patients 
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Figure 9-5 : Phenobarbitone dose and serum level relationship 
in adult Indian patients 
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Figure 9-6: Phenobarbitone clearance and dose relationship in 
adult patients 
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Figure 9-7: Phenobarbitone clearance and dose relationship in 
adult patients 
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Table 9-2 shows the correlation between dose in mg/day and mg/kg with 
serum levels according to ethnicity. Overall, dose and serum level relationship in all 
patient's groups were found to be statistically significant. 
Interindividual variation was clearly demonstrated by the wide scatter of data 
points from the plots of dose(dose/kg body weight) and serum levels in all ethnic 
groups(figure 9-3 to 9-5 ). Evidence towards the scale of interindividual variation was 
clearly highlighted by the coefficient of variation(mean serum level: dose(per kg body 
weight)) ranging between 35.53%-54.73%. 
9.3.2 Influence of ethnicity 
Inter-ethnic differences were determined by comparing the trend from the 
more reliable linear relationship of dose(mg/kg) and serum level in monotherapy 
treated patients. Summary effect on slope of regression lines in all ethnic groups again 
showed the relationship between dose and serum level was homogenous and indicated 
the absent of any inter-ethnic differences. The final result of analysis is presented in 
table 9-3. 
Table 9-3: Summary estimate of slope of dose and serum level relationship in various ethnic groups 
Variables Malay Chinese Indian Final results 
Dose(mgfkg) 
. Sample size(n) 
-slope 
-variance 
. weights 
. Summary slope 
-Q-statistic 
-df 
-P 
. 95% C-[ 
Dose(mg/daY) 
-Sample size(n) 
. slope 
. variance 
. weights 
. Summary slope 
_Q-statistic 
-df 
-P 
. 95% C. I 
67 
10.10 
1.37 
0.73 
67 
0.151 
0.0004 
2500 
8.86 
3.75 
2 
0.08 
7.78-9.49 
0.138 
0.23 
2 
0.45 
0.14-0.18 
Abbravirtiues C. 4 co. 6deIee 
iehrvaL 
82 41 
9.16 7.11 
0.58 1.24 
1.72 0.81 
82 41 
0.159 0.165 
0.0002 0.0005 
5000 2000 
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9.3.3 Dose and clearance relationship 
The regression equations that determined the linear relationship between 
clearance(CL) and dose(mg/kg) or dose(mg/day) were as follows; 
CI(L/day) = 17.0 + 0.0091D(mg/day) 
(r8d, =0.02, p=0.01) 
CL(L/kg. day) = 0.274 + 0.0115Dose(mg/kg) 
(radj =0.06, p<0.005) 
The above equations showed no significant linear relationship existed between 
clearance and dose and is presented graphically in figures 9-6 and 9-7. 
Table 9-4: Dose and clearance(CL) relationship of various ethnic groups 
Predictors Malays Chinese Indians 
a) Regression equation CL-0.12 - 0.0047Dose CL-5.08 -. 0.0032Dose CL-0.21 +0.0132Dose 
(dose, mgtkg) 
R-square(adj) 0.0% 0.0% 11.9% 
F-square 0.07 0.19 10.61 
p-value 0.80 0.67 0.00 
b) Regression equation CL, =6.68- 0.0037Dose CL-0.12- 0.0016Dose CL-0.06+ 0.0189Dose 
(doseinglday) 
R. square(adi) 0.0% 0.0% 29.5% 
F-value 0.06 0.02 16.34 
p-value 0.81 0.90 0.00 
Table 9-4 showed the correlation of clearance with respect to dose according 
to ethnic groups. Insignificant linear relationship was observed in all groups. These 
findings demonstrate that the poor correlation between phenobarbitone clearance and 
dose is not characterise of a dose-dependent relationship. 
The relationship between clearance(CL) and dose(D) can be predicted by 
transforming the highly significant linear relationship of dose and serum level of the 
current population into the formula by Wagner et al (1965). 
FxD 
Clearance(CL) _ 
Cssxr 
where F is the bioavailibility factor and equal to 1, and r dosage regimen(per day). 
Since the linear relationship of the studied population is, 
Css = 3.86 + 8.51 x Dose 
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Combining the two equation, the relationship between clearance(L/kg. day) and 
dose(mg/kg. day) is, 
0.12 xD 
CL(L/kg. day) _ 
0.45 +D 
The derived equation is clearly hyperbolic and characteristic of a curvilinear 
relationship and is depicted in figure 9-8. 
Figure 9-8: Predicted clearance and dose relationship in adult 
epileptics 
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9.4 Discussion and limitation of study 
The current finding of a linear relationship between dose and serum level in 
adult epileptics is concurrent with several earlier studies [Buchthal & Lennox- 
Buchthal 1972, Svensmark & Buchthal 1963, Buchthal et at 1972, Strandjord & 
Johannessen 1977]. The result however disagrees with that of Eadie et at (1977), 
Thomson and Brodie (1992) and Yukawa et at (1992) where a curvilinear or poor 
relationship was concluded. 
Although phenobarbitone interindividual variability relationship has been 
attributed to age-dependent variations in drug disposition and drug interactions on 
younger patients [Yukawa et at 1992], the question concerning the validity of the 
observed serum levels in this study still needs clarification. Nevertheless, the reasons 
for the existence of the observed significant linear relationship can be explained by 
phenobarbitone established pharmacokinetics. 
Phenobarbitone slow elimination which is characterised by its half-lives 
between 50-120 hours in adults means that its serum concentration does not fluctuate 
greatly throughout the dosing interval [Welty et at 1985]. The minimum time to 
achieve steady-state is about 20 days has made monitoring important if therapy has 
been initiated within the period. The period of 30 days allocated for this study is thus 
sufficient to attain and ensure steady-state serum concentration was achieved. 
Fluctuation of phenobarbitone serum concentration can occur due to drug-drug 
interaction. This is especially true in this study as 91.4% of all patients were on 2 or 
more antiepileptic drugs. Of these 52.4% were on phenytoin, 27.8% on carbamazepine 
and 21.4% on valproic acid. Drug interactions involving phenytoin, valproic acid and 
phenobarbitone are well established although their mechanism of interaction is 
sometimes not defined [Patsalos & Duncan 1993]. Its interaction with carbamazepine 
is still unconfirmed. 
A drug interaction is regarded as the modification of the effect of one drug by 
prior or concomitant administration of another [Patsalos & Duncan 1993]. Epileptics 
have been observed to receive a mean of 3.2 drugs [Guelen et at 1975] of which 
84.3% were antiepileptic drugs. Since most antiepileptic drugs behave as either liver 
enzymes inducers(phenytoin, carbamazepine, phenobarbitone) or inhibitors(valproic 
acid), potentiation of any pharmacological effects due to their interactions depend if 
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the drug has a short or long half-lives. These interactions will reach steady-state after 
4 to 6 half-lives after the interaction and monitoring before the minimum elapsed time 
will effectively affect serum concentration. Prescott (1980) listed the estimated 
minimum elapsed time for a new steady-state and complete pharmacological 
potentiation for phenobarbitone drug interactions with phenytoin, carbamazepine or 
valproic acid to be 20 days(table 9-5). This again showed the assigned 30 days in this 
study was adequate to achieve the desired steady-state serum concentration. 
Table 9-5: Comparison of minimum elapse time required for a new steady-state and complete 
pharmacological potentiation to be achieved consequent to a putative enzyme inhibitory Interaction 
Drug Half-lives Period to achieve steady-state 
Carbamazepine 5-15 hours 24 hours to 5 days 
Phenytoin 8-60 hours 40 hours to 14 days 
Valproic acid 4-20 hours 1- 5 days 
phenobarbitone 40-70 hours 10-15 days(children) 
20 days(adult) 
Serum concentrations of phenobarbitone have been reported to increase upon 
introduction of phenytoin co-medication [Lambie & Johnson 1981, Morselli et at 
1971] but Eadie et al (1977) however observed no significant elevation. The study by 
Duncan et al (1991) showed phenobarbitone serum concentration was increased by 
30%. Mechanism of interaction is probably competitive inhibition of phenobarbitone 
hydroxylation by phenytoin [Patsalos & Lascelles 1977,1981]. 
The effect of carbamazepine on phenobarbitone is less prominent if it is given 
as an associated therapy. Nevertheless, Callaghan et al (1977) reported that 
phenobarbitone serum concentration were significantly increased if taken with both 
carbamazepine and phenytoin. The elevation of phenobarbitone serum level is 
probably to the drugs combined inductive effects on liver microsomal enzymes. 
The variation in the elevation in serum level of a restrictively-cleared drug 
such as phenobarbitone is associated with increase of free non-protein bound 
component of the drug in the blood. This free unbound phenobarbitone will be easily 
metabolised and can then be associated with increased rate of elimination and the total 
serum concentration(which is commonly measured) can decrease. This decrease will 
nevertheless depend on the extend of drug-drug interaction [Patsalos & Duncan 1993]. 
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These together with phenobarbitone properties of being an inducer of liver 
microsomal enzymes and its dose-independent elimination kinetics [Duran et at 1988], 
can lead to the poor correlation between clearance and dose. 
The non-linearity relationship between clearance and dose in adult epileptics is 
in-line with that observed by Browne et al (1985). Their study however was of adult 
epileptics on monotherapy with a age range between 19-46 years. A similar finding is 
also reported by Duran et al (1988), where they utilised a mixed population of 
epileptics. The current finding has thus confirmed these earlier results that 
phenobarbitone does not exhibit a dose-dependent relationship. 
The predicted curvilinear plot on the relationship between clearance and dose 
showed a wide variation of phenobarbitone elimination rate. These variations occur in 
all doses although the variation at lower doses(1-2mg/kg. day) are more prominent 
than doses exceeding 2mg/kg. day. The results of the present findings on a mixed age 
population can be explained due to differences in genetic factors [Vessel & Page 
(1969)] and age differences which have been attributed for the differences in 
elimination rate. The effect of age have been demonstrated by Boreus et al (1978) and 
Kutt et al (1982) where the rate of phenobarbitone in infant and children was reported 
to be faster in than adults. 
Studies on phenobarbitone inter-ethnic differences are rare. The current results 
showed although there are some degrees of variation in the slope of dose and serum 
level, the difference is statistically insignificant( p= >0.05). This finding showed that 
there is no inter-ethnic differences in epileptic patients of Malay, Chinese and Indian 
origin in handling phenobarbitone therapy. The result for a linear relationship in 
Malaysian Chinese were however similarly reported by a study on 32 Taiwanese 
Chinese epileptic patients of mixed age group [Lai 1985]. 
Nevertheless, report from a Japanese study displayed that there could still be 
differences in certain ethnic groups. A report of a large study by Yukawa et at (1992) 
of 539 Japanese paediatric patients showed a poor correlation between dose and serum 
level relationship and was contradictory to that published by European-based studies 
palling 1974, Heimann & Gladtke 1977, Painter et al 1978, Martin et at 1979]. 
The linear relationship between serum level: dose ratios and dose in younger 
patients showed that Japanese [Yukawa et al 1992] presented a trend similar to 
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European studies [Rossi et al 1979, Eadie et al 1977]. Lee & Chan (1981) reported 
that in Singaporean Chinese ( mostly paediatric patients ), the plot of serum level: dose 
ratios against dose, is scattered but they did not mentioned the statistical significance 
of its relationship. Reports by Lai (1985) found the relationship were poorly 
correlated. These findings indicate a possibility that the Chinese paediatric epileptic 
population behave differently from similar epileptics of other ethnic groups. 
The explanation for the above inter-ethnic differences can be attributed to the 
genetically controlled phenobarbitone liver enzymes inducing capability [Vessel & 
Page 1969]. Phenobarbitone inducing properties on liver microsomal enzymes has 
been noted to be hereditary and the differing rate of metabolism among individuals 
could have contributed to the above non-linear relationship. 
9.5 Conclusion 
The relationship between phenobarbitone dose and serum level is highly 
correlated in either dose given in milligram per day or milligram per kilogram body 
weight. This finding indicates that dosage guidelines are important during the initial 
introduction of therapy and further changes in dosage strategy can be based on the 
targeted serum concentration. 
The observed non-linear correlation between clearance and dose could be due 
to phenobarbitone dose-independent properties. Interindividual differences and drug- 
drug interactions were the other reasons for the poor relationship. The relationship 
between clearance(Liters per kilogram per day) and dose(mg/kg body weight) were 
found to be curvilinear based on the formula, 
Clearance(L/kg. day) = 0.12 x Dose 
0.45 + Dose 
Finally, this study showed there was no evidence of inter-ethnic differences 
between Malay, Chinese and Indian epileptic. The final relationship between dose and 
serum level for the Malaysian adult population can be predicted by the following 
formula; 
Serum level(SL, mg/L) = 3.86 + 8.51 x Dose(mg/kg) 
The derived formula would be especially useful in predicting the targeted serum 
concentration for optimum therapeutic response. 
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Chapter 10: 
Phenytoin pharmacokinetics in a multiethnic epileptic 
population 
10.1 Introduction 
Phenytoin is an anticonvulsant used for the treatment of generalised and focal 
seizures [Brodie 1997]. At therapeutic doses phenytoin metabolism is non-linear due 
to saturable or capacity-limited kinetics [Richens 1979, Bochner et at 1972, Borofsky 
et at 1972, Martin et at 1977, Mawer et at 1974, Richens and Dunlop 1975]. Saturable 
kinetics of phenytoin can be described by the Michaelis-Menten formula, which 
indicate that small increases in dose can cause large increases in the concentration in 
plasma. 
The therapeutic concentration for phenytoin ranges between 10-20mg/L for 
adults and children [Brodie & Dichter 1997]. To achieve the targeted therapeutic 
range, dose administration must approach the maximum rate at which phenytoin is 
eliminated. The consequence of this dosing strategy is that the steady-state serum 
concentration shows high variability, particularly at higher doses. 
Phenytoin dose-dependent pharmacokinetics depend on the estimation of the 
two Michaelis-Meuten constants which are referred as the maximum metabolic 
rate(Vmax) and the constant equal to the plasma concentration at which the rate of 
metabolism is one-half the maximum(Km). This can only be derived at steady-state 
concentration(Cpss) during a dosing interval [Ludden et at 1977]. However, studies 
have shown that the interindividual variability of Vmax and Km is high. Reports by 
Allen et at (1979), Eadie et at (1976), Houghton et at (1975), Ludden et at (1977) and 
Martin et at (1977) showed that Vmax can vary between 100 to 1000mg per day and I 
to 15 mg/L for Km. Houghton et at (1975) even concluded that genetic differences and 
the effect of saturation kinetics are much more important than age, weight, height and 
sex. 
Phenytoin metabolism had been known for many years to be genetically 
controlled and patients on chronic therapy developed phenytoin intoxication on the 
basis of a familial deficiency in hydroxylation capacity [Edeki & Brase 1995]. Arnold 
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and Gerber (1969) reported pronounced difference in the mean plasma half-lives 
between Caucasian and Negro blacks which Buchanan et al (1977) later failed to 
substantiate. Interethnic differences were further observed by Dam et al (1977) where 
the phenytoin clearance of patients from Greenland Eskimos (Danish nationality) was 
significantly higher than identically treated Caucasian patients from Denmark. 
Ethnic differences in drug disposition of antiepileptic drugs with high 
interindividual variations in response such as phenytoin have been examined [Bauer & 
Blouin 1982, Bauer & Blouin 1983, Grasela et al 1983, Lee and Chan 1983, Andoh et 
al 1980, Kromann et al 1981]. Sheiner et al (1981) moreover reviewed phenytoin 
population pharmacokinetics and found considerable and significant differences 
between Japanese and European population. 
Objectively, this study aims to investigate the influence of ethnicity on the 
pharmacokinetics of phenytoin. This study also aims to propose ethnic specific 
population pharmacokinetic parameters of phenytoin (Km and Vmax) for the multi- 
ethnic Malaysian population. 
10.2 Methods 
A total of 432 epileptic patients comprising of 383 adults and 49 children were 
included in the study. A total of 864 steady-state dose and serum data pairs (two pairs per 
patient) were selected utilising the randomisation strategy described in appendix 5-11. 
Details concerning the methods for data retrieval are described in chapter 5. 
Patients were divided into groups according to age and ethnicity. Age groups were 
identified as children or adult. Children are defined as patients whose age is less than or 
equal to 18 years. Patients whose age were more than 18 years were all categorised as 
adults. The ethnic groups studied were Malay, Chinese and Indian and the clinical 
characteristics of the patients pertinent to the study are presented in table 10-1. 
Non-compliant patients were excluded. The method of recognising compliance 
was by reviewing through reading patients notes and comments made from the plasma 
concentration request forms. Details pertaining to each dose and serum concentration 
selected were checked from patient notes for confirmation. The serum level was measured 
by the fluorescence polarization immunoassay(FPIA) method. Patients were also included 
only if they were on phenytoin therapy for a minimum period of 30 days. 
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The three main variables investigated were dose, serum concentration and 
clearance. Dose(R) can either be in milligrams per day(mg/day) or milligrams per 
kilogram body weight(mg/kg. day). Serum levels were in milligram per liter(mg/L) 
while clearance was described in liters per day(L/day). Data were analysed using the 
software available in the Minitab Statistical package, version 10.2. Differences in age, 
sex, disease duration and epilepsy types in each group were evaluated by one way analysis 
of variance(ANOVA) with the degree of significance of p <= 0.05. Coefficient of 
variation(CV) for interindividual variation was calculated using the following formula: 
CV(%) = (SD + Mean) x 100, where `SD' denotes standard deviation. 
Linear regression was used to determine the influence of continuous variables 
such as age and weight on the Michaelis-Menten parameters(Km and Vmax). The graphic 
method was used to estimate Km and Vmax of each individual(figure 10-1). 
Table 10-1: Summary data of patients of various ethnic groups 
Characteristic Malay Chinese Indian 
No. of patients 171 158 104 
Ratio of male/female 99: 72 87: 71 53: 51 
A 
Mean, sd 33.96,12.36 33.21,13.38 30.81,11Z7 
Range 5.00-73.00 2.50-69.00 10.00-53.00 
Weight 
mearw 5834,12.71 56.97,13.95 54.45,12.61 
Range 11.75-90.00 10.00-87.00 10.00-87.00 
Disease duration(yr) 
Mean, sd 10.84,8.71 13.86,1 150 14.71,10.13 
Range 0.00-38.00 0.50-55.00 1.50-41.00 
Epilepsy Types 
Generalised 127 115 85 
partial 25 28 10 
others 19 13 9 
7bempy(M: p) 102: 69 90: 68 61: 43 
Dose(mg/day) 
Mean, sd 272.60,83.23 265.66,80.08 274.86,70.57 
Range 45.600 15-460 100-450 
Dose(mg/kg) 
Mean, sd 4.84,1.65 4.87,1.89 5.34,1.96 
Range 139-12.50 1.25-15.00 1.55.14.28 
Css(mg/L) 
Mean, sd 14.18,834 14.67.9.29 15.81,10.06 
Range 0.90-41.29 1.09-43.99 0.89-47.20 
CL(1/kg. day) 
Mean, sd 25.68,15.96 24.90,14.81 24.85,17.36 
Range 3.44-111.11 5.91-93.46 6.62-148.15 
Abbreviation: M- monotherapy, P- polytherapy 
In order to distinguish differences between Km and Vmax values between adult 
and children, the method proposed by Cochran 1954 was employed. This method 
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basically uses the Q statistic to test for homogeneity for the summary measure of effect 
size and is described in Chapter 3. 
The problem of sensitivity in the method of randomly selecting two dose/serum 
level pairs may produce unrealistic individualised values of Km and Vmax. This is clearly 
demonstrated by the estimated Km values and their distribution in Appendix 10-1 to 10-3. 
To address the problem, the upper and lower 10% of Km and Vmax values in each ethnic 
group were trimmed and the fmal values taken for analysis were those in the middle 
bracket of 80%( 100 ± 10 % ). 
10.2.1 Data analysis 
Using the Michaelis-Menten equation, for a series of dosage rate-steady-state 
level pairs from each individuals, the following relationship is employed. 
VmJ . Cpssj 
Rij = 
Kmj + Cpssy 
Ry is the dose rate(mg/day) for the ith pair in the jth patient, Vmj is the maximum 
elimination rate of the jth patient, Cpss j is the steady-state plasma 
concentration(ug/ml) measured in the jth patient while receiving the ith dosage and 
Kmj is the Michaelis-Menten constant for phenytoin metabolism. The parameters Vmj 
and Kmj are assumed not to vary within patient but may vary between patients. Vm 
and Km are calculated by assuming at steady-state condition and following Michaelis- 
Menten relationship of, 
S. F. R= Vmax - Km. 1 S. F. R. J 
Css 
where S. F. R is the dosing rate, which is dependent on the salt factor(S) form and is 
equal to 1, F is the bioavailibility while R is the rate of administration(dose/day, equal 
= 1). For this study, bioavailibility was assumed to similar to all patients for all 
patients. Vmax is defined as the maximum rate of metabolism (metabolic capacity) and 
Km is a constant with a value equal to the plasma concentration at which the rate of 
metabolism is one-half the maximum. 
The point of intercept on the y-axis is the value for Vmax (mg/day) while the 
slope is the value for Km(mg/1). Thus, at least two dose-level pairs are needed in 
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plotting the desired graph. The final regression equation y=a+ bx , will represent 
the dose/serum level pairs, where a(constant) is the intercept to the y-axis and equal to 
Vmax and b is the regression coefficient or gradient signify Km. The graphical 
estimation used is presented in figure 10-1. Each individual Km and Vmczx was 
estimated by plotting their two dose/serum concentration pairs where the gradient 
corresponds to Km and the y intersect is the Vmax. 
Figure 10-1: Graphic estimation of individual Vmax and Km values in a female 
Chinese, age 17 years old who had phenytoin concentration of 8.91 mgfL and 
22.34mg/Lwhile receiving a dose of300 and 400 mg daily. 
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Km and Vmax can also be estimated using simultaneous equations by substituting 
the value of y to serum concentration (mg/L) and x as the dose (mg/day) in the linear 
equation y=a+ bx. 
The mean estimates of Km and Vmax of each ethnic groups were then used to 
calculate the total daily dose needed to produce a given steady state phenytoin 
concentration, according to the following equation; 
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Vmaz . Cpss 
Dose = 
Km + Cpss 
where dose is in mg/day, Vmax (mg/day), Km(mg/L) and Cpss(steady-state) serum 
concentration in mg/L. 
10.3 Results 
A total of 306 adults and 40 paediatric patients were finally enrolled for the 
study. The characteristics of each ethnic groups according to age are presented in table 
10-2 and 10-3. Proportion of Malay, Chinese, and Indian in the adult groups were 
41.18%, 35.29% and 23.53%. The percentage for paediatric patients were 27.50%, 
45.00% and 27.50% respectively. 
The plot of phenytoin serum concentration versus dose(mg/lcg. day) is given in 
figure 10-2. These highly scattered graphs as expected showed that there were no 
obvious linear relationship between dose and serum concentration. Plots of 
dose(mg/day) and clearance of each patient groups also showed a wide scatter(figure 
10-3). This clearly indicate that the determination of Km and Vmax should be 
individualised. 
Analysis of variance showed that inter-ethnic differences in adults for age, 
weight, dose(mg/day and per/kg body weight), serum levels and clearance were 
insignificant(p> 0.05). Differences in length of disease years(epilepsy years) was 
statistically significant(p<0.00). Mean for length of disease years (95%, C. I) in years 
for Malay, Chinese and Indian adult patients were 11.21 years(10.09 - 12.33), 15.08 
years(13.49 - 16.67) and 15.65 years(13.89 -17.41). 
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Figure 10- 2: Plot of dose and serum concentration 
in Malay, Chinese and Indian patients 
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Figure 10- 3: Plot of Clearance and dose in Malay, 
Chinese and Indian patients 
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Table 10-2: Summary data of adult patients of various ethnic groups 
Characteristic Malay Chinese Indian 
No. of patients 126 108 73 
Ratio of male/female 70: 56 53: 55 35: 38 
Ate) 
Mean, sd 36.06,11.94 36.55,11.11 34.14,9.88 
Range 19.00-73.00 19.00-69.00 19.00-53.00 
Weight 
Mean, sd 58.94,10.91 59.58,10.92 57.06,10.84 
Range 39.00-88.00 36.00-87.00 31.00-82.00 
Disease duration(yr)* 
Mean, sd 11.21,9.03 15.08,11.89 15.65,10.42 
Range 0.50-55.00 0.50-55.00 1.50-41.00 
Epilepsy Types 
Generalised 99 82 58 
Partial 17 18 9 
Others 10 7 6 
1bmpy(M; p) 76: 50 63: 45 41: 32 
Dose(mg/day) 
Mean, sd 273.17,79.85 271.57,75.26 276.58,72.33 
Range 100-600 100-460 100-450 
Dose(nWM 
Mean, sd 4.83.1.64 4.69,1.53 5.00,1.56 
Range 1.39-10.17 1.39-11.11 1.55-9.76 
Mean, sd 14.22,8.33 14.67,9.29 15.40,9.08 
Range 0.90-41.29 1.23-38.93 0.89-40.62 
C aY) 
eans M 25.22,14.68 24.90,14.81 23.99,13.80 
Range 7.25-111.11 5.91-81.30 6.62-102.04 
Abbreviation: M- monotherspy, P- polytherapy ;* denotes significant difference between ethnic groups(t(L05) 
Similar non-significant differences were observed in the paediatric patients for 
age, weight, dose(mg/day) and clearance(p>0.05). There were, however, significant 
differences in the dose per kilogram body weight(p>0.05), serum 
concentration(p>0.01) and length of disease years(p>0.01). Average dose in milligram 
per kilogram ( 95%, C. I ) and the corresponding serum concentration for Malay, 
Chinese and Indian patients were 6.01 mg/L(5.10mg/L - 6.92mg/L), 
6.77mgfL(5.73mg/L - 7.81mg/L), 8.16mgfL(6.96mg/L - 9.35mgfL) and 
11.59mg/L(9.95mg/L - 13.83mg/L), 13.23mg/L(10.46 - 16.00), 
20.07mg/L(14.62mg/L - 25.52mg/L) respectively. These results clearly showed that 
Malay and Chinese patients were given distinctly lower doses per kilogram body 
weight than Indians which consequently produce lower serum concentration. 
Mean length of disease years(95%, C. I ) was again highest in Indian(11.57 
years, 10.18 years - 12.96 years) when compared with that of Malay (5.71 years, 3.89 
years- 7.53 years) and Chinese(5.92 years, 4.56 years- 7.28years) patients. 
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Table 10-3: Summary data on paediatric patients of various ethnic groups 
Characteristic Malay Chinese Indian 
No. of patients 11 18 11 
Ratio of male/female 9: 2 10: 8 8: 3 
Age(yr) 
Mean, sd 12.77,4.22 12.42,4.01 14.09,237 
Range 5.00-18.00 3.00-17.00 11.00-17.00 
Weight 
Mean, sd 37.61,1537 37.00,14.77 36.00,9.00 
Range 11.75-56.00 12.00-60.00 26.00-56.00 
Disease dura6on(yr)" 
Mean, sd 5.71,435 5.92,3.32 11.56,3.22 
Fange 150-14.00 2.00-17.00 3.00-15.00 
Epilepsy Types 
Generalised 7 10 11 
Partial 0 5 0 
others 4 3 0 
Thempy(M: P) 3: 8 10: 8 6: 5 
Dose(mg/day) 
Mean, sd 212.27,80.35 242.64,105.90 277.73,73.35 
Range 45-330 15-400 200-400 
Doseimg/kg) 
Memsd 6.01,2.18 6.77,3.18 8.16,2.86 
Range 3.57-12.50 1.25.15.00 3.92-14.28 
Css(mg/L) 
Mean, sd 11.59,5.36 13.23,8.49 20.07,13.04 
Range 4.59-24.86 1.37-34.71 2.07-47.20 
CI dBY) 
MemW 20.43,9.33 22.61,14.45 21ä2,18.11 
Range 3.44-43.57 6.56,66.82 7.10-88.11 
Abbreviation: M- monotherapy, P- polytherapy; ", significant difference between ethnic groups 
10.3.1 Factors influencing Km and Vmax 
a, Ethnicity 
Table 10-4 summarises the pharmacokinetic characteristics in both adult and 
paediatric patients. Mean estimated Km( 95%, C. I ) for adult Chinese 
epileptics(6.49mg/L, 5.92mg/L - 7.06mg/L) showed a significantly lower value than 
those for Malay(8.54mg/L, 7.81mg/L - 9.27mg/L) and Indian( 7.47mg/L, 6.71mg/L - 
8.23mg/L) patients. The difference between Malay and Indian adult patients was not 
significant(p >0.05 ). 
Inter-ethnic differences in Km were not observed in children(p = 0.22). The 
mean(C. 1,95%) values(mg/L) for Malay, Chinese and Indian patients were 
9.56mg/L(7.08mg/L-12.04mg/L), 7.02mg/L(5.11 mg/L-8.93mg/L) and 
9.78mg/L(7.22mg/L-12.34mg/L) . 
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Table 10-4: Estimates of pharmacokinetic variables for various ethnic groups 
Parameters Malay Chinese Indian p value Conclusion 
1. Children 
n 11 18 11 
Mean Km, sd 9.56,4.19 7.02,4.13 9.78,4.33 0.22 Homogenous 
(m82) 
C. V(%) 43.83 58.83 44.27 
Mean Vmar, sd 366.40,114.70 383.20,152.00 438.90,94.40 0.31 Homogenous 
(mg/day) 
C. V(%) 31.30 45.62 21.51 
Mean Vmax, sd 11.05,4.99 10.97,4.84 12.86,4.21 0.18 Homogenous 
(mg/kg. day) 
C. V(%) 45.16 44.12 32.74 
2. Adult 
n 126 108 73 
Mean Km, sd 8.54,4.18 6.49,3.01 7.47,3.33 <0.01 Heterogenous 
(mg/L) 
C. V(%) 48.95 46.38 44.58 
Mean Vmax, sd 472.30,157.50 432.40,98.00 440.00,103.60 0.04 Heterogenous 
C. V( V(/o) 33.34 22.66 23.55 
Mean Vmax, sd 8.30,3.22 7.54,2.23 7.95,2.32 0.11 Homogenous 
(mg/kg. day) 
C. V(%) 38.80 29.76 29.18 
3. Pooled 
(Adult +children) 
ICm, se 8.62,0.36 7.02,0.28 7.66,0.37 Homogenous in 
(mglday) all ethnic groups 
Q 0.60 0.27 2.87 
p value 0.38 0.67 0.06 
pes, se 457.33,13.02 429.21,13.02 439.101,11.18 - Heterogenous for 
(mg/day) Malay, others 
homogenous 
Q 8.05 1.76 0.001 
p value <0.01 0.12 11.21 
Vmax, se 8.39,0.28 7.66,0.21 8.17,0.27 - Heterogenous for 
(mg/kg. day) all ethnic groups 
Q 3.22 8.73 14.31 
p value 0.04 <0.01 <0.01 
The coefficient of variation for Km in children and adult patients range 
between 32%-45% and 33-58%. These values clearly indicate a high interindividual 
variation of Km estimates for all ethnic groups. 
The difference in Km values between children and adult patients for each 
ethnic group was investigated by pooling their weighted mean values and using the Q 
statistic to determine association. Pooled results for Km(95%, C. I) for Malay, Chinese 
and Indian patients of 8.62mg/L(7.91mg/L-9.33mg/L), 7.02mg/L(6.47mg/L. 
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7.57mg/L) and 7.66mg/L(6.93mg/L-8.38mg/L) revealed that the Km values of 
children and adult were not statistically different. 
Vmax estimates in mg/day and mg/kg. day for paediatric patients of Malay, 
Chinese and Indian origin did not indicate the presence of any inter-ethnic difference. 
Significant differences of Vmax in mg/day were nevertheless observed for adult 
patients. Vmax(95%, C. I) of Malay(472.30mg/day, 444.80mg/day-499.80ma/day), 
Chinese(432.40mg/day, 413.92mg/day-450.88mg/day) and Indian(440.00mg/day, 
416.23mg/day-463.77mg/day) showed the presence of inter-ethnic differences 
between Malay/Indian and Chinese adult epileptics. Differences between Malay and 
Indian patients were insignificant. 
The coefficient of variation of Vmax(mg/day and mg/kg. day) in paediatric and 
adult patients were between 32%-58% and 22%- 46%. These values again highlight a 
high degree of interindividual variation in Malay, Chinese and Indian patients. 
Pooled values of Vmax(mg/day and mg/kg, day) for adult and paediatric Malay 
epileptics were found to be different and statistically significant. Chinese and Indian 
patients only showed a similar significant difference when Vmax was measured in 
mg/kg. day. The present results show that Vmax(mg. kg. day) in children were higher 
than adults in all ethnic groups. 
b. Length of disease years and type of epilepsy. 
The effect of length of disease years and type of epilepsy on Km and Vmax 
were determined by dividing the adult and paediatric patients into several groups 
according to the number of disease years or the type of epilepsy. Altogether there were 
7 groups of disease years ranging between less than 5 to more than 25 years. The three 
types of epilepsy were group as generalised, partial and those not classified into the 
earlier two groups. 
Analysis of variance demonstrated the p values for the relationship between 
Km(rng/L) and Vmax(mg/day and mg/kg. day) and the length of disease in adult and 
children were statistically insignificant(Table 5a, 5b). Linear regression of Km, 
Vmax(mg/day and mg/kg. day) also showed a poor correlation. The equations which 
portrayed the relationship are as follows; 
1. Children 
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Km(mg/L) = 7.54 + 0.13(Eyrs) 
(r. dj =0.0%, p=0.39) 
Vmax(mg/day)= 350 + 5.93(Eyrs) 
(radj =2.3%, p=0.18) 
Vmaz(mg/kg. day) = 11.3 + 0.03(Eyrs) 
(r. dj =0.0%, p=0.85) 
where Eyrs signify length of epilepsy disease years(years). 
II. Adult 
Km = 8.20 - 0.0438(Eyrs) 
(r. dj =1.3%, p=0.03) 
Vmax(mg/day) = 462 - 0.797(Eyrs) 
(rjj=0.1%, p=0.25) 
Vmax(mg/kg. day) = 8.15 - 0.016(Eyrs) 
(r. dj=0.1%, p=0.28) 
These results proved that length of disease did not alter either Km and Vmax values in 
adult and paediatric patients. 
Table 10-5a: Influence of Length of Disease and Types of Epilepsy on phenytoin pharmacoklnetics 
in paediatric epileptics 
Variables n Km(mg/L) Vmax(mg/day) Vmax(mg/kg/day) 
i. Length of disease 
<=8 years 18 6.41,0.93 308.65,57.76 9.73,0.90 
>8 - <12 years 6 6.14,2.28 333.65,90.48 10.41,3.85 
12 -< 15 years 14 8.55,1.51 411.21,27.94 11.24,1.06 
15 - <=18 years 2 6.27,10.63 443.59,57.64 9.16,1.81 
p values 0.51 0.44 0.76 
ii. Type of epilepsy 
Generalised 28 7.79,0.96 375.70,29.42 10.90,0.78 
partial(focal) 5 4.24,1.24 367.82,120.38 9.62,2.35 
others 7 6.71,1.67 261.02,123.23 8.67,2.01 
p-values 0.10 0.26 0.37 
Results: mean sd 
The findings for both age groups similarly revealed that the differences 
between Km and Vmax in relation to type of epilepsy were poorly correlated( mg/day 
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or mg/kg. day). These showed that type of epilepsy have no significant influence on 
both of these Michaelis-Menten parameters. 
Table 10-Sb: Influence of Length of Disease and Types of Epilepsy on phenytoln pharmacoklnetics 
in adult epileptics 
Variables n Km(mg/L) Vmax(mglday) Vmax(mg/kg/day) 
i. Length of disease 
<5 years 61 7.34,0.51 435.46,14.32 7.52,0.26 
5- <10 years 74 6.67,0.42 453.09,14.25 7.66,0.30 
10 -< 15 years 64 6.90,0.46 434.68,14.21 7.75,0.29 
15 -< 20 years 28 7.23,0.77 430.52,20.96 7.95,0.41 
20 -< 25 years 27 5.80,0.60 448.18,17.05 7.65,0.46 
> 25 years 52 6.38,0.68 422.08,13.92 7.25,0.29 
p values 0.34 0.69 0.80 
ii. Type of epilepsy's 
Generalised 240 6.66,0.22 438.96,7.21 7.65,0.15 
partial(focal) 44 7.15,0.56 424.28,14.18 7.21,0.30 
Others 23 6.74,0.87 443.15,25.25 7.64,0.58 
p-values 0.70 0.68 0.48 
Results: Mean, sd 
c. Sex and therapy 
Tables 10-6a and 10-6b presented the differences between Km(mg/L) and 
Vmax(mg/day and mg/kg. day) in relation to sex and therapy in both age groups. The 
results on children showed the corresponding p values for F test between Km and 
Vmax to sex and therapy were greater than 0.05. These values indicate that the 
estimated pharmacokinetic parameters in children were not significantly affected by 
sex and therapy. 
Table 10-6a: Influence of Sex(male or female) and Therapy on phenytoin pharmacokinetics of 
paediatric epileptics. 
Variables n Km(mg/L) Vmax(mg/day) Vmax(mg/kg/day) 
1. Sex 
male 27 9.36,4.11 369.10,138.10 11.39,4.65 
female 13 6.65,4.27 445.40,90.90 11.77,4.89 
p values 0.06 0.08 0.82 
ii. Therapy 
Monotherapy 19 7.50,4.70 408.00,101.40 11.58,4.53 
polytherapy 21 9.37,3.81 381.10,150.70 11.45,4.91 
p-values 0.17 0.52 0.93 
Results: mean, sd 
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Km(mg/L) and Vmax(mg/day) in adult were similarly unaffected by the 
patient's sex or type of therapy. The correlation between Vmax measured in mg/kg 
body weight and sex was however highly significant in adult patients(p < 0.01). Result 
highlighted that female adults have a significantly higher Vmax(mg/kg body weight) 
than that of male adults. 
Table 10-6b: Influence of Sex(male or female) and Therapy on phenytoin pharmacokinetics of adult 
epileptics. 
Variables n Km(mg/L) Vmax(mg/day) Vmax(mg/kg. day) 
I. Sex 
male 158 7.54,3.71 453.30,105.80 7.42,2.14 
female 149 7.59,3.72 447.70,148.10 8.50,3.12 
p values 0.92 0.71 <0.01 
ii. Therapy 
Monotherapy 184 7.44,3.62 445.90,132.20 7.82,2.86 
Polytherapy 123 7.75,3.84 457.50,121.40 8.14,2.48 
p-values 0.48 0.44 0.32 
Results: mean, sd 
d. Age 
Adult and paediatric patients were categorically divided into 7 and 4 age 
groups respectively(table 10-7). The range in the lowest age group( 8 years or less) for 
paediatric patients were wider due to a small number of patients within the age group. 
Km(mg/L) was not significantly affected by age increases in either adult(p = 
92) or paediatric(p = 0.31) patients. Vmax in mg/day and mg/kg. day in adult similarly 
showed a poor correlation with age although the latter did show a decreasing trend 
with respect to age. 
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Figure 104: Relationship of Vmax and age in paediatric 
patients 
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Figure 10-5: Relationship between Vmax(mg/kg) and age in 
paediatric patients 
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Evidence however showed that the values of Vmax in mg/day and mg/kg. day 
in paediatric patients differed significantly with age. Linear regression between Vmax 
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in both in mg/day(radl = 26.5% , p<0.01 ) and mg/kg. day(rdl = 9.5%, p= 0.03 ) with 
age nevertheless showed the relationship were weakly related(figure 10-4,10-5). 
Table 10-7: Influence of age on phenytoin pharmacokinetics 
Variables n Km(mg/L) Vmax(mg/day) Vmax(mg/kg. day) 
i. Adult 
>18- <23 years 31 8.06,3.89 454.80,98.20 8.65,2.47 
23 - <28 years 54 7.80,3.81 454.90,109.50 8.22,1.96 
28 -< 33 years 44 7.36,3.52 469.10,202.60 8.66,4.46 
33 -< 38 years 52 7.29,3.72 447.00,127.90 7.73,2.68 
38 -< 44 years 56 7.38,3.95 446.90,128.30 7.34,2.13 
44 -< 49 years 33 8.02,3.27 444.60,70.50 7.51,1.91 
49 -< 63 years 29 7.06,3.63 438.90,96.10 7.85,2.43 
>63 years 8 8.24,4.41 418.50,133.60 7.23,2.43 
p values 0.92 0.97 0.17 
ii. Children 
<8 years 6 9.65,4.45 213.20,136.70 11.43,5.49 
8-< 12 years 8 10.56,4.65 386.30,102.50 15.35,5.49 
12 -< 15 years 8 7.03,4.79 436.50,143.20 12.59,5.55 
15 -: 5 18 years 
18 7.81,3.79 438.60,72.30 9.35,1.93 
p values 0.31 <0.01 0.02 
Results: mean, sd 
Figure 10-6: Relationship between Km and weight in paediatric 
patients 
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Figure 10-7: Relationship between Vmax and weight in 
paediatric patients 
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Figure 10-8: Relations hip between Kmandweight in adult 
patients 
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Figure 10-9: Relationship between Vmaa and weight in adult 
patients 
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Linear regression was used to determine the relationship of Km and Vmax to 
weight in kilograms. The correlation between Km (radj = 0.0%, p=0.93 ) and 
Vmax, mg/day (raaj = 0.0%, p=0.48) to weight in adult patients was low and 
insignificant(figure 10-6 and 10-8). The relationship between Km and weight in 
paediatric patients was similarly insignificant(radj= 4.9%, p=0.09). Nevertheless, the 
correlation between Vmax, mg/day and weight was linear although the relationship was 
statistically weak(rd; = 16.8%, p= <0.01). 
10.4 Discussion 
The use of phenytoin pharmacokinetic parameters( i. e. Km and Vmax) for use 
in optimizing therapy is highly dependent on the accuracy with which these 
parameters were estimated. The present method of estimating these parameters has 
been used by various authors in determining population-specific pharmacokinetics in 
European [Bauer & Blouin 1983, Blain et al 19811, Japanese [Chiba et al 1980, 
Watanabe et al 1997] and Asian [El-Sayed et at 1989, Ismail & Rahman 1990] 
population. Results of these studies have also showed the accuracy of the estimated 
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serum concentration to that of observed concentrations [El-Sayed et al 1989, Chiba et 
al 1980]. 
Genetic differences have been shown to influence phenytoin pharmacokinetics 
[Arnold & Gerber 1970, Andoh et al 1980] and Grasela et al (1983) gave evidence 
that Km values of Japanese adult and paediatric epileptics(<15 years) are 57% and 
67% lower than a standard European 70kg individual. They also found that Vmax 
between Japanese and European population did not differ significantly. 
The present study showed that Km of Malaysian adult Chinese epileptics were 
significantly lower than that of Malay and Indian patients. Km(mg/L) values(95%, C. I) 
of Malaysian Chinese(6.49mg/L, 5.92mg/L-7.06mg/L) were also found to be 
significantly lower than that reported by Blain et al (1981) for Caucasian(9.40mg/L, 
8.43mgfL-10.34mg/L) and higher than that of Japanese adults(3.14mg/L, 2.22mg/L- 
4.06mg/L) [Watanabe et al 1997]. 
Km of Malay(8.54mg/L, 7.81mgIL-9.26mg/L) epileptics were found to be 
similar to Caucasian and significantly higher than Japanese. The current result for 
Malay adult epileptics was also similar to those reported by Ismail & Rahman 1990 on 
Malaysian Malay epileptics(7.45mg/L, 2.50mg/L-12.35mg/L) although a wider range 
of Km values was estimated. This difference may be due to the small sample size(9 
patients) used. The findings on Indians(7.47mg/L, 6.71mg/L-8.23mg/L) epileptics 
revealed that they differed significantly from Caucasian and Japanese adult patients. 
Thus, although Km values of Indian and Malay epileptics were similar, differences 
with other ethnic population do exist and care should be taken when these patients are 
to be treated in countries outside Malaysia. 
Results for children similarly showed that Chinese have lower Km value than 
Malay or Indian patients. Statistically, there were no interethnic differences between 
Malay, Chinese and Indian paediatric epileptics. These findings should be taken 
cautiously since the small sample size can lead to the observed high interindividual 
variation and may mistakenly portrayed the current homogeneity between them. 
However, comparing Km values of the current population to those of Japanese and 
Caucasian are suggestive of interethnic differences. 
The mean Km in mg/L(95%, C. I) of Malaysian paediatric 
population(8.44mg/L, 7.10mg/L-9.77mg/L) is definitely higher than Japanese [Chiba 
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et al 1980,3.70mg/L(2.88mg/L-4.52mg/L)]. Reports for Caucasian population 
showed that the current population was similar to those reported by Blain et al 
(1981)(7.50mg/L, 5.07mg/L-9.95mg/L) but significantly different from those of Bauer 
et al (1983)(6.26mg/L, 6.08mg/L-6.45mg/L). These differences could be attributed to 
the former using a population age of less than 8 years old while the latter age range 
was between 0.5 to 16 years. Since the present study employed an age range of 2.5 to 
18 years, the current results did show that Malaysian paediatric population have a 
higher Km than Caucasian. Results of Arab paediatric patients [El-Sayed et al 1989, 
7.75mg/L(6.45mg/L-9.04mg/L)] nevertheless showed that Malaysian and Arab 
population were statistically similar. 
The Vmax in mg/kg. day of Malaysian Chinese, Malay and Indian adult and 
paediatric patients were found to be similar. Mean Vmax(95%, C. I) of Malaysian adult 
population(7.95mg/kg. day, 7.64mg/kg. day-8.25mg/kg. day) were found to be 
statistically higher than that of Japanese [Watanabe et al 1997, (5.34mg/kg. day, range 
4.67-6.01 mg/kg. day)] and similar to that of Arabs [El-Sayed et al 1989 
(6.91mg/kg. day, range 6.13-7.69mg/kg. day)] and Caucasian population 
(8.70mg/kg. day, range 7 31-10.09 mg/kg. day). 
The current results however revealed the estimated Vmax of Malay 
epileptics[8.30mg/kg. day, 7.73mg/kg. day-8.86mg/kg. day] were similar to that reported 
by another Malaysian author [Ismail & Rahman 1990, 
(8.62mg/kg. day, (7.80mg/kg. day-9.44mg/kg. day)]. Vmax measured in mg/day in 
adults showed that Malay patients(472.30mg/kg. day, 452.97mg/kg. day- 
486.63mg/kg. day) have a significantly higher values than that of 
Chinese(432.40mg/kg. day, 413.92mg/kg. day-450.88mg/kg. day). These results could 
indicate that the relative size of liver per body weight is larger in the Malay population 
which then demonstrated by the higher metabolic capacity [Bauer & Blouin 1983]. 
Vmax for children also showed that there were no inter-ethnic differences 
between Malay, Chinese and Indian epileptics. The mean Vmax(95%, C. I) in 
mg/kg. day of Malaysian paediatric population of 11.5lmg/kg. day(10.06mg/kg. day- 
12.96mg/kg. day) were different to that of Japanese [Chiba et al 1980, 
9.54mg/kg. day(9.12mg/kg. day - 9.95mg/kg. day)] and similar to that reported for 
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Caucasian [Bauer et al 1983,10.22mg/kg. day(5.77mg/kg. day - 14.66mg/kg. day)] and 
Arabs [El-Sayed et al 1989,10.93mg/kg. day(9.40mg/kg. day-12.46mg/kg. day)]. 
Table 10-7: Studies that utilised the graphical method to estimate Km and Vmar 
References Ethnic 
group 
-sample size 
Therapy Age-group 
(range) 
Km 
(mg/L) 
mean, sd 
Vmax 
(mg/day) 
mean, sd 
Vmax 
(mglkg. day) 
mean, sd 
1. Children 
Chiba et al Japanese Poly 0.5-16 3.7,0.42 256.00 3.54,4.30 
(1980) -104 
Blain et al Caucasian Mono <8 years 7.5,1.24 238.00,25.50 20.4,2.07 
(1981) -40 
Bauer et at Caucasian unstated 0.5-16 6.26,0.09 - 10.22,2.27 
(1983) -135 
El-Sayed et Arabs Mixed 2.5-17 7.75,0.66 234.00,49.06 10.93,0.78 
at (1989) -5 
Ismail & Malay Mixed 10-18 5.28,1.97 292.84,35.82 8.35,0.67 
Rabman -5 
(1990) 
2. Adult 
Blain et al Caucasian unstated 18-66 9.4,2.26 542.20,37.00 8.70,0.71 
(1981) -21 
El-Sayed Arabs Mixed 19-47 6.44,1.01 417.00,19.13 6.91,0.40 
(1989) -12 
Ismail & Malay Mixed 19-43 7.45,2.50 454.84,44.76 8.62,0.42 
Rahman 
(1990) 
Watanabe et Japanese Poly 19-35 3.14,0.47 5.34,0.34 
al (1997) -16 
3. Adult + 
Children 
Rambeck et German Mixed 6-72 6.01,3.71 355.00, 
at (1979) -127 106.00 
Lai (1985) Chinese Mixed Both 4.00 range 
-50 245-562 
Abbreviation: mono-monotherapy, poly-polytherapy, mixed-mined monotherapy and polytherapy, unstated- therapy not 
mentioned 
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The result(Vmax, mg/kg. day) for Malay paediatric 
epileptics(11.05mg/kg. day, 10.17mg/kg. day-11.92mg/kg. day) was different to an 
earlier report on Malaysian paediatric population by Ismail & Rahman 
1990(8.35mg/kg. day, 7.04mg/kg. day-9.66mg/kg. day). This difference can be attributed 
to the latter using an age range of 10-18 years while the present study utilising an age 
group of 2.5 - 18 years old. Another factor that could have affected the results of both 
study is the small sample size of only 11 and 5 patients respectively. 
The above observations in differences in Km and Vmax among different ethnic 
groups can be attributed to the number of slow and extensive metabolizers in the 
population. Individuals are segregated as slow or extensive metabolizers on their 
ability to metabolise phenytoin to 4'hydroxy-phenytoin [Kutt et al 1964, Vasko et al 
1980, Wolff et al 1983]. This differences in phenytoin hepatic metabolism or 
polymorphism is associated with the polymorphic enzyme called P4502C9 [Veronese 
et al (1993a), Veronese et al (1993b). 
The incidence of the poor metaboliser phenotype in the Japanese population is 
reported to be approximately 0.2% [Watanabe et al 1997]. Values for Caucasian have 
been found to be 0.002% [Inaba T 1986] and 0.03% [Arnold & Gerber 1970]. These 
differences of slow phenytoin metabolisers among ethnic groups thus displayed the 
possibility for the inter-ethnic differences observed in the studied population. 
Horsman et al (1997) later published findings in the existence of phenytoin 
genetic polymorphism in Caucasian. Their study reported the index for phenytoin 
hydroxylation in urine for 122 healthy Caucasian appear to be bimodally distributed 
with 92% of the population showing a mean(SE) value of 6.39 ± 0.099 and 8% a 
mean(SE) of 1.00 ± 0.18. They also found no apparent differences in phenytoin 
hydroxylation index values between males and females, between females taking and 
not taking oral contraceptives, smokers and non-smokers and drinkers and non- 
drinkers. Their final conclusion recommended that future studies on phenytoin 
pha nacokinetics should include P4502C9 genotyping in order to ascertain for genetic 
polymorphism. 
These findings may explained why Malaysian Chinese have a significantly 
lower Km than Malay, Indian, Arabs or Caucasian population. Unfortunately, studies 
on phenytoin genetic polymorphism among Malaysian Malay, Chinese and Indian 
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population has yet to be reported. Nevertheless, based on the above observations, the 
proportion of slow metabolisers among ethnic groups and percentage of slow 
metabolisers in each ethnic groups(genetic polymorphism) could be the two important 
factors for the observed high inter-individual variation and inter-ethnic differences. 
Houghton and Richens et al (1975) reported that factors such as age, weight, 
height and sex have little effect on the interindividual variation in serum phenytion 
concentration. They further pointed that adjustment of dosage by age, weight or height 
would only achieve marginal improvement. Their findings concluded that genetic 
differences and the effect of saturation kinetics are more important in determining 
steady-state concentrations. Based on these results, it is not surprising that very few 
authors quoted the impact of height, sex or weight on the pharmacokinetic 
parameters(Km and Vmax) of phenytoin. The current findings also provide further data 
that indicate that the influence of length of disease, type of epilepsy and types of 
therapy are also insignificant. 
Nevertheless, a significantly higher Vmax per kilogram body weight obtained 
in female adult epileptics might indicate that sex does have an impact on the overall 
pharmacokinetics of phenytoin. This finding was similarly observed by Ismail & 
Rahman (1990) but not by Bauer et al (1982) and can be explained by the observations 
of Travers et al (1972) and Houghton and Richens (1975). These authors found that 
women had a lower mean serum concentration than men although the difference did 
not reach statistical significance. The result of the current study was similar( p=0.62 ) 
but the difference might be attributed to the weight(kg, standard error) of 
female(54.16kg, 0.60) being significantly lower than male(63. Olkg, 0.60) patients(p = 
<0.01). 
The effect of age to Km has been reported to be insignificant in both adult and 
paediatric patients [Bauer et al 1982, Bauer et al 1983, Chiba et at 1980] and was 
similarly observed in this study. Reports on the linear relationship between 
Vmax(mg/kg. day) and age is quite established in the paediatric population [Chiba et at 
1980(r = -0.55), Bauer et al 1983(r = -0.55)]. Similar association in the adult 
population has only been shown to be significant by Bauer et al (1982)(r = -0.52)] 
although poor relationship have been noted by Sherwin et at (1974), Houghton and 
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Richen (1975) and Taylor et al (1983). Dodson (1982) published results that this 
relationship is highly correlated only after applying non-linear regression analysis. 
The results of the current study found a similar but weak relationship for 
Vmaz in mg/day( rd; = 26.5%, p= <0.01) and mg/kg. day( rdj = 0.1, p=0.03 ) for the 
paediatric patients. Results for adults(Vmax, mg/kg. day) however showed that the 
relationship was absent although the age range was similar to that used by Bauer et 
1982. 
These results may be expected as the current retrospective study is not 
specifically designed to investigate these relationship although a trend towards 
linearity( adults, rdj = 1.1% ,p=0.04) was observed. It should also be noted that the 
prospective study by Bauer et at (1982), although more controlled, displayed a similar 
and distinctively wide scatter along the regression line which thus indicate a high 
interindividual variation. The present study also comprises of a mixed population of 
Malay, Chinese and Indian patients which again might contribute to the lesser degree 
of significance. 
Weight is observed to be poorly related to Km in both population groups and a 
similar result on the adult population has been reported by Bauer et al (1982). This 
study provided results for Vmax and weight which only showed a weak linear 
relationship (raj = 16.8%, p <0.01) in the paediatric population. El-Sayed et al (1989) 
and Ismail and Rahman (1990) nevertheless published results that the relationship in a 
mixed age population is linear. The observed result for this study for a mixed 
population group however displayed that this relationship is again poor although a 
trend towards linearity is demonstrated(r = 2.1%, p<0.01). 
Theoretically, the observed linear relationship between Vmax with age and 
weight can be explained by phenytoin having a variable hepatic metabolism with 
increasing age. Mitsukawa (1967) relates these observation in children to changes in 
metabolic capacity(Vmax) with increased age. Metabolic capacity is shown to be 
dependent on the relative size of liver per body weight and the relative activity of drug 
metabolising enzyme per gram of liver [Bauer & Blouin 1983]. Thus, liver size per 
unit body weight decreases with age so that children have an increased relative hepatic 
size compared to adults. 
210 
The decline in Vmax with age in adults(especially the elderly) is described by 
Wood et al (1979) by alterations in drug metabolism which are related to changes in 
hepatic blood flow, liver enzyme content and response to environmental factors. 
Although phenytoin elimination is not limited by the amount of liver blood flow, the 
decrease in Vmax is probably reflected by age-dependent changes in the amount or 
efficiency of drug metabolising enzymes in the liver. Thus, with aging clearance is 
expected to decrease which then lead to lower Vmax in older patients which may 
explain the negative linear relationship with age. 
10.5 Therapeutic implication 
The results of this study provide evidence that inter-ethnic differences are 
present in the Malaysian population. Based on the resulting Km and Vmax values, the 
estimated baseline dose for initiation of therapy in order to achieve a serum 
concentration of. 10 mg/L for adult can be calculated by the following formula 
described by Ludden et al (1977). 
Vmax. Cpss 
R= 
Km + Cpss 
where R is the dosing rate(mg/day), Vmax, the maximum daily rate at which phenytoin 
is metabolised(mg/day) and Km(mg/L), is the elimination rate by which is half of 
Vmax. Substituting the population values of Km and Vmax of each ethnic group into 
the formula, the mean dose for Malay, Chinese and Indian epileptics are 254.7mg/day, 
262.2mg/day and 251.9mg/day. Mean dose for the upper end of the therapeutic range 
(20mg/L) are 331.0mg/day, 326.5mg/day and 320.0mg/day. Similar estimates for 
Japanese(70kg individual) [Watanabe et al 1997], Caucasian [Blain et al 1981] and 
Arabs [El-Sayed et al 1989] are 284.5mg/day and 323.1mg/day, 279.5mg/day and 
368.8mg/day, and 253.6mg/day and 315.4mg/day. These estimates showed that 
although there are differences in Km values, the final mean daily dose looks almost 
similar and seems clinically unimportant. These findings however highlight the fact 
that the baseline and maximum mean dose for adults of any ethnic group is between 
200mg/daY to 400mg/day. This would definitely help medical practitioners to titrate 
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the most effective dose for each individual in the fastest time possible and the 
maximum dose would help to determine as to when toxic symptoms would be 
suspected. 
The corresponding values for the paediatric population to achieve similar 
concentration of 10mg/L and 20 mg/L are 180.7mg/day and 276.6mg/day. Values for 
Japanese [Chiba et al 1981], Caucasian [Blain et al 1981] and Arabs [El-Sayed et al 
1989] are 186.9mg/day and 216.0mg/day, 78.3mg/day and 117.8mg/day, and 
111.8mg/day and 151.1mg/day. These values clearly demonstrated that inter-ethnic 
differences population pharmacokinetics have an important role during initiation of 
therapy in paediatric patients. 
10.6 Limitation of study 
The present study suffers by not being able to establish the accuracy of the 
estimated Km and Vmax values of real patients. This is of clinical importance since the 
resultant population pharmacokinetic parameters are derived from data that were 
gathered retrospectively. Thus it is proposed that the observed Michaelis-Menten 
parameters be tested prospectively on patients of each ethnic groups so as to ascertain 
its true relevance in a clinical setting. 
10.7 Conclusion 
This study has provided evidence of the existence of inter-ethnic differences in 
phenytoin pharmacokinetic parameters (Km and Vmax, mg/day) among Malay, 
Chinese and Indian adults patients of Malaysia. Results for paediatric patients did not 
display similar findings. 
Km which is a value equal to the plasma concentration at which the rate is one- 
half the maximum of Chinese was found to be lower and differed significantly to that 
of Malay and Indian adult patients. The differences between Malay and Indian adult 
patients were however insignificant. Maximum metabolic rate capacity 
(Vmax, mg/kg. day) of all three ethnic groups were statistically similar. 
There was no indication of a linear relationship between Km with age and 
weight in both adult and paediatric patients. Relationship between Vmax(mg/kg. day) 
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with age or weight showed the inclination towards a linear relationship in paediatric 
patients only. These relationships were however statistically weak. 
The mean dose for Malay, Chinese and Indian adult epileptics in order to 
achieve the minimum target concentration of 10mg/L range between 251.9 to 
262.2mg/day (4.5mg/kg. day - 4.6mg/kg. day). The doses for the upper end of the 
therapeutic range(20mg/L) are between 320.0mg/day to 331.0mg/day (5.7mg/kg. day - 
5.8mg/kg. day). The corresponding values for the paediatric population to 
achieve similar concentration of 10mg/L and 20 mg/L are 180.7mg/day(6.2mg/kg. day) 
and 276.6mg/day(8.1mgfkg. day). 
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Chapter 11 
Overall discussion 
Studies evaluating the impact of therapeutic drug monitoring (TDM) of 
antiepileptic drugs such as phenytoin, carbamazepine, valproic acid and phenobarbitone 
have demonstrated both significant [Wing & Duff 1989, loannides-Demos et al 1988] and 
insignificant improvement [Botha et al 1990, McFayden et al 1990] in seizure outcome. 
Based on these outcome studies, it is difficult to draw a general conclusion about its 
effectiveness since some patients or patient groups do benefit from TDM. These patients 
or patient groups need to be redefine since TDM based on data from different populations 
and indications provide no value in the provision in clinical care [Ensom et al 1998]. 
The impact of ethnicity on drug treatment has been shown to be clinically 
important in phenytoin but reports on carbamazepine, valproic acid and phenobarbitone 
have been rather inconclusive. The observations on phenytoin are however based mainly 
on reports by researchers from the developed countries while those from the developing 
world are few. Defining phenytoin ethnic-specific pharmacokinetic parameters is thus 
difficult and any attempt to extrapolate these data onto other ethnic groups might be 
clinically and therapeutically inappropriate. Similarly the few reports on the other three 
antiepileptic drugs have yet to be verified and the current thesis has objectively 
undertaken to investigate the impact of ethnicity on the therapeutic ranges and 
pharmacokinetics of these drugs in its current treatment practise. 
Quantitative evaluation of the influence of ethnicity on established antiepileptic 
drugs such as phenytoin, carbamazepine, valproic acid and phenobarbitone is restricted by 
the relatively limited number of published studies that disclosed the ethnicity of their 
studied subjects. Of those where the ethnicity was mentioned, differences in inter-study 
variation such as study design and /or pharmacokinetic models further hindered the 
possibility of either identifying, verifying or substantiating the existence of inter-ethnic 
differences. 
The current use of retrospectively collected data has always been deemed inferior 
to that of prospective study design. Problems of reliability, bias and improper study design 
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do restrict its overall use. However, this method is suitable and applicable within the 
limits of this study set of objectives. The present study aim to examine `real' patients 
from a clinical setting of a hospital. This is of clinical importance since the absence of 
restriction for study admittance of patients groups provide both typical, atypical and 
extreme results which controlled study designs find difficult to construct. Routine data is 
easily available as well as cheap and less time consuming to conduct. This type of data do 
have problems of extraneous factor or `noise' but these so called variability may suggest 
that further exploration may be valuable [Sheiner et al 1977]. 
Disparities in the inclusion and exclusion criteria defined in this study are not 
entirely absent. The most prominent setback of routine data is the belief that the written 
patients' notes were correct. Studies by Mckee et al (1993) and Schoenenberger et al 
(1995) have showed that the percentage of non-compliance to drug therapy of these drugs 
contributed to about 1 to 9 percent of the total number of requests for serial monitoring of 
these drugs. Based on these findings, to assume full confidence in the written 
information(patients notes) may be too idealistic. However, by admitting a large number 
of patients(1,215) into the study and defining the 95% confidence interval of each 
conclusion have manage to improve the degree of statistical strength of the findings. 
The current study has set 30 days for the baseline for the drugs to reach steady. 
state and is in-line with published data [Prescott 1980]. However, the lack of information 
in the studied population(Malay, Chinese, Indians) period for carbamazepine 
autoinduction to complete could raise some concern to the appropriateness of the set 
baseline period for admission. This point is not entirely unfounded since reports of the 
completion of autoinduction from two Asian countries such as Korea [Yoon et al 1996] 
and Taiwan [Lin et al 1991], have been shown to be 1.5 times longer and significantly 
different than in Caucasians. The effect of the possible differences in the time for 
completion of autoinduction on the present study may well be insignificant since most of 
the patients were on the same dose regime for more than 90 days and this time period is 
definitely higher than that is reported of 30 to 45 days. 
Differences in the bioavailability factor might also affect the final conclusion of 
this study. This information is important in the current study since bioavailability may 
varies between ethnic groups or products. The is another area where many developing 
nations such as Malaysia overlook since information given by the drug companies are 
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taken to be applicable to the local population. Diet is another factor that is known to affect 
bioavailability and inter-ethnic differences in diet could play an important role in the 
present study. Differences in bioavailability among ethnic groups could also contribute to 
the observed high inter-individual variation. 
The present study is however able to achieve its set objectives by utilising a total 
of 1215 patients data of Malay, Chinese and Indian origin in order to satisfy the 
population-based methodology implemented in the analysis. The advantageous of the 
current population analysis over individual analysis has been well-defined by Hashimoto 
& Sheiner (1991) and described in chapter 3 section 3.2.1. In summary, population 
analysis perform as well as individual analysis if the data is plentiful (in this study the 
smallest number of patients data(190) ) and observational errors due to poor study design 
(as described above) in population analysis is better control than individual analysis. The 
latter is described by Hashimoto & Sheiner (1991) due the ability of the population 
analysis being able to exploit all informations of patients data simultaneously. 
The linear model employed in this study is the simplest pharmacokinetic model. It 
predicts that effects (in this study, i. e, serum concentration or clearance) are directly 
proportional to the dose. The advantage of this model rests in that parameter estimation is 
easily performed using linear regression. The main disadvantage is however it cannot 
predict a maximum effect outside or above those which were used to estimate the 
parameters. Nevertheless, since the main objective of the current population study is to 
investigate for variation in effects due to variables such as ethnicity, age, weight etc, the 
slope of the regression line provides the best technique to observe for differences. 
The present study reviewed literature on the issue of inter-ethnic differences and 
found statistical evidences of inter-ethnic difference in the population pharmacokinetics of 
phenytoin in both individual and population base studies. Published reports on 
comparative studies showed that phenytoin clearances between Eskimos, Blacks and 
Caucasian were significantly different. Grasela et al 1983 reanalysed data on reported 
Japanese and Caucasian population and found that Km values of Japanese to be fifty. 
seven percent lower than Caucasian. Individual and population based studies similarly 
showed the mean differences in pharmacokinetic parameters( clearance, Km and Vmax ) 
can be more than 1.5 fold among ethnic groups such as Caucasian, Japanese, Chinese, 
Arabs, Blacks and mixed Malaysian population. 
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This study also showed that there are inter-ethnic differences of phenytoin 
population phannacokinetics among Malaysian Malay, Chinese and Indian patients. Mean 
Km and Vmax(mg/day) values for adult Malay and Indian patients are statistically 
different to that of Chinese patients. These differences are however not observed in 
younger patients although this may be associated with the relatively small number of 
patients in each age group. The present study also showed that the range for inter- 
individual variation for Vmax (adult : 29.2% - 38.8%, children : 32.7% - 45.2%) and Km 
( adult : 44.6% - 49.9%, children : 43.8% - 58.8% ) in the studied population is 
considerably high and is the main determinant as is quoted by many other authors [Chiba 
et al 1980, Blain et al 1981, Ismail & Rahman 1990]. 
The findings of this study showed that both Km and Vmax are not significantly 
affected by variables such as length of disease years, type of therapy and type of epilepsy. 
Factors such as age [Bauer et al 1982, Bauer et al 1983] and weight [Bauer et al 1982] 
which have been found to be poorly correlated to Km has also been observed in the 
present study. The observed linear relationship between Vmax with variables such as 
weight and age in this study is statistically weak although several authors have earlier 
found the association to be significant [El-Sayed et al 1989, Ismail & Rahman 1990]. 
Inter-study differences in study design and patient characteristics and high inter-individual 
variation among ethnic groups could have contributed to the resultant poor correlation. 
The effectiveness of the current target range between 10 - 20mg/L for phenytoin 
was found to be clinically ineffective in all ethnic groups. This observation can be 
attributed to the high variation in odds ratios to therapeutic response which is directly 
linked to high inter-individual variation in Km and Vmax among all ethnic groups. Other 
factors that might also affect therapeutic response are age, weight and sex. These findings 
thus indicate that the target range should only be used as a guide and the use of phenytoin 
in treatment should be individualised. 
The possibility of inter-ethnic differences for carbamazepine has been denied by 
Eichelbaum et al 1985 but the present review of published literatures showed otherwise. 
Reports by Korean [Yoon et al 1996] and Chinese [Lin et al 1991 ] authors provide data 
on the existence of inter-ethnic differences in mean half-lives between the studied subjects 
and those of Caucasians. Comparison of reported mean clearances between Malaysian 
and Japanese patients also showed that ethnic differences are likely. 
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The present study observed a linear relationship between clearance and dose and 
the transformation of which has made its possible to predict the probable curvilinear 
relationship between carbamazepine dose and serum concentration. These findings are in 
line with studies reported by Kudriakova et al (1992) and Summers and Summers (1989) 
although reports by Hartley et al (1990) and Larkin et al (1991) found otherwise. 
Evidence of a linear relationship between clearance and dose also indicates the dose- 
dependent characteristic of carbamazepine. Both these findings have been reported by 
other researchers [Eadie & Tyrer 1980, Rambeck et al 1987]. This relationship is also 
found to be affected by age but not with ethnicity. 
The lack of efficacy of carbamazepine therapy within the target range of 4- 12 
mg/L can be explained by the high variation in odds ratio for therapeutic response among 
all ethnic groups. The effect of the high variation in odds ratios can be demonstrated for 
both adult and paediatric Malay, Chinese and Indian population ranging between 0.39 to 
1.00. The higher variation in odd-ratios among adult Indian(0.99) and Chinese(1.00) than 
that of Malay(0.42) patients is an indication of the genetic diversity in the two former 
populations. The high degree of variations also lead to the differences in response within 
the target range between Malay, Chinese and Indian patients being statistically 
insignificant. The lack of therapeutic differences can be contributed also by the high inter- 
individual variation in the ratio of serum concentration to dose in the present patients 
groups. 
Report on inter-ethnic differences for valproic acid has yet to be published. The 
comparison of results from two studies by Chiba et at (1985) and Botha et at (1995) 
however showed that clearances between Japanese and South African Black and Indian 
monotherapy treated patients are different. Evidence to compare similar differences on 
other ethnic groups cannot be ascertained as the ethnic compositions of most published 
reports were unknown. 
The present study showed that the relationship between valproic acid dose and 
serum concentration is linear in monotherapy patients. These observations also showed 
that the relationship is affected by associated therapy. Although similar findings have been 
reported by Tisdale et al (1992) and Mesdjian et al (1984), linear relationship in 
polytherapy treated patients have also been published [Hassan et al 1976, Rodenburg et al 
1977]. These latter studies however failed to provide statistical evidence for their findings. 
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The influence of age, weight or ethnicity on the observed linear relationship 
between dose and serum concentration were found to be insignificant. Nevertheless, the 
observed high inter-individual variation demonstrated by all ethnic groups of the current 
study is in concordance with the findings obtained by the above studies. 
Poor correlation between clearance and dose in this study showed that valproic 
acid has no dose-dependent properties. This finding is in line with reports by Dodson et al 
(1981) and Gram et al (1980) where they attributed the observed relationship tovalproic 
acid concentration-dependent protein binding properties. The current results however 
contradict the conclusions made by Tisdale et al (1992) of a linear relationship which they 
commented as a consequence to the saturation of binding sites of the concentration- 
dependent protein binding properties of vaiproic acid. 
Comparing valproic acid efficacy with respect to its target concentration range 
showed that difference between controlled and uncontrolled Malay, Chinese and Indian 
patients were statistically insignificant. The influence of ethnicity on the poor correlation 
in efficacy is also insignificant. These findings can be attributed to the considerably high 
variation in odds ratios which range between 0.15 - 0.85 for all ethnic groups. The lack of 
therapeutic differences can be contributed also by the high inter-individual variation in the 
ratio of serum concentration to dose in the present patients groups. Again these findings 
indicate that the cautious use of target range is essential in the management of patients 
with valproic acid. 
Reports on ethnic-specific studies of phenobarbitone are insufficient to verify it 
existence. Review of literature showed that inter-ethnic differences are possible in 
younger populations where level/dose ratios obtained by Japanese and European authors 
revealed variation in results for children in the age range of zero to 15 years old. 
The studied Malaysian adult population nevertheless showed ethnic differences 
among Malay, Chinese and Indian patients is highly improbable. It should be mentioned 
that phenobarbitone is currently not a popular drug of choice due to the availability of 
newer drugs that are more efficacious with less side-effects. 
Relationship between phenobarbitone dose and serum concentration in Malaysian 
base adult population is found to be linear and the correlation and relationship between 
clearance and dose is poor and non-linear. These findings are concurrent to earlier reports 
by Browne et al (1985), Svensmark and Buchthal (1963) and Strandford and Johannessen 
219 
(1977) and supported the theory that phenobarbitone pharmacokinetics are not dose 
dependent. 
The efficacy of phenobarbitone in the target range of 15 - 40mg/L showed there 
were no differences between controlled and uncontrolled of Malay, Chinese and Indian 
patients. The high variation in odds ratios displayed by the studied population (range 
between 0.14 to 0.65) can explain the reason for the absence of inter-ethnic difference 
among Malay, Chinese and Indian patients-The lack of therapeutic differences can be 
contributed also by the high inter-individual variation in the ratio of clearance to dose in 
the present patients groups. 
Finally, since serum concentration monitoring can be an important tool in 
identifying and resolving actual and potential problems during therapy, the need to pay 
special attention to recent studies evaluating the differences in outcomes in specific ethnic 
groups may be crucial in antiepileptic drug therapy of these drugs. Incorporating 
inappropriate population pharmacokinetics information could lead to misdirect dosage 
adjustments and would most likely offer little benefit in the provision of clinical care. 
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Chapter 12 
Conclusion 
Establishing the influence of ethnicity on the population pharmacokinetics for 
established antiepileptic drugs is restricted by the limited numbers of published ethnic- 
based studies and inter-study variations. Review of the literature found that inter- 
ethnic differences are evident in drugs such as phenytoin and carbamazepine but these 
differences are still unclear for valproic acid and phenobarbitone. Pharmacokinetic 
parameters that are associated with phenytoin inter-ethnic differences are the 
Michealis-Menten constant(Km), which is equal to the plasma concentration at which 
the rate of metabolism is one-half the maximum, maximum metabolic rate(Vmax), 
half-life(tln) and clearance(CL). By contrast, half-life and clearance were the two 
main pharmacokinetic parameters linked to inter-ethnic differences in carbamazepine, 
valproic acid and phenobarbitone. 
In the present study it was found that routine monitoring of established 
antiepileptic drugs in relation to their target ranges is clinically unimportant and had 
little bearing on achieving good therapeutic response. Therapeutic response, which 
was measured by the degree of seizure control was not dependent on inter-ethnic 
differences. These results were confirmed as the differences observed between 
Malays, Chinese and Indians pooled odds ratio of controlled and uncontrolled patients 
in the defined therapeutic ranges were statistically insignificant. The apparently high 
inter-individual variation displayed in all ethnic groups showed that the use of these 
drugs should be individualised. Age was not an important factor for the association 
between therapeutic response and the target therapeutic range. This was confirmed by 
the pooled odds ratio of carbamazepine and valproic acid. Similar observations were 
not conclusive for phenytoin and phenobarbitone due to inadequacy of data. These 
observations are thus in-line with the recommendation outlined by the Commission on 
Antiepileptic drugs, International League Against Epilepsy (1993). 
The relationship between dose and serum level for carbamazepine is found to 
be curvilinear and thus verified its dose-dependent properties. Linear relationship 
between valproic acid dose and serum level is highly variable and found to be highly 
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significant in patients on valproic acid monotherapy. Phenobarbitone dose and serum 
concentration relationship are highly correlated. This study also showed that neither 
valproic acid nor phenobarbitone displayed any dose-dependent kinetics. 
Factors such as weight, age or ethnicity has no influence on the relative 
relationship between dose and serum concentration for carbamazepine, valproic acid 
and phenobarbitone. The main factor that could have affected this relationship is the 
high interindividual variation between patients which clearly indicates that the use of 
these drugs must be individualised. 
The linear relationship between clearance and dose is used in determining the 
trend and influence of ethnicity on the population pharmacokinetics of carbamazepine. 
As for valproic acid and phenobarbitone, a similar linear relationship between serum 
concentration and dose is used to determine for inter-ethnic differences. Evidence of 
inter-ethnic differences for all three drugs among Malay, Chinese and Indian epileptic 
population in Malaysia was found to be statistically insignificant. High coefficient of 
variation of the ratio of clearances to dose(carbamazepine) and serum level to 
dose(valproic acid and phenobarbitone) displayed in all ethnic groups showed that 
interindividual variation is the important factor that could affect the observed 
relationships. 
Evidence showed that there are inter-ethnic differences in phenytoin 
pharmacokinetic parameters (Km, mg/L and Vmax, mg/day) among Malay, Chinese 
and Indian adults patients of Malaysia but not for paediatric patients. Elimination rate 
constant with a value equal to the plasma concentration at which the rate is one-half 
the maximum (Kin) was found to be lower for Chinese and differed significantly to 
that of Malay and Indian adult patients. Differences between Malay and Indian adult 
patients were insignificant. Metabolic rate capacity(Vmax, mg/kg. day) of all three 
ethnic groups were statistically similar. 
The relationships between Km with age and weight in both adult and paediatric 
patients were non-linear. Relationship between Vmax(mg/kg. day) with age or weight 
was weak although there is an inclination towards a linear relationship in paediatric 
patients. 
Finally, it should be mentioned that the results of this study are unique in that 
no other Malaysian study had ever reported or compared the effectiveness of the 
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current therapeutic range or the differences in dose and serum concentration 
relationship between Malaysian ethnic groups. This study showed that Malaysian 
Malays, Chinese and Indians did not differ significantly in handling carbamazepine, 
valproic acid and phenobarbitone. However, inter-ethnic differences between 
Malaysian Chinese with both Malay and Indian patients signify that the use of 
phenytoin on Malaysian patients must be adjusted to their racial background. This 
thesis support the use of ethnic specific phenytoin pharmacokinetic parameters during 
therapy. 
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Chapter 13 
Future work 
The present study has proposed population parameters for phenytoin, 
carbamazepine and phenobarbitone that are derived for the Malaysian population. These 
parameters are of clinical importance since these can simplify the estimation of serum 
concentration of these drugs during chronic therapy. However, the values of these 
population parameters need to be evaluated and it is suggested that a prospective study, 
that utilises the above recommendations on Malaysian epileptic patients need to be 
initiated. 
The proposed study should include all three important factors that can affect the 
overall outcome. First, blood or serum monitoring must be fixed for time of sampling 
which can either be the pre(trough) level or consistently done on the same time at every 
monitoring. Secondly, changes in medication due to other illnesses or fasting in the month 
Ramadan for Moslems [ Aslam et al 1997 ] can jeopardised treatment startegy and should 
either be included as another variable in the analysis or excluded during the selection 
process. Thirdly, paediatric patient's should be categorically group in smaller age range, 
such as lower or higher than 12 years old due to the changes in the liver metabolic 
capacity. Similarly, geriatric patients( age more than 65 years) should be grouped 
separately. 
The results obtained for phenytoin, carbamazepine, valproic acid and 
phenobarbitone are nevertheless lacking in statistical sophistication. Since the findings 
showed that high inter-individual variation can be the crucial factor for the variable degree 
of therapeutic response, the present method of estimating inter-individual variation does 
not permit for the 95% confidence interval to be calculated. This thus hindered any 
possibility to test for differences in inter-individual variation among the three ethnic 
groups. Inter-ethnic differences in inter-individual variation can be calculated by using 
specialised computer software such as NONMEM (Non-Linear Mixed Effect Model) 
where estimates of both intra-individual and inter-individual variation can be determined. 
Thus, it is proposed that the current data be reanalysed based on the NONMEM software 
where it is hoped that results from the current finding can be further validated. 
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Appendices 
Appendix 5-1 
Hospitals visited 
Hospitals Date 
Hospital Sultanah Aminah, 
Johor Bahru, 
Johor. 3-10-96 to 24-10-96 
2. Hospital Permai, 
Tampoi, Johor Bahru, 
Johor 26-10-96 to 14-11-96 
3. Hospital Tengku Ampuan Rahimah, 
Kelang, 
Selangor. 16-10-96 to 7-11-96 
Hospital Ipoh, 
Ipoh, 
Perak. 9-12-96 to 23-12-96 
5. Hospital Universiti, 
Kuala Lumpur. 10-11-96 to 13-11-96 
6. Hospital Pulau Pinang, 
Pulau Pinang. 15-11-96 to 7-11-96 
mmm/9.8.96 
Al 
Appendix 5-2 
Date : 
Content of worksheet: 
1, Name of Hospital: 
2. Hospital bed size: 
3. Number of Specialist(Neurologist, Psychiatrist): 
4, Type of facility: -1. outpatient clinic 
-2. Specialist clinic 
a. Neurology 
b. Psychiatric 
c. Paediatric 
d. Medical 
G. Others. Please specify: 
-3. inpatient(hospitalized) 
a. Neurology 
b. Psychiatric 
c. Paediatric 
d. Medical 
e. Intensive care 
f. Geriatric 
g. Others. Please specify: 
5, Patient Biodata: 
a. Registration number 
b. Age (years) 
c. Sex (MJF) 
d. Weight (kilogram) 
e. Height (cm) 
f. Race : (M/C/I/O) 
Malay-M 
Chinese-C 
Indian-I 
Other races-O 
g. Patient doctor : (HMO/MO/SP) 
Houseman Medical 
A2 
Officer-HMO 
Medical Officer-MO 
Specialist-SP 
h. 
1. 
J. 
k. 
1. 
m. 
n. 
0. 
0. 
Diagnosis : i. 
ii. 
iii. 
iv. 
V. 
Epilepsy Classn (Partial, focal-P) 
(Generalized-G) 
(Unclassified-U) 
(Special syndrome-S) 
Seizure type (Partial-F) 
(Generalized-L) 
(Unclassified-D) 
(Unknown-K) 
Length of disease (years) 
Cocomittant disease 
Drug therapy : i. 
Length of therapy : i. 
ii. 
iv. 
V. 
vi. 
vii. 
11. 
111. 
iv. 
V. 
A. 
vii. 
compliance : poor/good 
Present condition 
a. Seizure control: (Percentage) 
b. others diseases: (control/uncontrol) 
6, Laboratory Results 
a. Serum levels(ug/ml)-Total 
Date taken 
Time taken 
Type of assay 
Done by 
: 1.2. 
: 1.2. 
: (FPIA-f/HPLC-h/EMIT-e) 
: (Biochemist-b/Pharmacist-p) 
A3 
i. Carbamazepine : 1. 
ii. Phenytoin : 1.2. 
iii. Phenobarbitone : 1.2. 
iv. Sodium valproate : 1.2. 
b. Liver function Test 
Date 
SGOT : N/H/L 
APT : N/H/L 
Bilirubin : N/HJL 
Albumin : N/H/L 
Globulin : N/H/L 
c. Renal function test 
Date 
Urea : N/H/L 
Sodium ; N/H/L, 
Potassium : N/H/L 
Chloride : N/H/L 
Calcium ; NdM 
Bicarbonate : N/H/L 
Carbonate : N/H/L 
Creatinine : N/H/L 
d. Blood test 
Date 
Red Blood Cells : N/1-i/L/AB 
Platelets : N/HJL/AB 
WBC : N/H/L/AB 
Ph : N/HJL 
e. Blood Sugar 
Date 
Glucose : N/H/L 
g. EEG : N/AB 
(Abbreviation: N-Normal, H-High, L-Low, Abnormal-AB) 
Side-effects 
Drowzy-DZ 
Headache-HA 
ataxia-AT 
Unsteadiness-US 
Oculogyric crises-OC 
Insomnia-IN 
Hallucination-HU 
Allergic Rash-AR 
Hepatic-HP 
Steven Johnson Syn-ST 
Dizzy-DI 
Nausea-NU 
Diplopia-DP 
Behavioral changes-BC 
Asterixis-AS 
Orofacial Dyskinesia-OD 
Taste change-TC 
Haematological-HE 
Hypersensitivity-HS 
Lyell Syndrom-LS 
2. 
A4 
Dermatitis-DE 
Hypervolumia-HV 
Edema-ED 
Sedation-SE 
Depression-DP 
Decreased libido-DL 
Acne-AC 
Lack of coordination-LC 
Gum hypertrophy-GH 
Red cell aplasia-RC 
Folate deficiency-FD 
Vit. D deficiency-VD 
Hae'hagic pancreatitis-HS 
Hyponatremia-HN 
Weight Gain-WG 
Anorexia-AN 
Mental slowness-MS 
Hyperactivity-HY 
Impotence-IM 
Hirsutism-HR 
Dystonia-DS 
Thrombocytopenia-TH 
Agranulocytosis-AG 
Megaloblastic anemia-MA 
Hyperglycemia-HY 
A5 
Appendix 5-3a 
Flow chart for Therapeutic Drug Monitoring 
Start 
Clinician identify patient for TDM 
- Notify pharmacist 
Pharmacist recommends sampling times 
Clinician fills TDM Request Form 
Receives, check and verify Blood Samples 
TDM Request Form Complete ? 
Verify with 
requesting 
clinician 
'ES 
Pharmacy assistant Assay blood sample 
Pharmacist communicate results and 
recommendations to clinician 
Monitor therapy 
End 
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Serum Drug Concentration Assessment 
Serum Drug Conc 
(Post or Pre-dose) 
obtained 
Determination of 
Pharmocokinetic 
parameters 
Determine 
Maintenance Regimen 
Steady-State 
achieved? 
YES I 1NO 
Favourable 
response ? 
YES I -NO- I 
Obtain Follow-up 
SDC to document 
effective serum 
Concentration 
Obtain Follow-up 
SDC to refine 
Pharmacokinetic 
Parameters 
Adjust Regimen 
Toxicity? 
YES NO 
Adjust Regimen 
A7 
Wait for Steady 
Appendix 5-4 
THERAPEUTIC DRUG MONITORING 
SERVICE 
$SAJB 
2231666 EXT2016 
TDM NO: ............................... 
DATE ...................................... 
TO BE FILLED BY REQUESTING DOCTOR 
NAME OF DOCTOR: ..................................................... SIGNATURE ............................ »................. 
PATIENT BIODATA 
NAME ...................................................... 
AGE: ........................................................... WT(KG) :................................................... 
RACE ........................................................ SMOKER: YES/NO 
R/N(I C) :................................... ............. SEX: ............................................................... 
HT(CM) :.................................................. -»... 
WARD: ..................................................... ....... 
ALCOHOLIC: YES/NO 
2. MEDICAL HISTORY 
CLINICAL DIAGNOSIS: .......................................................................................................... VS:. T ......................... BP.............................. HR............................... RR...................................... CVS(AF/DRNM ETC): ............................................................................................................... DIALYSIS: YESINO 
FITS' CHART ............................................................................................................................. 
».... »...... ».... PRESENT CONDITION: .......................................................................... . .......... 
RX 
DATE DRUG REGIMEN DATE DRUG REGIMEN 
4. INDICATION FOR REQUEST(PLEASE TICK) 
THERAPEUTIC CONFIRMATION 
COMPLIANCE 
5. DRUG(S) FOR TDM 
SUSPECTED TOXICITY 
LOW THERAPEUTIC RESPONSE 
DATE 
STARTED 
DRUG REGIMEN (ROUTE, DOSE, 
FREQUEl1/Cy flIE OF 
FORMULATION AND BRAND) 
PRE- 
SAMPLING 
TIME 
DOSING TIME POST- 
SAMPLING 
TIME 
A8 
TART ITU(`i. `C 
RFT LFT ELECTROLYTE HEMATOLOGY OTHERS 
UREA: ALB: Na: RBC: RBS: 
SCR: GLB: K. ' WBC: ABG: 
RE"RX BIL : Cl: %LYM. ' 
SCR: BIL Ca: PLT: 
OST-RY ALP: M: PT' 
AST: Po : 
ALT. 
7. YASL IUM LUSIUVKY 
-DATE DRUG REGIMEN PRE-LEVEL POST-LEVEL REMARKS 
. ........................................................................................................................................................................... 
THERAPEUTIC DRUG MONITORING 
JABATAN FARMASI 
IISAJB 
2231666EXT2016 
PATIENT NAME:... »...... »».. »...... » .................. »»»». R/N:.. »»»»».. »»».... »»»»...... 
WARD:. »».. ».... ».. ».. »...... 
I. DM NU: »»».... ».... ».. »...... »».... ». DATE:....... »»».... ».. »»»»»».. »» DRUG REGIMEN PRE-LEVEL POST-LEVEL 
DESIRED THERAPEM IC RANGE: ........................................................ . ............ ............. 
»»»»w»w. NNw. »w. NN. ww w. N. w NNN»N»Nw»NNNN»NwwwN»N NNN w. ww" 
COMMENTS: Ke :................. whd 1ýýA:............. ..... hr Va:. »»w.. »»».. ».. »w».. w».. [/iCG 
»»»» PEGAWAX 
FARMAS[ Y/M 
TDM JABATAN FARMAST 
USA 
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Appendix 5-10 
Ramdomisation strategy for selection a single dose/serum pair 
Dose/serum level pair available 
Strategy 23456789 
1st patient 1232 1 6 2 2 
2nd patient 
2343 
2 7 3 3 
3rd patient 114 3 1 4 4 
4th patient 25 4 2 5 5 
5th patient 1 5 3 6 6 
6th patient 6 4 7 7 
7th patient 5 8 8 
8th patient 1 9 
9th patient 1 
Brief description of table; 
For example, column with number 3 signify patients with 3 dose/serum level pairs. 
Thus, for the first patient with this number of dose/serum level pair will have the 2nd 
dose/serum level pair to be selected. Second patient will then have the 3rd pair 
selected. Third patient will have the dose/serum level first pair. The cycle will be 
repeated at the end of dose/serum pair, i. e , with the fourth, fifth and sixth patients 
with 3 dose/serum level pair will follow the same regime that is described. 
A15 
Appendix 5-11 
Phenytoin : Randomisation strategy to select two dose/serum levels pairs 
Dose serum level pairs available 
Selection strategy 345 
-1st patient 2,1 4,1 5,3 
i 
-2nd patient 3,2 3,2 4,2 
i 
-3rd patient 1,3 1,2 3,1 
-4th patient 2,4 2,5 
-5th patient 3,1 1,2 
-6th patient 4,3 2,3 
-7th patient 3.4 
-8th patient 4,5 
-9th patient 5,1 
-10th patient 4,1 
Brief description of the above table: 
Column with the number 3 indicates patients with 3 dose/serum level pairs. The first 
patient with 3 dose/serum level pairs with follow the number 2,1. Number 2 and I 
signifies dose/serum level of 2nd and ist to be selected. Second patient with 3 
dose/serum level pairs, will have the 3th and 2nd dose/serum level pair(3,2) selected 
while the 3rd and 1st dose/serum level pairs will be selected for the third patient. The 
cycle will be repeated at the end of each assignment of each dose/serum level group, 
i. e, the fourth patient will follow the the number 2,1, fifth 3,2 and six 3,1. 
A16 
Appendix 7-1 
a. Regression Analysis of clearance(liter/kg) and dose(per 
kilogram body weight) 
The regression equation is 
Clearance(cUkg) = 0.0241 + 0.00557 Dose(d/kg) 
Predictor Coef Stdev t-ratio p 
Constant 0.024107 0.005546 4.35 0.000 
d/kg 0.0055663 0.0002983 18.66 0.000 
s=0.03579 R-sq = 71.8% R-sq(adj) = 71.6% 
Analysis of Variance 
SOURCE DF SS MS Fp 
Regression 1 0.44606 0.44606 348.19 0.000 
Error 137 0.17551 0.00128 
Total 138 0.62158 
Unusual Observations 
Obs. d/kg cl/kg Fit Stdev. Fit Residual St. Resid 
91 22.2 0.22584 0.14780 0.00363 0.07803 2.19R 
93 25.0 0.23728 0.16326 0.00414 0.07402 2.08R 
94 25.7 0.33274 0.16724 0.00429 0.16550 4.66R 
95 27.9 0.08931 0.17945 0.00477 -0.09014 -2.54R 98 39.1 0.22932 0.24192 0.00766 -0.01260 -0.36 X 99 42.9 0.20109 0.26266 0.00869 -0.06157 -1.77 X 100 51.3 0.28758 0.30956 0.01108 -0.02197 -0.65 X 101 75.0 0.50322 0.44158 0.01799 0.06164 1.99 X 
109 10.0 0.17883 0.07977 0.00346 0.09906 2.78R 
119 22.9 0.22949 0.15134 0.00374 0.07815 2.20R 
125 40.0 0.31626 0.24676 0.00790 0.06950 1.99 X 
129 8.8 0.15645 0.07322 0.00364 0.08322 2.34R 
R denotes an obs. with a large st. resid. 
X denotes an obs. whose X value gives it large influence. 
A17 
MTB > Regress 'cl/kg' 2'd/kg"WEIGHT; 
SUBC> Constant. 
b. Regression Analysis of clearance(L/kg) dose(per kilogram 
body weight and weight) 
The regression equation is 
cl/kg = 0.0557 + 0.00520 d/kg -0.000765 WEIGHT 
Predictor Coef Stdev t-ratio p 
Constant 0.05568 0.01132 4.92 0.000 
d/kg 0.0052042 0.0003107 16.75 0.000 
WEIGHT -0.0007650 0.0002415 -3.17 0.002 
s=0.03467 R-sq = 73.7% R-sq(adj) = 73.3% 
Analysis of Variance 
SOURCE DF SS MS Fp 
Regression 2 0.45812 0.22906 190.59 0.000 
Error 136 0.16345 0.00120 
Total 138 0.62158 
SOURCE DF SEQSS 
d/kg 1 0.44606 
WEIGHT 1 0.01206 
Unusual Observations 
Obs. d/kg cl/kg 
34 5.5 0.04996 
35 5.6 0.05739 
39 10.0 0.08300 
94 25.7 0.33274 
95 27.9 0.08931 
100 51.3 0.28758 
101 75.0 0.50322 
109 10.0 0.17883 
119 22.9 0.22949 
Fit Stdev. Fit Residual St. Resid 
0.02835 0.00927 0.02161 0.65 X 
0.03069 0.00884 0.02671 0.80 X 
0.04652 0.01102 0.03648 1.11 X 
0.16273 0.00439 0.17001 4.94R 
0.16802 0.00586 -0.07871 -2.30R 
0.31361 0.01081 -0.02603 -0.79 X 
0.43682 0.01749 0.06640 2.22RX 
0.08477 0.00370 0.09405 2.73R 
0.14786 0.00378 0.08163 2.37R 
R denotes an obs. with a large st. resid. 
X denotes an obs. whose X value gives it large influence. 
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